Unnamed: 0,patient_filename,t,text,type,n,cmem_n_is_parsed,cmem_n_reasoning,cmem_n_rules_str,cmem_n_ans_str,cmem_n_memory_str,cmem_n_memory_len,cmem_n_memory_str_len,cmem_n_edit_distance,cmem_n_is_updated
1366,TCGA-EW-A3E8.E4ECB8AA-0ECC-47A5-B940-045A2C3D9A1A,2,"surgical Pathology Report. (Age. F. Pathologic Interpretation: A. SENTINEL NODE COUNT 0 AXILLA, FS: No malignancy seen in one lymph node (0/1). Immunohlstochemistry for keratin to follow. B. SENTINEL NODE COUNT 609 AXILLA, FS: No malignancy seen in one lymph node (0/1). Immunohistochemistry for keratin to follow. c. LEFT BREAST MASTECTOMY SINGLE SUTURE SUPERIOR, DOUBLE SUTURE MEDIAL: INVASIVE LOBULAR CARCINOMA, high nuclear grade, 7.0 cm (gross examination). Previous biopsy site. No lymphovascular invasion identified. Specimen margins are negative for tumor. See Tumor Summary. D. ADDITIONAL MASTECTOMY SKIN: No malignancy seen. Pathology Cancer Case Summary. Specimen: Total breast (Including nipple and skin). Procedure: Total mastectomy (including nipple and skin). Lymph Node Sampling: Sentinel lymph nodes. Specimen Integrity: Single intact specimen (margins can be evaluated). Specimen Laterality: Left. Tumor Site: Invasive Carcinoma: Upper outer quadrant. Central. Tumor Size: Size of Largest Invasive Carcinoma: Greatest dimension of largest focus of invasion over 0.1 cm: 7.0 cm. Tumor Focality: Single focus of invasive carcinoma. Macroscopic and Microscopic Extent of Tumor: Skln: Invasive carcinoma does not invade into the dermis or epidermis. Lobular Carcinoma in Situ (LCIS): Present. Histologic Type of Invasive Carcinoma: Invasive lobular carcinoma. Histologic Grade: Nottingham Histologic Score: Glandular (Acinar)/Tubular Differentiation. Score 3: < 10% of tumor area forming glandular/ubular structures. Nuclear Pleomorphism. Score 3: Vesicular nuclei, often with prominent nucleoli. exhibiting marked variation in size and shape,. occasionally with very large and bizarre forms. Mitotic Count. Score 1. Overall Grade: Grade 3: scores of 8 or 9. Margins: Margins uninvolved by invasive carcinoma. Lymph-Vascular Invasion: Not identified. Lymph Nodes: Number of sentinel lymph nodes examined: 2. Number of lymph nodes with macrometastases (> 0.2 cm): 0. Method of Evaluation of Sentinel Lymph Nodes: Hematoxylin and eosin (H&E), one level. Immunohistochemistry. Pathologic Staging (pTNM): Primary Tumor (pT): pT3: Tumor > 50 mm in greatest dimension. Regional Lymph Nodes (pN): pNO: No regional lymph node metastasis identified histologically. Distant Metastasis (pM): Not applicable. Anciliary Studies: Estrogen Receptor: Pending. Progesterone Receptor: Pending. HER2/neu: Pending. MOTE: Some anabodies are analyte specific reagents (ASRs) validated by our laboratory. These ASRs are chrecally usejui indicators that to not require FDA approval. These clones are used: IDS=ER, P8R 636=PR, A485=HER2, H-11=80PR. All staus are used with formalive or molecular fixed, paraffin embedded assue. Detection. resultsure rand by a. pathologist as positive or regative. As the cattending pathologist, I attest that I: (i) Examined the relevant preparation(s). for the specimen(s); and (ii) Rendered the diagnosis(es). Addendum Diagnosis. A. SENTINEL NODE COUNT 0 AXILLA: Immunohistochemistry for keratin is negative. B. SENTINEL NODE COUNT 609 AXILLA: Immunohistochemistry for keratin is negative. C. LEFT BREAST MASTECTOMY SINGLE SUTURE SUPERIOR, DOUBLE SUTURE MEDIAL: The tumor cell are positive for ER (>90%) and PR (>90%) and negative for HER2 (0+) by immunohistochemistry. Intraoperative Consultation. A. Sentinel node count 0 axilla, FS: No obvious malignancy. Final pending permanent section and perhaps IHC as original tumor was a lobular carcinoma. B. Sentinel node count 609 axilla, FS: No obvious malignancy. Final pending permanent section and perhaps IHC as original tumor was a lobular carcinoma. Clinical History: Biopsy proven multifocal carcinoma left breast. Please evaluate margins and if sentinel nodes are H&E (-), do serial sections and IHC. Operation Performed. Left total mastectomy, Sentinel node biopsy, possible axillary node dissection. Pre Operative Diagnosis: Infiltrating lobular carcinoma left breast. Specimen(s) Received: A: SENTINEL NODE COUNT 0 AXILLA, FS. B: SENTINEL NODE COUNT 609 AXILLA, FS. C: LEFT BREAST MASTECTOMY SINGLE SUTURE SUPERIOR, DOUBLE SUTURE MEDIAL. D: ADDITIONAL MASTECTOMY SKIN. Gross Description: A. Received fresh labeled ""Sentinel node count 0 axilla"" is a tan piece of tissue measuring 2.5 x 2.0 x 0.3 cm. Submitted in. toto in one cassette for frozen section. B. Received fresh labeled Sentinel node count 609 axilla"" is a piece of soft tissue with areas of adipose tissue that. measures 3.0: 2.5x 0.4 cm. Submitted in toto in one cassette for frozen section. C. Received fresh labeled ""Left breast mastectomy, single suture superior, double suture medial"" is a one kelo left modified. radical mastectomy that measures 18.0 x 12.0 6.0 cm. There is a white skin ellipse that measures 7.0 x 3.0 cm and a. nipple that measures 1.8 cm in diameter. There are two sutures. The single suture is superior and the double suture is. medial. The specimen is inked in black. Upon sectioning, there are diffuse areas of white nodularities throughout the. parenchyma. There is a firm, white nodular lesion that extends 2.0 cm away from the lateral margin to the midline. It. measures 7.0 x 6.0 x 4.0 cm and it is 1.0 cm away from the deep margin, 4.0 cm from upper margin, 5.0 cm from the. lower margin. Adjacent to the upper pole of the lesion previously described, there is another irregular shaped lesion,. probably from a previous biopsy site that measures 6.0 x 5.0 x 3.0 cm. It is located 2.0 cm away from the superior. margin, 1.5 cm from the deeper margin, 5.0 cm from the inferior margin, 2.0 cm from the anterior margin. No other lesions are. grossly identified. There are 2/3 of stroma and 1/3 of adipose tissue. Sections submitted as follows: Cassette #1. Nipple. Cassettes #2-6. Several sections of tumor. Cassette #7. Sections of tumor in relation to the superior margin. Cassette #8. Deeper margin. Cassette #9. Portion of retro-areolar area. Cassettes #10&11. Superior inner quadrant. Cassettes #12&13. Inferior inner quadrant. Cassettes #14&15 Superior outer quadrant. Cassettes #16&17 Inferior outer quadrant. D. Received in formalin labeled ""Additional mastectomy skin"" is an irregular piece of skin tissue measuring 14.0 x 7.0x 1.2. cm. The specimen is white, pink and there were no abnormal lesions grossly identified. The specimen is not oriented. Representative sections are submitted in two cassettes.",BRCA,0,True,"The report states that two sentinel lymph nodes were examined and no malignancy was found in either one (0/2). This indicates that the cancer has not spread to the regional lymph nodes, which corresponds to N0 in the AJCC staging system.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.",7.0,549.0,,
1330,TCGA-E9-A5UP.B50AB6D5-3010-450E-9CCE-E9BFA0202736,1,"Gross Description: There is a quadrant of the breast with tumor up to 3.5 cm in size. In the fatty tissue. there are lymph nodes without morphological features. Microscopic Description: Intraductal papillary adenocarcinoma with invasion, G-2. Examined lymph. nodes demonstrated lipomatosis. Diagnosis Details: Tumor Features: Indeterminate, Tumor Extent: T2 tumor size more than 2cm not. more than 5 cm, Venous Invasion: Absent, Margins: Absent, Treatment Effect: Comments: Formatted Path Reports: BREAST TISSUE CHECKLIST. Specimen type: Partial mastectomy. Specimen size: Not specified. Tumor site: Breast. Tumor size: 0 X 0 X 3.5 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating papillary adenocarcinoma. Histologic grade: Moderately differentiated. Tumor extent: Not specified. Lymph nodes: 0/10 positive for metastasis (Axillary 0/10). Extracapsular invasion of the lymph nodes: Not specified. Margins: Uninvolved. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: Left.",BRCA,0,True,"The report indicates that 10 lymph nodes were examined and all of them were found to be negative for metastasis (0/10 positive for metastasis). According to the rules, if no malignancy is found in regional lymph nodes, the N stage is N0. The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage. In this case, the number of nodes with malignancy is 0, which supports the N0 stage.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.",7.0,549.0,100.0,True
1477,TCGA-OL-A5RY.C8297152-7551-49A1-8C9D-6B411391AC77,0,"FINAL PATHOLOGIC DIAGNOSIS. A. Right axillary sentinel lymph node #1, biopsy: - Metastatic ductal carcinoma (1.3cm) involving single lymph node (1/1). B. Right axillary sentinel lymph node #2, biopsy: - One lymph node, no tumor (0/1). C. Right axillary sentinel lymph node #3, biopsy: - One lymph node, no tumor (0/1). D. Right axillary non sentinel lymph node, biopsy: - One lymph node, no tumor (0/1). E. Right breast, wire-guided lumpectomy: - Invasive ductal carcinoma, SBR III, multiple foci (largest 1.3cm). - Ductal carcinoma in situ high grade, solid, cribriform and micropapillary. types with central necrosis and associated calcifications; DCIS spans entire. specimen (8cm in greatest dimension). F. Right breast, new inferior lateral margin, excision: - Ductal carcinoma in situ, intermediate grade, microscopic foci (largest 5mm). - Microscopic foci (each 1mm) of DCIS present at outer medial aspect of specimen. G. Right breast, new outer lateral margin, excision: - Ductal carcinoma in situ, rare microscopic foci (largest 1mm). - DCIS >1cm from nearest new margin. Breast Pathologic Parameters. 1. Invasive carcinoma: A. Microscopic measurement: Multifocal; largest focus (measures 1.3cm). B. Composite histologic (modified SBR) grade: III (largest focus). - Architecture: 2. - Nuclear grade: 3. - Mitotic count: 3. C. Associated intraductal carcinoma in situ (DCIS): - High grade, solid, cribriform and micropapillary types. - DCIS involves entire specimen and spans 8cm in greatest dimension. 2. Excisional biopsy margins: Positive. - DCIS present at medial margin, <1mm from anterior, posterior, lateral,. superior, and inferior margins (tumor approaches margins at multiple foci. throughout specimen). - Invasive carcinoma at inferior and 1mm from posterior margin; additional. margins greater than 2mm away. 3. Blood vessel and lymphatic invasion: Present in breast parenchyma. 4. Axillary lymph nodes: Positive (1/4). - Size of largest metastatic deposit: 13 mm. - Extranodal extension: absent. 5. Special studies. - ER: Weak expression in 10% of invasive tumor nuclei. - PR: No expression. - Her2/neu antigen (FISH): Amplified (ratio: 7.6). 6. pTNM (AJCC, 7th edition, 2010): pT1c(m), N1(sn), MX. Effective. is Checklist utilizes the 7th edition TNM staging. system for breast of the American Joint Committee on Cancer (AJCC) and the. International Union Against Cancer (UICC). has1. Interpretation performed by the Attending Pathologist and reviewed with the. Resident/Fellow. Clinical History: Patient is a. -year-old female with right breast IDC undergoing lumpectomy and. sentinel lymph node biopsy. Specimens Received: A: Sentinel lymph node #1. B: Sentinel lymph node #2. C: Sentinel lymph node #3. D: Non-sentinel lymph node. E: Right wire-guided lumpectomy. F: Right breast new inferior lateral margin. G: New outer lateral margin. Gross Description: The specimens are received in seven containers each labeled with the patient's. name and medical record number. A. The first container is additionally identified as, 'sentinel lymph node #1'. Received fresh and placed in formalin the specimen consists of a 1.5x1x1cm. lymph node which is serially sectioned and entirely submitted in cassette A1. B. The second container is additionally identified as, 'sentinel lymph node. #2'. Received fresh and placed in formalin the specimen consists of a 1x 0.5 X. 0.3 cm lymph node which is bisected and is entirely submitted in cassettes B1. C. The third container is additionallyidentified as, 'sentinel lymph node #3'. Received fresh and placed in formalin the specimen consists of a 0.7 x 0.3 x 0.3. cm lymph node which is entirely submitted in cassette C1. D. The fourth container is additionally identified as, 'non-sentinel lymph. node'. Received fresh and placed in formalin the specimen consists of a 0.5 X. 0.3 x 0.3 cm lymph node which is entirely submitted in cassette D1. E. The fifth container is additionally identified as, 'right wire guided. lumpectomy'. Received fresh on a radiographic grid is a 102 gm lumpectomy. specimen measuring 8 cm from medial to lateral, and 8 in cm from superior to. inferior and 3 cm from anterior to posterior. The specimen is oriented with a. short suture designating the superior pole and a long suture designating the. lateral pole. There is a wire entering the antero-lateral aspect of the specimen. through grid coordinate E5. Accompanying the specimen is an x-ray demonstrating. a metallic clip located in grid coordinate E3. There is a circled mass in grid. positions C3, C4, D3, D4, centered on the clip. The wire enters the specimen in. grid coordinates E5 terminates in E3. 2 other areas of calcifications are. circled in grid coordinates D6 (#2) and F4-F5 (#3). The margins are inked as follows: anterior - black;. posterior - red;. superior - blue;. inferior - green;. medial - yellow;. lateral - violet. The specimen is serially sectioned from medial to lateral into 8 slices. The. area of calcifications noted in grid D6 begins in the slides #2 and extends. laterally the tumor the main to mass and measures 3 X 2 x 1.5 cm. is found in. the slices #2 and 3 adjacent to the red and green ink. The main mass, which is. irregular and firm, is present in slices #5 to #7 and measures 3.5 X 2.5 X 2 cm. It is present adjacent to red ink and is 1 cm from black ink, 3 cm from green. ink, 1.5 cm away from blue ink. The area of calcification noted in grid F4 and. F5 is present in the slices numbers 7 and activated ink measuring 1.5 X 1.1 x 1. cm and is continuous with the main mass. The metallic clip is identified in. slice 6. The wire enters the specimen in slice 5 and terminates in slice 5. The. remainder of the breast parenchyma is white-yellow and lobulated with no. additional masses or lesions. Entire mass including both calcified area was has a largest dimension of 5 cm. Specimen is submitted in toto. Block summary: E1-E4: medial margin, slice 1. E5-E9: slice 2, area of calcification. E10-E23: slice 3, area of calcification. E24-E31: slice 4. E32-E44; slice 5. E45-E62: slice 6, clip in E49-E50. E63-E78: slice 7. E79-E86: lateral margin, slice 8. F. The sixth container is additionally identified as, 'right breast, new. inferior lateral margin'. Received fresh on the radiographic grid is a 13.5 gm,. 6.5 X 4 X 1.2 cm medial inferior lateral margin which is oriented as follows: - new outer lateral margin is marked with a long black stitch (violet). - new outer medial margin is designated with a short black stitch (yellow). - new outer anterior margin is designated with a short blue stitch (black). - new outer posterior margin is designated with a long blue stitch. (red). Inner cauterized margin is inked green. An area of calcification is noted on the. accompanying x-ray in grid D4-D5-E5. Specimen is a serially sectioned from. lateral to medial in to 14 slices. An area of calcification is present in slice. #6 and measures 1 X 0.5 X 0.3 cm. No other lesions are identified. The specimen. is entirely submitted from lateral to medial. F1: slice 1-3. F2: slice 4-5. F3: slice 6. F4: slice 7. F5-F6: slice 8. F7: slice 9. F8: slice 10. F9: slice 11. F10: slice 12. F11: slice 13-14. G. The seventh container is additionally identified as, 'new outer lateral. margin'. Received fresh ona radiographic grid is a 20 gm, 8 x 3.5 X 1 cm new. outer lateral margin. Specimen is oriented as follows. - new outer superior is designated with a short black stitch (blue). - new outer inferior is designated with a long black a stitch (green). - new outer anterior is designated with a short blue stitch (black). - new outer posterior is designated with a long blue stitch (red). Inner cauterized margin is inked violet. Specimen is serially sectioned from. lateral to medial into 14 slices and does not contain any distinct masses or. lesions. Specimen is submitted in toto in cassettes G1-14.",BRCA,1,True,The report indicates that there is metastatic ductal carcinoma found in one out of four examined lymph nodes (1/4). This satisfies the criteria for N1 staging according to the AJCC 7th edition staging system for breast cancer.,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.",8.0,761.0,84.0,True
525,TCGA-A2-A0YE.C58701EF-98C4-448E-978C-B39D125CC7E8,1,"SURGICAL REPORT. Sex: F. Date Collected: Date Received: M.R. Number. Doctor: Account Number. PRE-OPERATIVE DIAGNOSIS. RIGHT BREAST CA. POST-OPERATIVE DIAGNOSIS. RIGHT BREAST CA. PROCEDURE. RIGHT BREAST LUMPECTOMY WITH SENTINEL LYMPH NODE BIOPSY, F.S., POSSIBLE AXILLARY DISSECTION, POSSIBLE. CED INSERTION. TISSUES. A. LYMPH NODE (S) - RIGHT SENTINEL LYMPH NODE #1 FS. B. LYMPH NODE (S) - RIGHT SENTINEL LYMPH NODE #2 FS. C. LYMPH NODE (S) - RIGHT SENTINEL LYMPH NODE #3 FS. D. LYMPH NODE (S) - RIGHT SENTINEL LYMPH NODE #4. E. AXILLARY - CONTENTS. F. BREAST EXCISION, NEEDLE LOC, SIMPLE, MARGINS,ETC. - RIGHT BREAST. LUMPECTOMY. G. MARGINS - ADDITIONAL LATERAL. ADDENDUM. ESTROGEN AND PROGESTERONE RECEPTOR RESULTS: ESTROGEN RECEPTORS -. NEGATIVE (0%) IN THE MALIGNANT CELLS. PROGESTERONE RECEPTORS -. NEGATIVE (0%) IN THE MALIGNANT CELLS. Comment: Immunohistochemical (IHC) stains for Estrogen Receptors (ER) and Progesterone. Receptors (PR) display an appropriate staining pattern on control tissue. Revlewed and electronically signed outby: FS DIAGNOSIS. A. RIGHT SENTINEL LYMPH NODE #1, F.S. -. ONE NEGATIVE LYMPH NODE (0/1). B. RIGHT SENTINEL LYMPH NODE #2, F.S. -. ONE NEGATIVE LYMPH NODE (0/1). SURGICAL REPORT. C. RIGHT SENTINEL LYMPH NODE, #3, F.S. -. ONE POSITIVE LYMPH NODE (1/1). F. RIGHT BREAST LUMP (GROSS MARGINS) -. 4.7 CM. TUMOR MASS AND FOCALLY INVOLVING LATERAL SURGICAL MARGIN. (REPORTED TO SURGEON: Diagnosed by: FINAL DIAGNOSIS. A. RIGHT SENTINEL LYMPH NODE #1 -. LYMPH NODE, REACTIVE. B. RIGHT SENTINEL LYMPH NODE #2 -. LYMPH NODE, REACTIVE. C. RIGHT SENTINEL LYMPH NODE, #3 -. METASTATIC POORLY DIFFERENTIATED DUCTAL ADENOCARCINOMA IN THE. LYMPH NODE. THE METASTATIC TUMOR INVOLVES APPROXIMATELY 40% THE SIZE OF THE. OF THE NODE AND BEST SEEN IN THE CRYOSTAT SECTIONS WITH NO EXTRA-. CAPSULAR EXTENSION. D. RIGHT SENTINEL LYMPH NODE #4 -. LYMPH NODE, ONE REACTIVE. E. RIGHT AXILLARY CONTENTS. LYMPH NODES, TOTAL OF FIFTEEN REACTIVE LYMPH NODES. F. RIGHT BREAST LUMP. BREAST TISSUE DISPLAYING POORLY DIFFERENTIATED DUCTAL ADENOCARCINOMA. OF THE BREAST, HIGH GRADE (2+3+3), 47 MM. IN GREATEST DIMENSION. THE NEAREST MARGIN IS THE LATERAL MARGIN APPROXIMATELY 1 MM. ALL OTHER MARGINS ARE FREE. ASSOCIATED FIBROADENOMA OF THE BREAST. G. ADDITIONAL LATERAL MARGIN -. FIBROADIPOSE AND BREAST TISSUE, NO PATHOLOGIC CHANGE. PTNM CLASSIFICAITON: T2 N1 MX, STAGE IIB, DUCTAL ADENOCARCINOMA OF BREAST,. G3. PQRI CATEGORY II: 3260F. Diagnosed by: COMMENT. Patient Nams. SURGICAL REPORT. Pathology Numbe. This case is discussed with Dr. by Dr. Breast cancer prognostic. profile will be performed and reported separately. GROSS DESCRIPTION. The specimen is received in seven separate containers labeled. signated A. through E. A. The container is received fresh unfixed labeled ""right sentinel lymph node #1 for frozen section"". and consists of an ovoid mass of apparent fatty material measuring 1.5x 1 x 0.6 cm. Sectioning. reveals a 0.5 cm. pink-tan firm nodule. Touch prep and frozen section are obtained by Dr. The entire specimen including frozen section is submitted In two blocks. B. The container is received fresh unfixed labeled ""right sentinel lymph node #2 for frozen section"". and consists of an irregular mass of apparent fat which is 1 x 0.6 x 0.4 cm in greatest overall. dimenslon. Sectioning reveals a 0.8 cm. purple-tan firm nodule. Touch prep and frozen section. are obtained by Dr. The entire specimen Including frozen section Is submitted in two. blocks. C. The container is received fresh unfixed labeled ""right sentinel lymph node #3 for frozen section"". and consists of an irregular mass of apparent fat which is 1 x 0.4 x 0.4 cm. in greatest overall. dimension. Sectioning reveais a pink-tan nodule 0.5 cm. in greatest dimension. Touch prep and. frozen section are obtained by Dr. The entire specimen including frozen section is. submitted in two blocks. D. The container is received fresh unfixed labeled ""right sentinel lymph node #4 for frozen section"". and consists of an irregular mass of apparent fat which is 0.6 x 0.4x 0.3 cm. The specimen is. deferred for permanent. The entire specimen is submitted in one block. E. The container is received fresh unfixed labeled ""right axillary contents"" and consists of an. irregular mass of fat which is 4.5 x 4 x 3 cm. in greatest overall dimension. Sectioning reveais. purple-tan nodules varying up to 2 cm. in greatest dimension. The specimen is submitted in four. blocks. F. The container is received fresh unfixed labeled ""right breast lump"" and consists of a 57 gm. ovoid. mass of apparent fatty and fibrous-encased tissue measuring 6,5 x 5 x 5 cm. in greatest overali. dimension. Sectioning reveals a tumor mass which is 6x 5 x 5 cm. in greatest overall dimension. There are two short sutures indicating superior margin inked with red dye, inferior is inked yellow. There Is a single short suture Indicating anterior margin Inked with orange dye, deep is inked with. black. There is a single long suture indicating lateral margin inked with blue dye, medial is inked. green. Gross margins are observed by Dr. The tumor mass grossly appears to be 0.6. away from the superior, 1 cm. away from the inferior, 1.5 cm. away from the anterior, 1 cm. away. from the deep and grossly appears to Involved the lateral or less than 0.1 cm. from the lateral; is. approximately 0.4 cm. away from the medial. The specimen is submitted in ten blocks. Key Note Block Summary: 1-superior, 2-inferior, -anterior, 4-deep, 5-lateral, 6-. medial, 7 through 10-random. G. The container Is received fresh unfixed labeled ""additional lateral margin"" and consists of a 7 gm. irregular mass of apparent fatty tissue which is 3 x 2.5 x 2 cm. in greatest overall dimension. There is an attached suture indicating new lateral margin inked with black dye. Serial sectioning. reveals apparent fatty tissue. The entire specimen is submitted as six blocks. Pathology Numbr. SURGICAL REPORT. Pathology Numbe. MICROSCOPIC EXAM. MICROSCOPIO EXAMINATION CONDUCTED BY PATHOLOGIST CONFIRMS FINAL DIAGNOSIS. SPECIAL STAINS PERFORMED: ER, PR, Her-2 (IHC) (specimen F-2) -. Pathology Numbe. SURGICAL REPORT.",BRCA,1,True,"The report indicates that one out of four sentinel lymph nodes is positive for metastatic poorly differentiated ductal adenocarcinoma. This corresponds to N1 in the AJCC staging system, which indicates 1-3 positive lymph nodes.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.",8.0,761.0,100.0,True
1086,TCGA-BH-A1FU.58B02C83-2AF7-4978-A3F7-A8B9E0D914A1,0,"Procedure Date: Procedure Physician: Attending Physician/Copies To: PATIENT HISTORY: DATE OF LMP: DATE OF LAST DELIVERY: PRE-OP DIAGNOSIS: R BREAST CANCER. POST-OP DIAGNOSIS: SAME. OPERATIVE PROCEDURE: RIGHT MODIFIED RADICAL MASTECTOMY. CLINICAL HISTORY. MATERIAL SUBMITTED: RIGHT (MOD) RADICAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE. INTRAOPERATIVE CONSULTATION: FROZEN SECTION: Right breast measuring 18.0 by 17.0 by 5.2 cm with 16.0 by 6.3 cm skin and nipple and. partial axillary contents. A tan-white irregular mass measuring 1.8 by 1.0 by 1.2 Cm is identified 1.3 cm. from the deep resection margin. Mass lies in the center of the mass. FS Diagnosis: Infiltrating duct. carcinoma. ER/PRS taken. (1. Delow. FINAL DIAGNOSIS: RIGHT BREAST MASS AND AXILLARY CONTENTS: - MULTIFOCAL INVASIVE DUCTAL CARCINOMA, 1.8 BY 1.2 BY 1.0 CM., POOR NUCLEAR GRADE. - EXTENSIVE DUCTAL CARCINOMA IN-SITU, COMEDO TYPE. - VASCULAR PERMEATION SEEN. - SKIN, NIPPLE AND DEEP MARGINS FREE OF TUMOR. - FIVE (5) LYMPH NODES FREE OF TUMOR. - HEMORRHAGE AND HEMOSIDERIN LADEN MACROPHAGES CONSISTENT WITH BIOPSY SITES. - FIBROCYSTIC CHANGES. NOTE: Within the invasive tumor, the ductal carcinoma ;in-situ component is about 30%. S U P P L x M E N T R E P o R T. (HER2/NEU). My signature below is attestation that I have reviewed all slides and agree with the findings as noted. below. AS PER THE REQUEST OF. OF THE. c-erb82 (HER-2/NEU). DMMUNOSTAINING IS CARRIED OUT ON PREVIOUS MAGKE SURGICAS. BBOCK ""A4"" (BREAST CANCER) USING A 1:300. DILUTION of DAKO'S POLYCLONAL ANTIBODY A485 (DIRECTED AGAINST THE INTRACELLULAR DOMAIN OF c-erbB2) WITHOUT. ANTIGEN RETRIEVAL. DISTINCT COMPLETE MEMBRANE STAINING IS IDENTIFIED IN 90% OF TUMOR CELLS THEREFORE, c-. erbB2 (HER-2/NEU) IS INTERPRETED AS POSITIVE (SCORE 3+). SIGNED COPY ON FILE. s. (ER/PR). My signature below is attestation that I have reviewed all slides and agree with the findings as noted. below. IMMUNOPEROXIDASE IDENTIFICATION OF ESTROGEN AND PROGESTERONE RECEPTORS IS CARRIED OUT ON SLIDE. ""A4"". DISTINCT INTRANUCLEAR STAINING IS IDENTIFIED TOCALLY FOR PROGESTERONIS RECEPTOR (20%) BUT NOT FOR. ESTROGEN RECEPTOR. THEREFORE, PROGESTERONE RECEPTOR IS INTERPRITED AS BOR DERLINE AND ESTROGEN RECEPTOR AS. NEGATIVE.",BRCA,0,True,"The report states that five lymph nodes were examined and found to be free of tumor. According to the rules, if no malignancy is found in regional lymph nodes, the N stage is N0.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.",10.0,920.0,91.0,True
675,TCGA-A8-A09K.56C24ABB-CF1D-447F-A5A8-B762C4B01566,0,"Diagnosis: 4. Resected material from'l left breast segment with a 1.4 cm poorly differentiated (G3). invasive ductal breast carcinoma. Carcinoma-free resection margins, carcinoma-free skin. Fibrous mastopathy of surrounding tissue. Tumor stage: pTlc pN1mi (intranodal micrometastasis), MX, R0; G3 (L0, V0).",BRCA,1,True,"The report indicates a pN1mi (intranodal micrometastasis) stage, which corresponds to N1 according to the AJCC staging system. This is stated in the rule: 'N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.'","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.",11.0,994.0,96.0,True
1301,TCGA-E9-A226.7C8F01DC-9CD9-4D61-9032-BC9F28A687EE,1,"Laterality:Left, lower inner quadrant. Path Report: BREAST TISSUE CHECKLIST. Specimen type: Radical mastectomy. Specimen size: Not specified. Tumor site: Lower inner quadrant. Tumor size: 2.7 x 0 x 3.2 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal carcinoma. Histologic grade: Moderately differentiated. Tumor extent: Skin. Lymph nodes: 6/10 positive for metastasis (Axillary 6/10). Extracapsular invasion of the lymph nodes: Not specified. Margins: Uninvolved. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: None.",BRCA,2,True,"The report indicates that 6 out of 10 examined lymph nodes are positive for metastasis (Axillary 6/10). This corresponds to the N1 stage, as it falls within the range of 1-3 positive nodes.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.",11.0,994.0,100.0,True
1122,TCGA-D8-A1JF.03724E51-8430-414F-B483-2CB92D6A878F,0,page 1 / 1. copy No. Examination: Intraoperative examination. Cost of diagnostic procedure. Gender: F. Material: Lesion excision - Lesion in the left breast - outer upper quad. iterial received on. Expected time of examination: 20 minutes (from receipt of material). Clinical diagnosis: Cancer of the left breast. Result of intraoperative examination: Carcinoma invasivum. Macroscopic description: Fragment of the breast sized 6 x 5 x 2 cm. Tumour sized 1.2 x 0.8 x 0.7 cm in the middle. Minimum margin: 1 cm. Histopathological diagnosis: Carcinoma ductale invasivum NHG3 (3 + 3 + 2/10 mitoses/10 HPF - visual area 0.55 mm). pT1c. Invasive ductal carcinoma of the left breast. Results of immunohistochemical examination: No estrogen receptors found in neoplastic cell nuclei. No progesterone receptors found in neoplastic cell nuclei. HER2 protein stained with HercepTestâ„¢M by DAKO. Negative reaction in invasive cancerous cells ( Score = 1+.,BRCA,2,True,"The report does not mention any malignancy found in regional lymph nodes, and it explicitly states 'minimum margin: 1 cm', which implies that the lymph nodes were examined and found to be negative. Therefore, the N stage is N0.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.",12.0,1065.0,97.0,True
785,TCGA-AO-A03T.D5EF8C37-811E-42B7-84E5-E6ED71217971,1,"Clinical Diagnosis & History: Palpable left breast cancer showing IDC on core. Specimens Submitted: 1: SP: Sentinel node #1, level one, left axilla (fs). 2: SP: Sentinel node #2, level one, left axilla (fs). 3: SP: Sentinel node #3, level one, left axilla (fa). 4: SP: Left breast. 5: SP: Level one anu two lymph nodes left axilla. DIAGNOSIS: 1). LYMPH NODE, SENTINEL #1, LEFT AXILLA LEVEL I, BIOPSY: - METASTATIC CARCINOMA INVOLVING ONE OUT OF ONE LYMPH NODE (1/1). - NO EXTRANODAL EXTENSION SEEN. 2). LYMPH NODE. SENTINEL #2, LEFT AXILLA LEVEL I, BIOPSY: - ONE BENIGN LYMPH NODE (0/1). 3). LYMPH NODE, SENTINEL #3, LEFT AXILLA LEVEL I, BIOPSY: - METASTATIC CARCINOMA INVOLVING ONE OUT OF ONE LYMPH NODE (1/1). - NO EXTRANODAL EXTENSION SEEN. 4). BREAST, LEFT, TOTAL MASTECTOMY: - INVASIVE DUCTAL CARCINOMA, NOS TYPE, HISTOLOGIC GRADE III/III (SLIGHT. OR NO TUBULE FORMATION),. NUCLEAR GRADE II/III (MODERATE VARIATION IN. SIZE AND SHAPE), MEASURING 2.5 CM, GROSSLY. - DUCTAL CARCINOMA IN SITU (DCIS) IS ALSO IDENTIFIED, SOLID TYPE WITH. INTERMEDIATE NUCLEAR GRADE AND MODERATE NECROSIS. LOBULAR INVOLVEMENT BY DCIS IS PRESENT. - THE DCIS CONSTITUTES <= 25% OF THE TOTAL TUMOR MASS, AND IS PRESENT. ADMIXED WITH AND AWAY. FROM THE INVASIVE COMPONENT. - THE INVASIVE CARCINOMA IS LOCATED NI THE UPPER OUTER QUADRANT AND. CENTRAL AREA. - THE DCIS IS LOCATED IN THE UPPER OUTER QUADRANT AND CENTRAL AREA. - NO INVOLVEMENT OF THE NIPPLE BY EITHER IN SITU OR INVASIVE CARCINOMA. IS IDENTIFIED. VASCULAR INVASION IS PRESENT. - NO INVOLVEMENT OF THE SURGICAL MARGINS BY EITHER INVASIVE OR IN SITU. CARCINOMA IS IDENTIFIED. NO SKIN INVOLVEMENT BY CARCINOMA IS IDENTIFIED. - THE NON-NEOPLASTIC BREAST TISSUE SHOWS BIOPSY SITE CHANGES, STROMAL. FIBROSIS, ADENOSIS. AND FIBROCYSTIC CHANGES. - RESULTS OF SPECIAL STAINS (ARE AS FOLLOWS: Immunohistochemical stains were performed on formalin-fixed tissue with the. following results for invasive carcinoma (block 4 T 11). ESTROGEN RECEPTOR (6F11,. 95% nuclear staining with moderate intensity. PROGESTERONE RECEPTOR (1E2;. 60% nuclear staining with moderate intensity. HER2 (HercepTest; -. Negative (0 ). Controls are satisfactory. Comment: HercepTestTM. ) is an FDA-approved method for assessment of. HER2 protein overexpression in breast cancer tissue routinely processed for. histological evaluation. The HER2 test results are reported in accordance. with the ASCO/CAP guideline recommendations for HER2 testing in breast. cancer (J Clin Oncol 2007; 25 (1) :1-28) . 5). LYMPH NODES, LEFT AXILLA LEVELS I AND II, RESECTION: - NINE BENIGN LYMPH NODES (0/9). I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL), AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. Special Studies: Special Stain. Comment. NEG-HER2. Gross Description: 1) The specimen is received fresh for frozen section consultation, labeled. ""sentinel node number one level 1 left axilla"" and consists of a pink-tan. lymph node measuring 1.2 x 1.0 x 0.4 cm. Bisected and entirely submitted. for frozen section. Summary of sections: FSC -- frozen section control. 2) The snecimen is received fresh for frozen section consultation, labeled. ""sentinel node number two level 1 left axilla"" and consists of tan lymph. node measuring 1.0 x 0.5 x 0.5 cm. Bisected and entirely submitted for. frozen section. Summary of sections: FSC frozen section control. 3) The specimen is received fresh for frozen section consultation, labeled. ""sentinel node number three level 1 left axilla"" and consists of a tan lymph. node measuring 1.5 x 0.8 x 0.8 cm. Bisected and entirely submitted for. frozen section. Summary of sections: FSC - frozen section control. 4). The specimen is received fresh, labeled ""left breast stitch marks. axillary tail"" and consists of a breast measuring 21.5 x 17.5 x 4 cm with. overlying skin ellipse measuring 9.5 x 3 cm. Situated centrally on the skin. surface is an everted nipple measuring 1.5 x 1.2 x 0.8 cm and areola. measuring 3.4 x 2.5 cm. A suture demarcates the axillary aspect. The. posterior surface of the breast is inked black and the specimen is serially. sectioned to reveal a centrally located white-tan firm tumor measuring 2.5 x. 2.5 x 2 cm with extension into upper outer quadrant, and located 1.1 cm from. the deep margin. A metal clip marking the previous biopsy site is. identified. Sectioning of the axillary aspect reveals no grossly. identifiable lymph nodes. Representative sections are submitted. TPS. is. taken. Summary of sections: N - nipple. NB - nipple base. D - deep margin. BX - biopsy site with tumor. T - tumor. UIQ - upper inner quadrant. LIQ - lower inner quadrant. UOQ - upper outer quadrant. LOQ - lower outer quadrant. 5) The specimen is received fresh, labeled ""level 1 and 2 lymph nodes left. axilla"" It consists of a 8 x 8 x 1.5 cm fragment of fibroadipose tissue. without orientation. Multiple lymph nodes are identified, ranging in size. from 0.3 cm to 1.2 cm. All identified lymph nodes are submitted. Summary of sections: LN - whole lymph nodes. Summary of Sections: Part. 1: SP: Sentinel node #1, level one, left axilla (fs). Block. Sect. Site. PC's. 1. FSC. 1. Part 2: SP: Sentinel node #2, level one, left axilla (fs). Block. Sect. Site. PCs. 1. FSC. 1. Part 3: SP: Sentinel node #3, level one, left axilla (fs). Block. Sect. Site. PCs. 1. FSC. 1. Part 4: SP: Left breast. Block. Sect. Site. PCs. 5. BX. 5. 1. D. 1. 2. LIQ. 2. 2. LOQ. 2. 2. N. 2. 1. NB. 1. 7. T. 7. 20. TEST. 20. 2. UIQ. 2. 2. UOQ. 2. Part 5: SP: Level one and two lymph nodes left axilla. Block. Sect. Site. PCs. 4. LN. 9. Intraoperative Consultation: Note: The diagnoses given in this section pertain only to the tissue sample. examined at the time of the intraoperative consultation. 1). FROZEN SECTION DIAGNOSIS: METASTATIC DUCT CARCINOMA. PERMANENT DIAGNOSIS: SAME. 2). FROZEN SECTION DIAGNOSIS: BENIGN. PERMANENT DIAGNOSIS: SAME. 3). FROZEN SECTION DIAGNOSIS: METASTATIC DUCT CARCINOMA. PERMANENT DIAGNOSIS: SAME. M.D.",BRCA,1,True,"The report indicates that two out of the eleven lymph nodes examined were positive for metastatic carcinoma (sentinel nodes #1 and #3). This corresponds to N1 stage, as per the rule: 'N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.'","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.",13.0,1186.0,95.0,True
926,TCGA-B6-A0RI.F2B21F52-74F4-44C5-9991-60EBCC4E43A6,3,"Surgica. CLINICAL HISTORY: Not provided. GROSS EXAMINATION: Estrogen receptor tissue sent for estrogen and progesterone receptor. A. ""Tru-cut breast biopsy. Received fresh. The specimen is a 1 cm x 0.1. cm tan piece of breast tissue. This frozen as frozen section AF1. The. frozen section remnant consists of two pieces of tan tissue measuring 0.8. x. 0.1 x 0.1 and 0.7 x 0.1 x 0.1 cm. They are submitted in toto in Block A1. B. ""Right breast. Received fresh. The specimen consists of breast with an. overlying ellipse of skin. The overall dimensions of the specimen are 15 x. 11 x 2 cm with an attached axillary tail which in addition measures 7.8 x 3.5. cm. The skin ellipse measures 11.5 x 4 cm in greatest dimensions. And. contains a nipple at its center. The deep surgical margin is inked blue and. the lateral surgical margins are inked black. Several sections have been. made through the deep aspect of of the specimen revealing a 1.5 x 2.8 x 1.0. cm firm mass which radially retracts the adjacent breast tissue and which is. located approximately 0.2 cm from the deep surgical margin at one point. The. mass appears located in the upper outer quadrant of the breast. Further. sectioning through the specimen reveals unremarkable breast parenchyma in. areas away from the tumor. Material submitted for ER/PR. Block Summary: B1 and B2-Closest sections of tumor to the deep surgical margin inked blue. B3 and B4-Further sections of tumor to the deep surgical margin. B5-Section through the nipple. B6-Representative sampling from the upper inner quadrant. B7-Representative sampling of the lower inner quadrant. B8-Representative sampling of the upper outer quadrant. B9-Representative sampling of the lower outer quadrant. B10-Further sections through the lower outer quadrant. The axillary tail is dissected. Tumor margin has been marked with surgical. suture. These are present in zone 2 at the juncture with zone 1 and are. submitted separately in Block B11. B12-Sections of fat from zone 1 appear that no definite lymph nodes are. identified in zone 1. B13-Candidate lymph nodes from zone 2. B14, 15 and B16-Candidate lymph nodes from zone 3. INTRA OPERATIVE CONSULTATION: AF1 ""Tru-cut breast biopsy"": infiltrating ductal carcinoma. DIAGNOSIS: A. ""TRU CUT BREAST BIOPSY"": INFILTRATING DUCTAL CARCINOMA. B. ""RIGHT BREAST"": 1. INFILTRATING DUCTAL CARCINOMA, NSABP HISTOLOGIC GRADE 3, NUCLEAR. GRADE MODERATELY DIFFERENTIATED. THE TUMOR COMES WITHIN 0.2 CM. OF THE DEEP MARGIN GROSSLY. THE TUMOR SIZE IS 1.5 X 2.8 x 1.0 CM. VASCULAR INVASION IS PRESENT. THE TUMOR IS LOCATED IN THE UPPER. OUTER QUADRANT ONLY. 1 of 2. 2. SIX OF FIFTEEN LYMPH NODES CONTAIN METASTATIC CARCINOMA. AM. 2 of 2.",BRCA,1,True,"The report states that six out of fifteen lymph nodes contain metastatic carcinoma. According to the rules, N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes. Therefore, in this case, the N stage is N1.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.",13.0,1186.0,100.0,True
661,TCGA-A8-A092.93D66EAD-B7D3-4688-8EC9-75C4380619D9,1,Diagnosis: 5. Moderately differentiated invasive ductal carcinoma (tumor diameter: 3.8 cm) with. focal intraductal components and focal angioinvasion. NS.,BRCA,2,True,"The pathology report does not mention any malignancy found in regional lymph nodes. Therefore, based on the rule 'If no malignancy is found in regional lymph nodes, the N stage is N0', the N stage for this patient is N0.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.",13.0,1186.0,100.0,True
1290,TCGA-E9-A1R6.8A865E33-082A-454F-A6DF-89E994206E65,1,"OC ID: Gross Description: Lump with the tumor of 2.5 x 2.2 cm in size; fatty tissue lymph nodes demonstrate lipomatosis, hyperemia. Microscopic Description: Infiltrating duct carcinoma, G2. Ten dissected lymph nodes demonstrate sinus histeocytosis. Diagnosis Details: Tumor Features: Unknown, Tumor Extent: T2 tumor size more than 2cm not more than 5 cm, Venous Invasion: Absent,. Margins: Absent, Treatment Effect: Comments: BREAST TISSUE CHECKLIST. Specimen type: Lumpectomy. Specimen size: Not specified. Tumor site: Upper outer quadrant. Tumor size: 2.2 x 0x 2.5 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal carcinoma. Histologic grade: Moderately differentiated. Tumor extent: Not specified. Lymph nodes: 0/10 positive for metastasis (Axillary 0/10). Extracapsular invasion of the lymph nodes: Not specified. Margins: Uninvolved. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: None. Laterality: Right, upper outer quadrant.",BRCA,0,True,"The report indicates that 10 lymph nodes were examined and none of them were positive for metastasis (Axillary 0/10). This aligns with the rule that the N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.",13.0,1186.0,100.0,True
1335,TCGA-EW-A1IZ.F5EF4698-364C-4A5B-A8EC-1CF231BEEF31,1,"F. Pathologic Interpretation: A. Right breast short stich superior long lateral right single mastectomy: - Benign mammary parenchyma, no malignancy seen. B. Left breast and level I and II of axilla to tumor short superior, left lateral: - Invasive ductal carcinoma, Nottingham grade 3 (3+3+2), 2.8 cm in greatest linear dimension, focally presert at the. anterior specimen margin. - Ductal carcinoma in situ, high grade (DIN 3) solid type. - Organizing previous biopsy cavity. - Lymphovascular space invasion is present. - Metastatic carcinoma in four out of nine lymph nodes (4/9). - Receptors to follow. C. Additional fat above left breast tumor: - No malignancy seen in adipose tissue. D. Left level III axilla: - No malignancy seen in four lymph nodes (0/4). Tumor Summary (Invasive Carcinoma of the Breast): Specimen Type: Total breast (including nipple and skin). Procedure: Total mastectomy (including nipple and skin). Lymph Node Sampling: Axillary dissection (partial or complete dissection). Specimen Integrity: Single intact specimen (margins can be evaluated). Specimen Laterality: Left. Tumor Site: Lower outer quadrant; Lower inner quadrant. Tumor Size: Size of Largest Invasive Carcinoma: Greatest dimension of largest focus of invasion: 2.8 cm. Tumor Focality: Single focus of invasive carcinoma. Macroscopic and Microscopic Extent of Tumor: Skin: Invasive carcinoma does not invade into the dermis or epidermis. Nipple: DCIS does not involve the nipple epidermis. Skeletal Muscle: No skeletal muscle present. Ductal Carcinoma in Situ: DCIS is present. Architectural Patterns: Solid. Nuclear Grade: Grade III (high). Lobular Carcinoma in Situ: Not identified. Histologic Type of Invasive Carcinoma: Invasive ductal carcinoma (no special type or not otherwise specified). Histologic Grade: Glandular (Acinar)/Tubular Differentiation: Score 3. Nuclear Pleomorphism: Score 3. Mitotic Count: Score 2. Overall Grade: Grade 3. Margins: Uninvolved by invasive carcinoma. Distance from posterior margin: 2 cm. Uninvolved by DCIS (if present). Lymph-Vascular Invasion: Present. Dermal Lymph-Vascular Invasion: Not identified. Lymph Nodes: Number of sentinel lymph nodes examined: 0. Total number of lymph nodes examined (sentinel and nonsentinel): 13. Number of lymph nodes with macrometastases: 4. Size of largest metastatic deposit: 2.0 cm. Extranodal Extension: Not identified. SURGICAL PATHOL Report. Method of Evaluation of Sentinel Lymph Nodes: Hematoxylin and eosin (H&E), one level. Pathologic Staging (pTNM). TNM Descriptore: m (multiple foci of invasive carcinoma). Primary TumorÂ¿pT2. Regional Lymph Nodes: pN2. Distant Metastasis: Not applicable. Anciliary Studies: Estrogen Receptor: Pending. Progesterone Receptor: Pending. Her2: Pending. NOTE: Some immunohistochemical antibodies are analyte spectific reagents (ASRs) validated by our laboratory (Her 2, Pervo, H. pylori, HBcore). These ASRs are clinically indicators that do. not require FDA approval. These clones are used: ID5=ER, POR 636=PR, A485HER2, H-11=EGFR, CCH2/DDG9=CMV, F39.4 1=AR and HPV by ISH. All immunohistochemidelt stains are used. with formalin or molecular fixed, paraffin embedded fissue. Detection is by LSAB. The results are read by a pathologist as positive or negative. As the attending pathologist, / attest that 1: (i) Exemined the relevent. preperation(s) for the specimen(s); and (i) Rendered the diagnosis(es). Procedures/Addenda. Addendum. Date Complete: Addendum Diagnosis. The tumor cells are positive for ER and PR and negative for HER2 by immunohistochemistry. Immunohistochemistry for p63 was. used in the evaluation of the specimen. Clinical History: female with left breast cancer. Pre Operative Diagnosis: Left breast cancer. Specimen(s) Received: A: Right breast short stich superior long lateral right single mastectomy (fresh). B: Left breast and level 1 and Il of axilla to tumor short superior, left lateral (fresh). C: Additional fat above left breast tumor (perm). D: Left level III axilla (perm). Gross Description: A. Received fresh and labeled ""right breast short stich superior long lateral right single mastectomy (fresh)"" is a breast. specimen measuring 18.0 x 15.0 x 5.0 cm. It has a white-tan ellipse of skin measuring 4.0 x 1.0 cm. The nipplÃ© measures. 1.0 x 1.0 cm. The skin is unremarkable and nipple is unremarkable. Deep margin is smooth, facial plane without any. SURGICAL PATHOL Report. skeletal muscle. Deep margin is inked in black. Serial sectioning of the mastectomy specimen does not reveal any gross. lesion. Specimen submitted as follows: 1&2. Sections from upper outer quadrant. 3&4. Representative section from lower outer quadrant. 5&6. Representative section from upper inner quadrant. 7&8. Representative section from lower inner quadrant. 9&10. Representative section from central quadrant. 11. Representative section from nipple. B. Received fresh and labeled ""left breast and level 1 and II of axilla to tumor short superior, left lateral (fresh)"" is a. mastectomy specimen measuring 19.0 x 17.0 x 3.0 cm. It has a white-tan ellipse of skin measuring 2.5 x 2.0 cm. The. axillary tail measures 13.0 x 9.0 cm. The skin and nipple are unremarkable. Deep margin is smooth, facial plane without. any skeletal muscle. Deep margin is inked black, superior margin is inked blue, medial margin is inked red and inferior. margin is inked green. Serial sectioning of the mastectomy specimen reveals a 2.8 x 2.0 x 1.5 cm firm gray mass located. in the lower outer quadrant, less than 0.1 cm from the inked anterior specimen margin. There is also a 1 x 1 1 cm. mass. in the lower inner quadrant. The mass is well defined. It has a clip in it. in the upper inner quadrant, there is an area of. necrosis measuring 2.0 x 2.0 x 1.0 cm. it is brown in color and soft in consistency. Remainder of the breast parenchyma is. predominantly white and firm with small cyst measuring up to 0.3 cm in greatest dimension. The axillary tail is yellow and. soft. There are 13 possible lymph nodes. The largest measures 3.0 cm in greatest dimension. Sections submitte as. follows: 1-8. Mass in the lower inner quadrant. 9&10. Area of necrosis. 11&12 Representative section from upper outer quadrant. 13&14 Representative section from lower outer quadrant. 15&16 Representative section from upper inner quadrant. 17&18 Representative section from lower inner quadrant. 19820. Representative section from the central quadrant. 21. Representative section from the nipple. 22-24. Contains representative section from the largest lymph node. 25-37. One fymph node per cassette. 38-41. Additional section of mass in lower outer quadrant. C. Received in formalin and labeled ""additional fat above left breast tumor"" is a soft fragment measuring 2.5 x 1.0x 1.0 cm. Submitted in toto in three cassettes. D. Received in formalin and labeled ""left level III axilla"" is a pale yellow, soft tissue fragment measuring 4.0 x 3.0 x 2.0 cm. Four possible lymph nodes are bisected and submitted in toto in four cassettes. ICD-9(s);. 174.5 174.3 196.3.",BRCA,2,True,"The report states that there are 13 lymph nodes examined in total, out of which 4 have metastatic carcinoma. This corresponds to the N2 stage, as per the rule: 'The N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.'","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.",N2,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.",13.0,1186.0,100.0,True
1392,TCGA-GM-A3XG.E76B5204-99E5-42D0-AE7E-ED5525796CCB,2,"MODIFIED REPORT - REVIEW ADDEN. DIAGNOSIS. (A) RIGHT AXILLARY SENTINEL LYMPH NODE #1, BIOPSY: METASTATIC CARCINOMA IN ONE LYMPH NODE. LARGEST FOCUS OF METASTATIC CARCINOMA MEASURES 2.5 MM IN GREATEST DIMENSION. FOCAL EXTRANODAL EXTENSION IS PRESENT. CYTOKERATIN IMMUNOSTAINING CONFIRMS THE PRESENCE OF METASTATIC CARCINOMA. (B) RIGHT AXILLARY SENTINEL LYMPH NODE #2, BIOPSY: METASTATIC CARCINOMA IN ONE LYMPH NODE. LYMPH NODE METASTASIS MEASURES 5 MM IN GREATEST DIMENSION. Extranodal extension is not identified. CYTOKERATIN IMMUNOSTAINING CONFIRMS THE PRESENCE OF METASTATIC CARCINOMA. (C) RIGHT AXILLARY SENTINEL LYMPH NODE #3, BIOPSY: One lymph node, no tumor present. Cytokeratin immunostaining ie negative for metastatic carcinoma. (D) RIGHT-BREAST, MASTECTOMY: INVASIVE LOBULAR CARCINOMA, LOW NUCLEAR GRADE WITH AREAS OF INTERMEDIATE NUCLEAR GRADE,. NOTTINGHAM HISTOLOGIC GRADE 2. INVASIVE CARCINOMA EXTENDS OVER AN AREA OF APPROXIMATELY 8 CM, PREDOMINATELY IN THE. SUPERIOR CENTRAL PORTION OF THE BREAST. Definitive lymphovascular is not identified. INVASIVE CARCINOMA IS PRESENT 3 MM FROM THE SUPERIOR SUPERFICIAL MARGIN (FROZEN SECTION),. AND AT LEAST 1 CM FROM OTHER MARGINS. LOBULAR CARCINOMA IN SITU (CLASSIC TYPE), WITH INVOLVEMENT OF DUCTS INCLUDING NIPPLE DUCTS. Fibrocystic changes including ductal hyperplasia without atypia, apocrine metaplasia. Intraductal papilloma and columnar cell change. One lateral lymph node, no tumor present. (E) RIGHT AXILLARY CONTENTS, DISSECTION: METASTATIC CARCINOMA IN ONE OF SEVENTEEN LYMPH NODES. LARGEST FOCUS OF METASTATIC CARCINOMA MEASURES 3.0 MM IN GREATEST DIMENSION. Extranodal extension is not identified. Additional four lymph nodes, pending cytokeratin immunostain. (F) ADDITIONAL LEVEL Il LYMPH NODE, EXCISION: One lymph node, no tumor present. (G) ADDITIONAL LEVEL I NODE, EXCISION: One lymph node, no tumor present. (H) LEFT BREAST, MASTECTOMY: Atypical lobular hyperplasia with involvement of ducts. Fibrocystic changes including sclerosing adenosis, ductal hyperplasia without atypia and apocrine metaplasia. Nipple, no tumor present. COMMENT. In specimen D, the main focus of invasive carcinoma measures approximately 6 cm in greatest dimension, with multiple. surrounding microscopic foci. The entire area involved by invasive carcinoma is approximately 8 cm. Cytokeratin immunostaining performed on sections E1, E4 and E8 confirms the presence of metastatic carcinoma in one lymph. node (section E8). GROSS DESCRIPTION. (A) SENTINEL LYMPH NODE #1, RIGHT AXILLARY,. - One pale-pink lymph node, 1.0 x 0.8 x 0.6 cm. The specimen is serially sectioned and entirely submitted for frozen section evaluation. FS/DX: METASTATIC CARCINOMA (AT LEAST 2.5 MMY. (B) SENTINEL LYMPH NODE #2, RIGHT AXILLARY,. - One pale-gray possible lymph node, 2.0 X 1.4 x. 0.4 cm. The lymph node is serially sectioned and entirely submitted in B1 and B2 for frozen section evaluation. FS/DX: METASTATIC CARCINOMA. (C) SENTINEL LYMPH NODE #3, RIGHT AXILLARY,. - One pale-pink lymph node, 2.0 X 0.7 X 0.5 cm. The lymph node is serially sectioned and entirely submitted in C for frozen section evaluation. FS/DX: NEGATIVE FOR CARCINOMA. (D) RIGHT BREAST, STITCH MARKS 12 O'CLOCK - SPECIMEN X-RAY, IMMEDIATE - One skin sparing total mastectomy. specimen. (19 x 18.5 x 3.5 cm) with an unremarkable areola (4.1 cm) and nipple (1.5 cm) with a stitch to mark 12 o'clock. The. specimen is inked and serially sectioned from lateral to medial into thirteen slices with nipple at slice #8. Located at slice #6 to. slice. #8,. there. is one pale-gray, firm, ill-defined nodule (4.0 X 2.0 x 2.0 cm), located at approximately 12 o'clock position, 4.0 cm. from. the. nipple,. 1.0. cm from the closest superior superficial margin. Adjacent to the nodule there is one firm area at slice #6 and. #7, approximately 2-cm in largest dimension, inferior from the nodule. One cyst (3.0 x 1.7 x 1.3 cm) is identified at slice #7 and. slice #8 adjacent to the nodule. The specimen is x-rayed after sectioning and multiple radiographic interest areas are identified at. slice #1 inferior portion, slice #6 to slice #8, central to inferior portion with a clip at slice #6, central portion. A portion of normal. tissue and tumor is submitted for tumor bank. INK CODE: Blue - superior, orange - inferior, black - deep. SECTION CODE: D1, D2, slice #6, superior portion, close to the areola, frozen section evaluation; D3, slice #8, the. nipple serially sectioned; D4, slice #8, base of nipple; D5, slice #8, fibrous tissue beneath the nipple; D6, slice #1, inferior portion. radiograph. interest area intramammary lymph node bisected; D7, lateral margin, perpendicular close to the intramammary lymph. node; D8, slice #3, central portion, fibrous area; D9, slice #3, superior portion; anterior from D8 with superficial superior margin;. D10,. slice. #3,. central. portion, fibrous area; D11, slice #3, inferior portion, fibrous area; D12, slice #4, central portion, fibrous tissue;. D13,. slice. #4,. central portion, inferior from D12, fibrous tissue; D14, slice #5, central portion, section adjacent to the lesion at slice. #6; D15, slice #5, central to inferior portion, fibrous tissue, section adjacent to the lesion at slice #6; D16, slice #6, central portion. the. nodule. area,. associated. with the clip; D17, slice #6, deep margin close to the nodule; D18, slice #6, central to inferior area,. fibrous tissue, associated with nodule; D19, slice #6, central to inferior area with the superficial inferior margin; D20, slice #7,. central. to. superior. portion, representative section of the nodule; D21, slice #7, central portion, fibrous tissue, associated with the. cyst;. D22,. slice #7, inferior portion, fibrous area; D23, slice #7, inferior portion with inferior margin; D24, slice #8, central portion,. radiograph. interest. area. associated with the nodule; D25, slice #8, superficial superior margin, close to the nodule; D26, slice #8,. central. portion,. fibrous. tissue, close to the nipple; D27, slice #8, inferior portion, fibrous tissue; D28, slice #8, inferior portion, with. the. inferior. margin,. close. to the D27; D29, slice #8, inferior portion, radiograph interest area; D30, slice #9, central portion, section. adjacent to the lesion at slice #8; D31, slice #10, central portion, fibrous area; D32, slice #7, superior portion, upper outer. quadrant. FS/DX: INVASIVE CARCINOMA, 3 MM FROM INKED MARGIN. (E) RIGHT AXILLARY CONTENTS - One pink-yellow fibroadipose tissue (9.0 x 5.5 x 3.4 cm) with multiple lymph nodes ranging. from 0.4 x 0.3 x 0.3 cm to 2.8 x 1.4 x 0.9 cm. The lymph nodes are entirely submitted. SECTION CODE: E1-E7, each containing four possible lymph nodes; E8, three possible lymph nodes; E9,E10, each. containing one lymph node serially sectioned; E11, E12, one lymph node serially sectioned. (F). ADDITIONAL LEVEL Il NODE, RIGHT AXILLA - One pale-gray fibroadipose tissue (2.2 X 1.3 X 0.4 cm) with two possible. lymph nodes, 0.5 x 0.4 x 0.4 cm, 0.6 x 0.3 x 0.2 cm. The lymph nodes are entirely submitted in F. (G). ADDITIONAL. LEVEL I NODE - One pale-gray tissue fragment, 2.2 x 1.2 x 0.6 cm with two possible lymph nodes, 0.5 x 0.4 x. 0.4 cm, 0.5 x 0.2 X 0.2 cm. Lymph nodes are entirely submitted in G. (H) LEFT BREAST, STITCH MARKS 12 O'CLOCK - One skin sparing total mastectomy specimen (21.0 X 15.5 x 3.0 cm) with an. unremarkable areolar (4.0 cm) and nipple (1.6 cm) with a short stitch to mark 12 o'clock. The specimen is inked, serially sectioned. from medial to lateral into twelve slices with the nipple at slice 6. No nodule identified at the cut surface. A pale-gray ill-defined. central. fibrous. area is identified at slice 5 through slice 10. Multiple cysts ranging from 0.2 to 0.7 cm in largest dimension are. identified. The specimen is representatively submitted. INK CODE: Blue - superior; orange - inferior; black - deep. SECTION CODE: H1, nipple; H2, base of nipple; H3, fibrous tissue beneath the nipple; H4, slice 8, representative of the. cyst;. H5,. slice. 2,. upper inner quadrant; H6, slice 5, upper inner quadrant; H7, slice 3, lower inner quadrant; H8, slice 5, lower inner. quadrant; H9, slice 7, upper outer quadrant; H10, slice 9, upper outer quadrant; H11, slice 9, lower outer quadrant; H12, slice 11,. lower outer quadrant; H13, slice 7, representative section of the central fibrous area. CLINICAL HISTORY. Right breast cancer. SNOMED CODES. T-04050, M-85203, M-85202, T-C4710, M-85206. ""Some tests reported here may have been developed and performance characteristics determined by. These tests have not been. specifically cleared or approved by the U.S. Food and Drug Administration."". Start of ADDENDUM. ADDENDUM. For HER-2/neu FISH results, please see &. for accession number. END OF REPORT-.",BRCA,1,True,"The report indicates that there are 17 lymph nodes in the right axillary contents, and metastatic carcinoma is found in one of them, with the largest focus of metastatic carcinoma measuring 3.0 mm in greatest dimension. This information is sufficient to determine the N stage, which is N1 according to the AJCC staging system.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
Micrometastasis is considered a positive lymph node and classified as N1.
The N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.",13.0,1186.0,59.0,False
773,TCGA-AN-A0XR.1351520E-9B6A-4F06-B631-DF374396C7E6,1,Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: OCT. Container: block Type of Procurement: surgery Grade: 2. T Stage: 2 N Stage: 2b M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.,BRCA,2,True,"The N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes. According to the report, the N Stage is 2b, which corresponds to 4-9 positive lymph nodes, making the N stage N2.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.
Substaging information is not considered in determining the N stage.",N2,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.
Substaging information is not considered in determining the N stage.",14.0,1255.0,97.0,True
588,TCGA-A7-A3IY.63F5F3D8-6393-4DA7-BB74-7D587199D7FD,0,"Final Surgical Pathology Report. Procedure. Diagnosis. A. Breast, right, excisional biopsy: Invasive mucinous carcinoma,. Nottingham grade 1. Note: The inked margins are negative for malignancy. Carcinoma is. focally 0.3 mm from the superior margin. B. Breast, right, new lateral margin, biopsy: Fibrocystic changes. Negative for malignancy. C. Sentinel lymph node, biopsy: A single lymph node is negative for. malignancy. Microscopic Description: A. Invasive carcinoma: Histologic type: Mucinous carcinoma. Nottingham grade: 1. Architectural score: 1. Nuclear score: 1-2. Mitotic score: 1. Mitotic index: 1 mitoses/ 10 HPFs (1 HPF = 1.96 sq. mm). Tumor size: 1.3 cm. Specimen margins: Negative for malignancy. Carcinoma is focally. 0.3 mm from the yellow (superior) inked margin in block. A1. Vessel invasion: Absent. Calcification: Absent. Non-tumorous breast: Fibrocystic changes including apocrine. metaplasia, cyst formation, intraductal epithelial. hyperplasia without atypia, columnar metaplasia, benign. calcification and intraductal papilloma. TNM stage: Tlc. Prognostic markers: See previous biopsy. B. sections of the right breast lateral margin specimens show focally. florid intraductal epithelial hyperplasia without atypia and other mild. fibrocystic changes. The specimen is negative for malignancy. C. A single lymph node is negative for malignancy. [At the request of some staff oncologists and in keeping with the. opinion of some experts in breast pathology, immunohistochemical stains. for keratin were not used on the sentinel lymph node sections in this. case. These stains can be obtained if desired. Our paraffin blocks. are. retained for 10 years. (Weaver DL et al. New Engl J Med 364:412,. 2011. Schwartz GF et al. Cancer 94 (10):2542, 2002)]. Specimen. A. Right breast tissue long lateral short superior. B. Right breast lateral margin. C. Sentinel lymph node. Clinical Information. Mucinous carcinoma. Gross Description. The specimen is received unfixed in a Transpec container labeled right. breast tissue long lateral short superior it consists of a yellow piece. of soft tissue measuring 6.3 by 4.6 cm. The external surface the. specimen is inked as indicated below. Anterior: Red. Posterior: Orange. Lateral: Blue. Medial: Green. Superior: Yellow. Inferior: Black. There is a palpable mass in the specimen measuring 1.5 cm in diameter. the external palpation on cut section the mass 1.3 cm in diameter and. has a mucoid appearance. A portion of the tumor is taken for research. purposes. Sections after fixation. R$8. Received unfixed labeled right breast new lateral margin short anterior. long lateral is a piece of yellow and red soft tissue measuring 6.2 x. 2.5 x 1 cm. The external surface the specimen is exhibited below. Anterior: Red. Posterior Orange. Lateral: Blue. Medial: Green. Superior: Yellow. Inferior: Black. Sections after fixation. RS7. Specimen C. is received in formalin labeled central lymph node and. consists of a piece of yellow soft tissue measuring 3 x 2.5 x 0.6 cm. AS-2.",BRCA,0,True,"The report states that a single sentinel lymph node was negative for malignancy. This is consistent with an N0 stage, which indicates no positive lymph nodes.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.",13.0,1186.0,97.0,True
1178,TCGA-D8-A3Z6.A8F63D86-37DF-472E-AF29-FB734EAB7E5C,2,": XXX. Examination result. Clinical diagnosis (suspicion): Cancer of the left breast. Date of admission: (urgency: Standard). Material: 1) Material: left breast and axillary tissue. Method of collection: Total organ resection. Histopathological diagnosis: Invasive, multifocal labular carcinoma of the left breast. Cancer metastases to axillary lymph nodes (19/22) (NHG2, pT3, pN3a). Macroscopic description: Left breast, sized 27.4 x 15.4 x 6.8 cm, removed without axillary tissues sized 10x11x5 cm and with a skin flap of. 20.2 x 8.2 cm. Tumour sized 6.2 x 3.6 x 4.8 cm found in the central part, placed 1.4 cm from the upper boundary, 0.8 cm from the. base and 0.6 cm from the skin. State after removal of a tumour fragment. Lymph nodes of 3.3 cm in length. Microscopic description: Invasive multifocal lobular carcinoma (histocytoid type) - NHG2 (3 + 3 + 1/5 mitoses/ 10 HPF - vision area 0,55. mm). Ductal carcinoma in situ (solid type, with high nuclear atypia and comedo necrosis, 10% of the tumour). The nipple. without pathological lesions. Glandular tissue showing fibrocytoid lesions adenosis. Axillary lymph nodes: Cancer metastases to axillary lymph nodes. (19/22). Signs of perilymphatic invasion.",BRCA,3,True,"The report states that there are cancer metastases to axillary lymph nodes, with 19 out of 22 lymph nodes being positive. This corresponds to the N3 stage, which is defined as 10 or more positive lymph nodes.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.",N3,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.",13.0,1186.0,100.0,True
998,TCGA-BH-A0DH.79B22278-2BA1-4904-BCA6-2B1368C77475,1,"To: P.9/33. OIAGNOSIS: f: AXILLARY CONTENTS. LEFT. RESECTION -. A. METASTATIC ADENOCARCINOMA (1H, 1Q-1R and 13-1T) INVOLVING THREE OF TWENTY-EIGHT LYMPH. NODES (3/28), UP TO 1.5 CM (1R). WITH EXTRACAPSULAR EXTENSION (0.2 CM). B. CHANGES CONSISTENT WITH PREVIOUS FINE NEEDLE ASPIRATION SITE, SEE PRIOR. PART 2: BREAST. LEFT. SEGMENTAL MASTECTOMY -. A. INFILTRATING OUCIAL CARCINOMA (ZA thru 21, 2M thru 20 and 2S), WITH ASSOCIATED. MICROCALCIFICATIONS. THE INVASIVE TUMOR INVOLVES THE POSTERIOR RESECTION MARGIN (2A),. THE INFERIOR RESECTION MARGIN (2F, 2N and 20), AND COMES TO WITHIN 0.2 CM FROM THE ANTERIOR. RESECTION MARGIN (2H). B. THE TUMOR SIZE IS 3.5 2.5 x 1.7 CM. C. NOTTINGHAM SCORE 6/9 (TUBULES 3. NUCLFI 2, MITOSIS 1). D. LYMPHOVASCULAR INVASION IS PRESENT. E. DUCTAL CARCINOMA IN SITU, SOUD AND CRIBRIFORM TYPES, NUCLEAR GRADE 2, WITH. COMEDONECROSIS, ASSUCIATED MICROCALCIFICATIONS AND RETROGRADE CANCERIZATION OF. LOBULES, REPRESENTING ABOUT 2% OF TUMOR VOLUME. F. DUCTAL CARCINOMA IN SITU IS PRESENT ADMIXED WITH INVASIVE TUMOR. G. ALL OTHER MARGINS OF RESECTION ARE FREE OF TUMOR. H. ATYPICAL DUCTAL HYPERPLASIA. I. DUCTAL PAPILLOMAS. J. RADIAL SCARS WITH DUCTAL EPITHELIAL HYPERPLASIA AND COLUMNAR CELL CHANGES,. K. PROLIFERATIVE FIBROCYSTIC CHANGES WITH DUCTAL EPITHELIAL HYPERPLASIA, COLUMNAR CELL. CHANGE8 AND MULTIFOCAL SCLEROSING ADENOSIS WITH ASSOCIATED MICROCALCIFICATIONS. L. CHANGES CONSISTENT WITH PREVIOUS BIOPSY SITE, SEE PRIOR. M. IMMUNOHISTOCHEMICAL STAINING FOR ESTROGEN RECEPTOD D. ICRUME RECEPTOR AND HER. 2/NEU WERE PREVIOUSLY PERFORMED ON CORE BIOPSY. AND WERG REPORTED AS. FOLLOWS: ESTROGEN RECEPTOR - POSITIVE, PROGESTERONE RECEPTOR - POSITIVE AND HER-2/NEU. NEGATIVE (SCORE 0). PART 3: BREAST, LEFT, NEW POSTERIOR-LATERAL MARGINS, EXCISION -. A. MICROSCOPIC FOCUS OF INVASIVE DUCTAL CARCINOMA (3E), COMING TO WITHIN 0.3 CM FROM THE. NEW INKED RESECTION MARGIN (9ce comment). B. ATYPICAL DUCTAL MYPERPLASIA. c. DUCTAL PAPILLOMA. D. RADIAL SCARS WITH DUCTAL EPITHELIAL HYPERPLASIA AND ASSOCIATED MICROCALCIFICATIONS. E. PROLIFERATIVE FIBROCYSTIC CHANGES. CHANGES AND EXTENSIVE SCLEROSING ADENOSIS WITH ASSOCIATED MULTIFOCAL. MICROCALCIFICATIONS. F. MEDIAL CALCIFICATIONS OF BLOOD VESSEL. G. NEW RESECTION MARGINS ARE FREE OF TUMOR. CASE SYNOPSIS: SYNOPTIC PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Segmentel. SIZE OF TUMOR: Not specified. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: Maximum dimension invasivo component: 3.5 cm. TUMOR TYPE (Invanive componant): Ductal adenocarcinoine. NOS. NOTTINGHAM SCORE: Nuclcar grade: 2. Tubule formation: 3. Mitotic activity scoie: 1. Total Nottingham score: A. ANGIOLYMPHATIC INVASION: Nollingham grede (1. 2, 3). 2. DERMAL LYMPHATIC INVASION: Not applicable. Yes, benign zones. TUMOR TYPE. IN SITU: Yes. malignent zones. Cribriform. Solld. DCIS admixod with invasivo cancinoma. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Percent of tumor occupied by In situ component: 2 %. Yes, diffuse. SURG MARGINS INVOLVED BY IN SITU COMPONENT: LYMPM NODES POSITIVE: 3. LYMPH NODES EXAMINED: 28. METHOD(S) OF LYMPM NODE EXAMINATION;. H/E stuin. SENTINEL NODE METASTASIS: SIZE OF NODAL METASTASES: Diameter of targuet lymph node metastaus: 15 min. LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: T STAGE, PATHOLOGIC: NON-NEOPLASTIC BREAST TISSUE: ADH, Redial scar, Papillonn, FCU. pT2. N STAGE, PATHOLOGIC: pN1a. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTOR9: positive. HER2/NEU: zoro or 1+.",BRCA,1,True,"The report states that there are 3 positive lymph nodes out of 28 examined (3/28). According to the rules provided, this would correspond to an N1 stage, as N1 indicates 1-3 positive nodes.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.",13.0,1186.0,100.0,True
656,TCGA-A8-A08T.5780D50C-5BF0-4392-BC9B-894D1369866A,1,"Diagnosis: ). Two foci of a moderately differentiated invasive ductal carcinoma. (tumor diameters: 3 cm and 2 cm) with focal intraductal components and. circumscribed angioinvasion. No infiltration or ulceration of the skin. Tumor classification: NOS, G II, pT2(mult)N1aL1VOM1RO.",BRCA,1,True,"The report indicates that this is a moderately differentiated invasive ductal carcinoma with a primary tumor size of 3 cm and 2 cm (pT2(mult)), and there is lymph node metastasis (N1a). The N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes. In this case, N1a indicates that 1-3 lymph nodes are positive, so the N stage is N1.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.",13.0,1186.0,100.0,True
1482,TCGA-OL-A66K.8A19AA55-9B1F-4325-B730-068F928F1C13,1,"FINAL PATHOLOGIC DIAGNOSIS. A. Right axillary sentinel node #1: - One lymph node, negative for metastatic carcinoma (0/1)(HE and CKAE1/AE3). B. Right axillary sentinel node #2: - One lymph node, negative for metastatic carcinoma (0/1)(HE and CKAE1/AE3). C. Right breast, simple mastectomy: - Invasive lobular carcinoma, SBR grade II, multicentric, see breast pathologic. parameters. - Lobular carcinoma in situ and atypical lobular hyperplasia. - Margins of resection are negative, distance to the closest margin. (anterior-inferior) is > 1.5 mm for invasive carcinoma, see comment. - Previous biopsy sites identified. - Intraductal hyperplasia, usual type. - Ectatic ducts. - Apocrine metaplasia. - Nipple focally involved by LCIS. - Skin with scar, negative for malignancy, see comment. D. Skin; lateral corner, excision: - Skin and subcutaneous tissue, no evidence of malignancy. Breast Pathologic Parameters. 1. Invasive carcinoma: Three mass lesions: A. Gross measurement: a) 9:30 to 10:30 position: 4.4 cm. b) 8:30 position: 2 cm. C) 4:00 position: 1 cm. B. Composite histologic (modified SBR) grade: Il. - Architecture: 3. - Nuclear grade: 2. - Mitotic count: 1. C. Associated intraductal carcinoma in situ (LCIS): - Within main masses (forming 10 % of tumor volume). - Extending away from main masses. 2. Excisional biopsy margins: Free of tumor. - Invasive carcinoma > 1.5 mm from anterior-inferior (closest) margin. (lesion C). - Additional margins from lesions A and B are > 2 mm away. 3. Blood vessel and lymphatic invasion: Highly suspicious in breast parenchyma. 4. Nipple: focally involved by LCIS. 5. Skin: uninvolved. 6. Skeletal muscle: absent. 7. Axillary lymph nodes: Negative (0/2). 9. Special studies (see outside case. biopsy of upper outer and lower. inner quadrant): - ER: Moderate in > 75% of invasive tumor nuclei. - PR: Strong expression in > 90 % of invasive tumor nuclei. - Her2/neu antigen (IHC): 2+, equivocal. - Her2/neu antigen (FISH): pending on block C7 (9:30 to 10:30 position). 10. pTNM (AJCC, 7th edition, 2010): pT2(m), No(sn), MX. Effective. this Checklist utilizes the 7th edition TNM staging. system for breast of the American Joint Committee on Cancer (AJCC) and the. International Union Against Cancer (UICC). Clinical History: The patient is a year old female with a history of invasive lobular carcinoma. grade 2 of 3 and lobular carcinoma in-situ of the right breast. She undergoes. right simple mastectomy and sentinel lymph node biopsy. Comment. C. CKAE1/AE3 is negative in the skin section with scar. Myosin heavy chain. performed on C12 reveals absence of a myoepithelial cell layer supporting. invasive carcinoma. Specimens Received: A: Right axillary sentinel node #1. B: Right axillary sentinel node. C: Right breast. D: Skin; biopsy. Gross Description: Received are four containers, each labeled with the patient's name and medical. record number. A. Container A is further designated '1. Right axillary sentinel node #1. Received fresh for frozen section diagnosis is a 3 X 1.5 X 1 cm lymph node which. is bisected and entirely frozen. Frozen section diagnosis is 'one lymph node. negative for tumor' by Dr. The frozen section remnant is submitted. entirely in cassettes A1-A2FS. B. Container B is further designated '2. Right axillary sentinel node #2. Received fresh and placed in formalin is a 0.9 X 0.8 x 0.4 cm blue lymph node. which is submitted entirely incassette B1. C. Container C is further designated '3. Right breast, double short stitch. superior, double long stitch lateral.' Received fresh is a 1,259 gm mastectomy. specimen measuring 30 cm from medial to lateral, 21 cm from superior to. inferior, and 8 cm from anterior to posterior. There is a short stitch marking. the superior edge and a long stitch marking the lateral edge. There is a 25.5 x. 14.5 cm ellipse of pink-tan skin with a 4.1 cm areola and a 1.1 cm nipple. The. anterior-superior margin is inked in blue, the anterior-inferior margin is inked. in green, and the posterior/deep margin is inked in black. The specimen is then. sliced into 16 slices with slice #1 being the most lateral slice. In slices. 9-10 at the 9:30 to 10:30 position is a main mass measuring 4.4 X 4 X 2.6 cm. The mass extends to 2 cm from the inked, black margin. In addition at the 8:30. position in slices 7-8 there is a 2 X 1.5 X 1 cm mass which is 6 cm from the. inked, black margin and 0.4 from the inked green margin. In slice 15 at the 4. o'clock position there is a 1 X 1 X 0.5 cm firm, white nodule which is 0.5 cm. from the inked, green margin and 3 cm from the inked, black margin. The nipple. is amputated, bisected and submitted entirely in cassette C1. the skin. surrounding the tissue just deep to the nipple are submitted in cassette C2. At. 6 cm lateral to the nipple is a 0.5 X 0.3 cm slightly raised area of skin which. is the same, pink-tan color as the surrounding skin. This is submitted in. cassette C3. Representative sections are submitted as follows: C4: lesion from slice 7. C5: lesion from slice 8. C6-C7: mass from slice 9 with the black ink in C6. C8: additional representative section of mass from slice 9. C9-10: mass from slice 10 with the inked blue margin in C9 (grossly tumor is. only in C10). C11: scar like area from slice 15. C12: scar like area from slice 15. In the superior area of slices 13-14 is a 3 x 2 X 2 cm vaguely nodular area. dense, white-tan parenchyma. This area is 1.5 cm from the inked, blue margin. and 3 cm from the black margin. C13: vaguely nodular area from slice 13. C14: vaguely nodular area from slice 14. C15: representative section from the upper-outer quadrant from slice 3. C16: representative section from the lower-outer quadrant from slice 5. C17: representative slice from the upper-inner quadrant from slice 16. C18: representative section from lower-inner quadrant from slice 14. D. Container D is further designated '4. Skin; biopsy.' Received fresh and. placed in formalin is a 14 gram, 4 X 2.5 cm ellipse of pink-tan skin with a. central 1.9 X 0.9 cm defect. It is excised to a depth of 1 cm. The deep margin. is inked black. The circumferential margin is inked blue. The specimen is. serially sectioned to reveal yellow, lobular unremarkable subcutaneous adipose. tissue. Representative sections are submitted in cassettes D1-D2. M.D. Pathologist Sign Out:",BRCA,0,True,"The report indicates that two sentinel lymph nodes were examined and both were negative for metastatic carcinoma. Therefore, the N stage is N0, as there are no positive lymph nodes.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.",13.0,1186.0,100.0,True
1253,TCGA-E2-A1LE.42E3E8C1-D18A-4457-B2F0-FE49F4C027D7,1,"SPECIMENS: A. NON-SENTINEL NODES RIGHT AXILLA Path Site-breast, upperimen. B. RIGHT BREAST. SPECIMEN(S): A. NON-SENTINEL NODES RIGHT AXILLA. B. RIGHT BREAST. INTRAOPERATIVE CONSULTATION DIAGNOSIS: TPA: Lymph nodes, right axillary non-sentinel, biopsy: Two lymph nodes positive for carcinoma on. tough prep. By Dr. called to Dr. GROSS DESCRIPTION: A. NON-SENTINEL NODES RIGHT AXILLA. Received fresh and labeled with the patient name designated ""A - non-sentinel nodes right axilla"", are 2. portions of fibroadipose tissue demonstrating 2 presumptive palpable lymph nodes; one lymph node. measures 3.5 x 1.2 x 0.8 cm, the second measures 2.0 x 1.2 x 0.7 cm. Both nodes are bisected. Touch prep performed. One lymph node is submitted in cassette A1 and the second is submitted in. cassette A2. B. RIGHT BREAST. Received fresh and labeled with the patient name designated ""B - right breast"", is a resected. mastectomy specimen weighing 1,383 grams and measuring 29.5 x 22.0 x 4.0 cm. The attached. axillary tail measures 13.0 x 7.2 x 1.5 cm. A suture indicates the axillary region. The posterior margin. is inked black. The white-beige ellipse of overlying skin measures 21.8 x 11.0. The light beige areola. measures 3.5 cm in diameter. The inverted nipple measures 1.0 cm in diameter. The surface of the. skin is dense and wrinkled. The specimen is serially sectioned from medial to lateral. Cut section. shows two firm beige distinct lesions; the larger lesion is located in the lower inner quadrant in the. subareolar region and measures 3.6 x 2.2 x 1.5 cm located 4.4 cm from the smaller lesion. The smaller. lesion is firm present in the upper inner quadrant measuring 1.0 x 0.9 x 0.8 cm. The larger lesion is 5.1. cm from the deep margin. The smaller lesion approaches the deep margin at a distance of 2.0 cm. The. remainder of the specimen shows dark yellow lobulated adipose tissue. Many firm lymph nodes are. demonstrated in the axillary tail ranging in size from 0.5 x 0.5 x 0.4 cm up to 2.5 x 2.0 x 1.0 cm. A. portion of the specimen is submitted for tissue procurement. Representative sections are submitted as. follows: B1-B2: The smaller lesion submitted entirely with overlying deep margin. B3-B9: Sections from the larger lesion. B10: Margin overlying the larger lesion. B11-B13: Sections of nipple. B14: Section of skin adjacent to nipple. B15: Additional section of skin. B16-B17: Representative sections upper outer quadrant. B18-B19: Representative sections lower outer quadrant. B20: Additional section upper inner quadrant. B21-B22: One bisected lymph node. B23: One-half of one bisected lymph node. B24: One bisected lymph node. B25: Three possible lymph nodes. B26: Three possible lymph nodes. B27: Four possible lymph nodes. B28: Four possible lymph nodes. B29: Four possible lymph nodes. B30: One lymph node. B31: One lymph node. B32: One lymph node. DIAGNOSIS: A. LYMPH NODE, NON-SENTINEL, RIGHT AXILLA, BIOPSY: METASTATIC CARCINOMA TO TWO OF TWO LYMPH NODES (2/2),. MEASURING 2-CM, WITH EXTRANODAL EXTENSION. B. BREAST, RIGHT, MASTECTOMY AND AXILLARY NODE DISSECTION: - MULTIFOCAL, INVASIVE, DUCTAL CARCINOMA, SBR GRADE 3, LARGEST. MEASURING 3.6-CM, PRESENT IN THE LOWER INNER AND UPPER INNER. QUADRANTS AND INVOLVES NIPPLE AND ADJACENT SKIN. - SURGICAL RESECTION MARGINS NEGATIVE FOR TUMOR. - EXTENSIVE LYMPHOVASCULAR INVASION IDENTIFIED. - METASTATIC CARCINOMA TO TWENTY FIVE OF TWENTY SIX LYMPH. NODES (25/26), LARGEST MEASURING 2.1-CM, WITH EXTENSIVE. EXTRANODAL EXTENSION. - SEE SYNOPTIC REPORT AND SEE NOTE. NOTE: Breast biomarkers have been ordered and addendum report to follow. SYNOPTIC REPORT - BREAST. Specimen Type: Mastectomy. Needle Localization: No. Laterality: Right. Invasive Tumor: Present. Multifocality: Yes. Tumor size: 3.6cm. Tumor Site: Upper inner quadrant. Lower inner quadrant and nipple and adjacent skin. Margins: Negative. Tubular Score: 3. Nuclear Grade: 3. Mitotic Score: 3. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Absent. Vascular/Lymphatic Invasion: Present. Extent: extensive. Lobular neoplasia: None. Lymph nodes: Axillary dissection. Lymph node status: Positive 27/28 Extranodal extension. DCIS not present. ER/PR/HER2 Results. ER: Pending. PR: Pending. HER2: Pending. Pathological staging (pTN): pT 2 N 3a. CLINICAL HISTORY: A -year-old Caucasian female post menopausal abnormal mammogram. Biopsy showed an. adenocarcinoma, ER/PR-, Her2+, 2 masses at right breast seen. One at 12 o'clock position subareolar,. 2nd mass at 1 o'clock posterior to 1st mass (3.0 cm). PRE-OPERATIVE DIAGNOSIS: Infiltrating adenocarcinoma. ADDENDUM: SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimen: Surgical Excision. Block Number: B4. ER: Negative Allred Score: 0 = Proportion Score 0 + Intensity Score 0. PR: Negative Allred Score: 0 = Proportion Score 0 + Intensity Score 0. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the. proportion score (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of. cells staining, 4 = 31-60% of cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak. intensity of staining, 2 = intermediate intensity of staining, 3 = strong intensity of staining), with a scoring. range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score. of less than or equal to 2. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Immunohistochemistry was performed using the mouse anti-human ER (ER 1D5, 1:100) and PR (PGR. 136, 1:100) provided by. following the manufacturer S instructions. This. assay was not modified. Interpretation of the ER/PR immunohistochemical stain is guided by published. results in the medical literature, information provided by the reagent manufacturer and by internal. review of staining performance. SYNOPTIC REPORT - BREAST HER-2 RESULTS. Specimen: Surgical Excision. Block Number: B4. Interpretation: POSITIVE. Intensity: 3+. % Tumor Staining: 90%. Fish Ordered: METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Her2 analysis was performed using the FDA approved. HercepTest (TM) test kit. using rabbit anti-human HER2. This assay was not modified. External kit-slides. provided by the manufacturer (cell lines with high, low and negative HER2 protein expression) and in-. house known HER2 amplified control tissue were evaluated along with the test tissue. Adequate, well. preserved, clear-cut invasive carcinoma was identified for HER2 evaluation. Interpretation of the HER2. immunohistochemical stain is guided by published results in the medical literature, information provided. by the reagent manufacturer and by internal review of staining performance. This assay has been validated according to the 2007 joint recommendations and guidelines from. ASCO and CAP and from the NCCN HER2 testing in Breast Cancer Task Force. Pathology. Department takes full responsibility for this test's performance. Microscopic/Diagnostic Dictation: Pathologist. Final Review: Pathologist. Final: Pathologist,. Addendum: Pathologist,. Addendum Final: Pathologis'.",BRCA,3,True,"The report states that there are 25 positive lymph nodes out of 26 examined in the right axillary node dissection. This corresponds to N3 stage according to the rule: 'N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.'","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.",N3,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.",13.0,1186.0,100.0,True
694,TCGA-AC-A23E.C976ACED-7FF8-4287-9D68-C6FD17895FC0,1,"Hospital of Origin: QC Pathologist: FINAL PATHOLOGIC DIAGNOSIS: A. Right axillary sentinel lymph node: One lymph node, total replacement by metastatic. adenocarcinoma. Confirms frozen section diagnosis. Size of involved node: 2 cm. B. Right breast mastectomy: Invasive ductal carcinoma. Architectural score: 1 of 3. Nuclear score: 2 of 3. Mitotic score: 2 of 3. Total score: 5.of 9 = Grade I. Size: 3.8 cm. No evidence of skin or nipple involvement. Deep margin of excision is free of carcinoma. C. Right axillary sentinel lymph node #2: One lymph node, no evidence of metastatic carcinoma. pTNM classification: pT2 pN1 Mx. COMMENTS: CLINICAL HISTORY: Preoperative Diagnosis: Right breast cancer ER positive. Site : breast. NOS 650.4. 32%, PR 84%. Postoperative Diagnosis: Symptoms/Radiologic Findings: SPECIMENS: A. Right axillary sentinel node at 900 with frozen section. B. Right breast. C. Right axillary sentinel node #2. CODES: PROCEDURAL DEMOGRAPHICS: 4. u. Accession Date/Time: GROSS DESCRIPTION: The specimen is received in three containers labeled with. the patient's name. A. Container A is agaitionally labeled 'right axillary. sentinel node' and contains a 1.5 cm yellow-tan firm fatty. nodule consistent with possible lymph node. The nodule is. bisected and entirely submitted for frozen section with the. residual entirely resubmitted for permanent section in. cassette A labeled. B. Container B is additionally labeled 'right breast' and. contains a 1050.0 g, 22.0 x 18.5 x 6.5 cm simple mastectomy. specimen partially surfaced by a 22.5 x 12.5 cm portion of. pink-tan skin bearing a central 1.5 x 1.3 x 0.7 cm everted. nipple. Orientation is not offered or possible. Located 5.0. cm from the nipple is a 2.3 cm partially healed pink-tan. linear incision possibly consistent with previous biopsy. site. Additionally, three tan-brown granular lesions are. identified. These lesions range from 0.4 up to 1.0 cm in. greatest dimension and reside 3.0 to 6.0 from the nipple. The deep margin is inked and the specimen is serially. sectioned to reveal a 3.8 x 3.5 x 2.6 cm gray-white firm,. gritty mass surrounded by fibrosis. This mass resides 2.0 cm. below the skin's surface and approaches to within 2.3 cm of. the inked deep margin. The remainder of the cut surface is. comprised of predominantly yellow-tan adipose tissue admixed. with moderate amounts of interspersed gray-white cystic. fibrous tissue. No additional lesions are identified. Representative sections are submitted in cassettes B1 - 11. labeled. designated as follows: B1, nipple;. B2, skin lesions; B3, inked deep margin, perpendicular; B4 -. 88, mass; 89 - B11, uninvolved tissue from each of the three. uninvolved quadrants. Additionally, a yellow and green. cassette are submitted for genomics research each labeled. C. Container C is additionally labeled 'right axillary. sentinel node #2' and contains a 0.9 cm yellow-tan firm. fatty nodule consistent with possible lymph node. The. specimen is bisected and entirely submitted in cassette C. labeled. INTRA-PROCEDURE CONSULTATION: A. FROZEN SECTION DIAGNOSIS: Positive for tumor per Dr. resuits were communicated to. after confirming patient. identity.",BRCA,1,True,"The report indicates that one out of the two sentinel lymph nodes (right axillary sentinel lymph node #1) had metastatic adenocarcinoma with a size of 2 cm. This is consistent with N1 stage, which is defined as 1-3 positive lymph nodes. The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage. The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.",14.0,1305.0,95.0,True
869,TCGA-AR-A24H.C373F2EE-C601-4E17-8E2D-D9BC6AC0301A,1,"Final Diagnosis. Breast, right, excision: Invasive lobular carcinoma, Nottingham II (of. III), forming a 2.8 x 2.6 6 x 2 cm mass (AJCCpt2) No lymphovascular. involvement or carcinoma in situ component is identified. The surgical. resection margins, after one re-excision are negative for tumor. The. uninvolved breast tissue shows duct ectasia and stromal fibrosis. Lymph node, right axilla, sentinel, excision: A single right sentinel. lymph node is negative for tumor. Lymph nodes, right axilla, excision: Multiple (3) right axillary lymph. nodes are negative for tumor. Staining for estrogen and progesterone receptors is positive.",BRCA,0,True,"The report states that there is no malignancy found in the sentinel lymph node and multiple (3) right axillary lymph nodes. This indicates that the N stage is N0, as there are no positive lymph nodes.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
The absence of malignancy in regional lymph nodes implies an N0 stage.
The N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.",14.0,1305.0,100.0,True
863,TCGA-AR-A1AT.D52A6E4B-C80A-4947-96FE-3295E418EC67,1,"Final diagnosis. Breast. neft wide local excision: Infiltrating mammary carcinoma with predominantly lobular. features, solid variant, Nottingham grade III (of III) [tubules 3/3, nuclei 3/3, mitoses 2/3;. Nottingham score 8/9], forming a 2.5 x 2.1 x 1.9 cm mass [AJCC pT2]. Focal lobular carcinoma. in situ is also present. Angiolymphatic invasion is absent. The non-neoplastic breast parenchyma. shows proliferative fibrocystic changes. Biopsy site changes are present. All surgical resection. margins are negative for tumor (minimum tumor free margin, 0.4 cm, anterior margin). (See. comment.). Lymph nodes, left axillary sentinel, excision: A single (of 3) left axillary sentinel lymph node is. positive for isolated tumor cells [AJCC pN0(i+)(sn)], with multiple (5) isolated tumor. cells/clusters, the largest measuring 0.05 mm. These isolated tumor cells/clusters are seen on. sentinel lymph node #2 and by cytokeratin only staining. Blue dye is identified in left axillary. sentinel lymph node No. 1. Blue dye is not identified in left axillary sentinel lymph nodes No. 2. or No. 3. Comment: Immunohistochemical stain (e-cadherin) was performed on the paraffin embedded. breast tissue and shows lack of cytoplasmic membrane staining supporting a lobular. immunophenotype. Faxitron done.",BRCA,0,True,"The report states that there is a single sentinel lymph node positive for isolated tumor cells (AJCC pN0(i+)(sn)), but the N stage is determined by the number of positive lymph nodes, regardless of the total number of lymph nodes examined. The rule is that isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage. Therefore, the N stage is N0.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.",12.0,1113.0,83.0,True
1353,TCGA-EW-A1P8.6CB5A0ED-5569-4FDC-B651-758BFC6B59D8,1,"F. Pathologic Interpretation: A. LEFT BREAST LUMPECTOMY 1 STITCH SUPERIOR, 2 STITCHES LATERAL, SKIN IS ANTERIOR: - Invasive poorly differentiated ductal carcinoma, 2.2 cm in greatest linear dimension, Nottingham Grade 3 (3+3+3). Tumor is less than 0.1 cm from the posterior and lateral margins. - Lymphovascular invasion is present. - Tumor cells are negative for ER, PR, HER-2 by immunohistochemistry. B. SENTINEL LYMPH NODE #1 COUNT 171: - Metastatic carcinoma in one lymph node with extranodal extension (1/1). C. SENTINEL LYMPH NODE #2 COUNT 82: - Metastatic carcinoma in one lymph node with extranodal extension (1/1). D. NON-SENTINEL NODE: - Metastatic carcinoma in one lymph node with extranodal extension (1/1). E. LEFT AXILLARY CONTENTS: - Metastatic carcinoma in eleven out of twelve lymph nodes (11/12) with extranodal extension. Tumor Summary. Specimen: Partial breast. "". Procedure: Excision without wire-gulded localization. Lymph Node Sampling: Sentinel lymph node. Axillary dissection. Specimen Integrity: Single intact specimen. Specimen Size: Greatest dimension: 9 cm. Additional dimensions: 5 x 6 cm. Specimen Laterality: Left. Tumor Size: Greatest dimension of largest focus of invasion over 0.1 cm: 2.2 cm. Tumor Focality: Single focus of invasive carcinoma. Macroscopic Extent of Tumor: Skin: Invasive carcinoma does not invade into the dermis or epidermis. Skeletal Muscle: No skeletal muscle present. Histologic Type: - Invasive ductal carcinoma. Histologic Grade (Nottingham Histologic Score): Score 3. Nuclear Pleomorphism: Score 3: Mitotic Count: Score 3. Overali Grade: - Grade 3: Margins: - Uninvolved by invasive carcinoma. - Distance from closest margin: <1.0 mm. SURGICAL PATHOL Report. - Distance from posterior margin: <1.0 mm. - Distance from lateral margin: <1.0 mm. Treatment Effect: - In the breast: - No known presurgical therapy. In the Lymph Nodes: No known presurgical therapy. Lymph-Vascular Invasion: Present. Dermal Lymph-Vascular Invasion: Not identified. Extranodal Extension: - Present. Method of Evaluation of Sentinel Lymph Nodes: - H&E multiple levels. Pathologic Staging (pTNM): - Primary Tumor (pT): pT2. - Regional Lymph Nodes (pN): pN3a. - Distant Metastasis (pM): Not applicable. Anciliary Studies: - Estrogen Receptor: - Performed on this specimen: Results: Less than 1% immunoreactive cells present. - Progesterone Receptor: Performed on this specimen: Results: Less than 1% immunoreactive cells present. - HER2/neu: - Performed on this specimen: Results: Negative (Score 0). Microcalcifications: Present in invasive carcinoma. NOTE: IDS-ER, Some PgR immunohissochemical 636=PR. 1485=HER2, antibodies H-II=EGFR. are analyte All immunohistac specific reugents hemical (ASRs) stains validated are used by with our formalin laboratory. or molecular These ASRs fixed, are paraffin clinically embedded useful indicators tissue. Detection that do not is by requdre Emision FDA Method. approval. The These results clones are read are used: by a. pathologist as positive or negative. As the attending pathologist, I attest that I: (1) Examined the relevant preparation(s). for the specimen(s); and (ii) Rendered the diagnosis(es). , MD. Intraoperative Consultation. B. Sentinel lymph node #1 count. FS: Metastatic carcinoma in lymph nodes, consistent with a breast primary. C. Sentinel lymph node #2 count , FS: Metastatic carcinoma in lymph node. MD. Clinical History: None provided. SURGICAL PATHOL Report. Operation Performed. Left breast lumpectomy with sentinel node biopsy. Pre Operative Diagnosis: Left breast mass. Specimen(s) Received: A: Left breast lumpectomy 1 stitch superior, 2 stitches lateral, skin is anterior (permanent). B: Sentinel lymph node #1 count. C: Sentinel lymph node #2 count. FS. D: Non-sentinel node. E: Left axillary contents. Gross Description: A. Received in formalin is a yellow ovoid tissue weighing 74 grams and measuring 9 x 5 x 6 cm. The specimen is oriented. with one short suture-superior margin and double black sutures-lateral margin. At the anterior aspect, there is an ellipse of. white skin, 4 x 1.2x0.3 cm. Margins inked as follows: superior margin in blue, inferior margin in green, lateral margin in. orange, medial margin in red, anterior margin in yellow and posterior margin in black. On multiple cross sections, there is. an ill-defined firm tumoral mass with focally hemorrhagic areas measuring 2.2 x 2 x 2 cm, present at less than 0.1 cm from. deep margin (closest margin) and 0.5 cm from anterior margin, 2 cm from superior and inferior margins. The rest of the. breast presents a white fibrotic breast tissue, the stroma to fat ratio is approximately 30-70%. Representative sections are. submitted in twelve cassettes as follows: 1. Superior margin. 2. Inferior margin. 3. Lateral margin. 4. Medial margin. 5. Anterior margin (skin). 6&7. Deep margin with tumor. 8-10. Tumor. 11&12. Breast stroma. B. Received fresh are two lymph nodes measuring from 1 cm to 4 x 1 x 0.8 cm. Submitted in toto in three cassettes for. frozen section as follows: 1. Small lymph node. 2&3. Large lymph node. C. Received fresh is a possible lymph node, 1.5 x 1 x 0.6 cm. Submitted in toto in one cassette for frozen section. D. Received in formalin are two yellow, pale tan tissue fragments, the smaller one is 1.2 x 1 x 0.2 cm and the bigger one is. 1.5 x 1.4 x 0,5 cm. Submitted in toto in two cassettes as follows: 1. Smaller tissue. 2. Bigger tissue, bisected, submitted in toto. E. Received is a yellow fibroadipose tissue segment, 11 x 9 x 2 cm. There are twelve possible lymph nodes ranging from 0.5. to 1.8 cm in greatest dimension. They are bisected. Representative sections are submitted In twelve cassettes as follows: One possible lymph node, bisected per block.",BRCA,3,True,"The report indicates that there are metastatic carcinomas in 12 lymph nodes out of 13 examined, with 11 of those 12 having extranodal extension. This exceeds the criteria for N3a (metastasis in 4-9 axillary lymph nodes) and N3b (metastasis in the infraclavicular lymph nodes), and is therefore classified as N3 (metastasis in 10 or more axillary lymph nodes).","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.",N3,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.",13.0,1194.0,96.0,True
1021,TCGA-BH-A0GZ.C956B4B1-99E6-4823-886A-FA8FCD1E3E4D,0,"FINAL DIAGNOSIS: PART 1: BREASI, LEFT,12 O'CLOCK, SEGMENTAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA, NO SPECIAL TYPE. B. NOTTINGHAM GRADE 2 (TUBAL FORMATION: 2, NUCLEAR PLEOMORPHISM: 2, MITOTIC ACTIVITY: 2;. TOTAL SCORE 6/9). C. THE INVASIVE TUMOR MEASURES 1.5 CM IN LARGEST DIMENSION. D. LYMPHOVASCULAR SPACE INVASION IS IDENTIFIED. E. DUCTAL CARCINOMA IN SITU (DCIS), NUCLEAR GRADE 2, CRIBRIFORM TYPE WITH COMEDO NECROSIS. F. THE DCIS CONSTITUTES 20% OF THE TOTAL TUMOR VOLUME AND IS PRESENT ADMIXED WITH AND. AWAY FROM THE INVASIVE COMPONENT. G. MARGINS ARE NEGATIVE FOR CARCINOMA; INVASIVE CARCINOMA IS 0.5 CM FROM THE NEAREST. (SUPERIOR) MARGIN. H. FIBROCYSTIC CHANGES, COLUMNAR CELL CHANGE, AND DUCTAL EPITHELIAL HYPERPLASIA. I. PREVIOUS BIOPSY SITE CHANGES. J. INVASIVE TUMOR CELLS ARE POSITIVE FOR ESTROGEN AND PROGESTERONE RECEPTORS AND. NEGATIVE FOR HER-2/NEU BY FISH. K. PATHOLOGIC STAGE: pTic, pN1a, pMX. PART 2: SENTINEL LYMPH NODE #1, LEFT AXILLA, BIOPSY -. A. ONE LYMPH NODE, POSITIVE FOR METASTATIC CARCINOMA (1/3). B. THE LARGEST TUMOR DEPOSIT IS 2.1 MM. C. EXTRACAPSULAR EXTENSION IS NOT PRESENT. PART 3: SENTINEL LYMPH NODE #2, LEFT AXILLA, BIOPSY -. ONE LYMPH NODE. NEGATIVE FOR NEOPLASM (0/1). CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Segmental. Upper outer quadrant. Upper inner quadrant. SIZE OF TUMOR: Maximum dimension invasive component: 1.5 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 2. Mitotic activity score: 2. Total Nottingham score: 6. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: Not applicable. CALCIFICATION: Yes, malignant zones. TUMOR TYPE, IN SITU: Cribriform. DCIS admixed and outside of invasive carcinoma component. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 5.0 mm. SURG MARGINS INVOLVED BY IN SITU COMPONENT: LYMPH NODES POSITIVE: 1. LYMPH NODES EXAMINED: 4. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. NON-NEOPLASTIC BREAST TISSUE: FCD, Other: columnar cell change, ductal epithelial hyperplasia. T STAGE, PATHOLOGIC: pT1c. N STAGE, PATHOLOGIC: pN1a. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTORS: positive. HER2/NEU: 2+.",BRCA,1,True,"The report indicates that one out of four sentinel lymph nodes examined is positive for metastatic carcinoma. This corresponds to the N1 stage, as N1 indicates 1-3 positive nodes. The size of the tumor deposit in the lymph node (2.1 mm) and the absence of extracapsular extension do not affect the N stage.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.",14.0,1263.0,97.0,True
651,TCGA-A8-A08L.BC0E0F93-B183-44E8-B551-EA463B2FBCE4,2,"Diagnosis. 1. Left-sided ablated breast tissue with a poorly differentiated invasive ductal breast. carcinoma measuring a maximum of 6 cm with focal invasion of the lymph vessels, extension. to the base of the nipple and the pectoral muscle and excision extending just into the healthy. tissue in the basal epidermis. No pagetoid tumor propagation or skin infiltration. Tumor classification: M-8500/3, G 3, pT3, pN2a (5/13), pMX, stage III A. R0.",BRCA,2,True,"The N stage is provided in the report as pN2a (5/13), which indicates that there are 5 positive lymph nodes out of 13 examined lymph nodes. This corresponds to the N2 stage in the AJCC staging system.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.",N2,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.",15.0,1406.0,95.0,True
489,TCGA-A2-A0CY.CB780DE7-E98C-4F7E-9487-8F25FE80DC21,1,"Specimen #: Race: WHITE. Physician (s) : SPECIMEN: A: RIGHT BREAST B: LEFT BREAST C: SENTINEL LYMPH NODE #1. D: LEFT AXILLARY CONTENTS E: NON SENTINAL , ,LT AXILLARY L.N. FINAL DIAGNOSIS: A. BREAST, RIGHT, MASTECTOMY: - BENIGN BREAST TISSUE WITH FIBROCYSTIC CHANGES INCLUDING SCLEROSIS,. MICROCYST FORMATION, USUAL DUCTAL HYPERPLASIA, DUCT ECTASIA, AND. FOCAL MICROCALCIFICATION . B. BREAST, LEFT, MASTECTOMY: TUMOR TYPE: INVASIVE DUCTAL CARCINOMA. NOTTINGHAM GRADE: III/III. NOTTINGHAM SCORE: 9/9. (Tubules= 3, Nuclei= 3, Mitoses= 3). TUMOR SIZE (GREATEST DIMENSION OF INVASIVE COMPONENT) : 3.5 CM. (MEASURED GROSSLY). TUMOR NECROSIS: PRESENT. VENOUS / LYMPHATIC INVASION: IDENTIFIED. MARGINS : - DISTANCE OF TUMOR FROM NEAREST MARGIN IS 0.4 CM, FROM THE. SUPERFICIAL LOWER OUTER QUADRANT (BLUE INK) MARGIN. INTRADUCTAL COMPONENT: MULTIFOCAL, HIGH GRADE, SOLID AND COMEDO TYPE. EXTENDING WELL BEYOND THE INVASIVE COMPONENT. NIPPLE INVOLVEMENT: NOT IDENTIFIED. LYMPH NODES 1 OF 22 POSITIVE FOR TUMOR (PARTS C-E). SKIN INVOLVEMENT: NOT IDENTIFIED. ESTROGEN RECEPTORS : POSITIVE (STRONG, >75% OF CELLS, FROM. HER 2 NEU by IHC: NEGATIVE (1+ STAINING, FROM. PROGESTERONE RECEPTORS: NEGATIVE (WEAK, <5% OF CELLS, FROM. PATHOLOGIC STAGE: pT2 N1 MX. ADDITIONAL PATHOLOGIC CHANGES: FIBROCYSTIC CHANGES INCLUDING MICROCYST. FORMATION, FOCAL DUCT ECTASIA, SCLEROIS, USUAL DUCTAL HYPERPLASIA, AND. APOCRINE METAPLASIA. C. LYMPH NODE, LEFT SENTINEL, EXCISION: - AND ONE (1) LYMPH NODE NEGATIVE FOR METASTATIC CARCINOMA BY HEMATOXYLIN. EOSIN AND IMMUNOHISTOCHEMICAL (CYTOKERATIN) STAINS. Specimen #: FINAL DIAGNOSIS (continued) : D. LYMPH NODE, LEFT AXILLA, EXCISION: - TWENTY (20) LYMPH NODES NEGATIVE FOR METASTATIC CARCINOMA. E. LYMPH NODE, LEFT NON-SENTINEL, EXCISION: - ONE (1) LYMPH NODE POSITIVE FOR METASTATIC CARCINOMA. COMMENT: confirmed on the permanent sections. In specimen ""E"" the frozen section diagnosis of metastic carcinoma is. CLINICAL DIAGNOSIS AND HISTORY: year old white female with history of left breast cancer. FROZEN SECTION DIAGNOSIS: SPECIMEN TYPE:LYMPH NODE (SPECIMEN ""E"") . REPORTED TO: AND. # BLOCKS : 1. # SCRAPE PREPS : 1. FROZEN SECTION DIAGNOSIS : POSITIVE FOR METASTATIC CARCINOMA. GROSS DESCRIPTION: A. Received in fresh labeled with the patient's name. of labeled a 927 ""RIGHT BREAST SHORT STITCH SUPERIOR, LONG STITCH LATERAL consists. and gram mastectomy specimen oriented with a short stitch superior. pigmented 1.0 superficial skin ellipse measures 17 x 11.5 cm and. superior to inferior, and 5 cm anterior to posterior. The lightly. long lateral. The specimen measures 24 cm medial to lateral, 19 cm. The deep cm centrally located everted nipple. No discharge or scar displays is noted. a. tan margin is inked in black. Serial sections reveal lobulated yellow. tissue. adipose tissue admixed with 10% moderately dense tan white fibrous. catted grey cysts measuring up to 0.4 cm in greatest dimension. blue The fibrous tissue is predominantly centrally located and shows. 1. Specimen #: GROSS DESCRIPTION (continued) : discrete mass or lesion identified. No lymph nodes are identified. Cassette summary : A1: skin. A2: central. A3: upper outer quadrant. A4: lower outer quadrant. A5: lower inner quadrant. A6: upper inner quadrant. A7: upper outer quadrant. A8: lower outer quadrant. A9: lower inner quadrant. A10: upper inner quadrant. All: representative section of nipple. Matched sections of A1-A6 are submitted in OCT for CBCP protocol. B. Received fresh labeled with the patient's name. designated ""LEFT BREAST SHORT STITCH SUPERIOR, LONG LATERAL"" is a 954. gram mastectomy specimen oriented with a short stitch superior and long. lateral. The specimen measures 24 cm medial to lateral, 18 cm superior. inferior, and 6 cm anterior to posterior. The lightly pigmented. to. superficial located skin ellipse measures 19 x 12.5 cm and displays a medially. deep inked margin is inked black and the superficial lower outer quadrant is. 1.5 cm everted nipple free of discharge. No scar is noted. The. located lobulated pink white indurated mass with focal hemorrhage. The mass. blue. Serial sections reveal 3.5 x 3.2 x 2.8 cm well defined. deep the margin and 0.4 cm of the inked superficial surface. The remainder. within the lower outer quadrant and comes within 3.5 cm of the is. tissue which is diffusely nodular and focally cystic. The admixed. specimen is composed of approximately 50% dense tan white fibrous. of. adipose tissue is unremarkable. No additional masses are identified. No. lymph nodes identified. Cassette summary: B1: skin. B2: lower outer quadrant mass. B3: lower outer quadrant. B4: upper outer quadrant. B5: upper inner quadrant. B6: lower inner quadrant. B7: representative section of closest deep margin. blue B8-B9: ink representative sections of mass with closest point of approach to. margin. 10: representative section of nipple. 10CF. Specimen #: GROSS DESCRIPTION (continued) : C. Received fresh labeled with the patient's name. designated. SENTINEL LYMPH NODE #1"" consists of a 2.0 x 1.7 x 1.0 cm. pink yellow fatty lymph node. The specimen is trisected. Two thirds of the. lymph node are placed in cassette C1 and C2. Matched section of C1 is. placed in. for CBCP protocol. D. Received fresh labeled with the patient's name. designated ""LEFT AXILLARY CONTENTS"" consists of an unoriented irregular. portion of adipose tissue measuring 9.0 x 9.0 x 2.0 cm. Sectioning reveals. multiple pink yellow fatty lymph nodes ranging in size from 0.4 to 2.4 cm. in greatest dimension. Cassette summary. D1-D3: one lymph node each. D4-D7: one lymph node bisected. D8: two lymph nodes bisected, one inked black. D9: four intact lymph nodes. D10: one lymph node bisected. D11: two lymph nodes. D12: four possible lymph nodes. 12CF. E. Received fresh labeled with the patient's name. designated ""NON SENTINEL CLINCALLY SUSPICOUS LEFT AXILLARY LYMPH NODE'. consists of a 1.7 x 1.5 x 1.3 cm lymph node. Cut surface is homogeneous. and firm. A portion is submitted for frozen section. 1C1.",BRCA,1,True,"There are 22 lymph nodes examined, with 1 positive node. This falls under N1 as per the rules.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.",15.0,1406.0,95.0,True
1382,TCGA-GM-A2DF.CA6B733A-6030-422C-9DE9-B9718CBB2FDC,0,"ACC # 26. A) ADDITIONAL MARGIN OF MOST MEDIAL TUMOR, EXCISION: Benign breast tissue, no tumor present. (B). LEFT BREAST, SEGMENTAL MASTECTOMY: MULTIFOCAL INVASIVE DUCTAL CARCINOMA WITH ASSOCIATED LYMPHOCYTIC. INFILTRATE, HIGH NUCLEAR GRADE, NOTTINGHAM HISTOLOGIC GRADE. 3. (SEE COMMENT). LARGEST FOCUS OF INVASIVE CARCINOMA MEASURES 1.2 CM IN GREATEST. DIMENSION IN THE MEDIAL ASPECT OF THE SPECIMEN. MULTIPLE SATELLITE FOCI OF INVASIVE CARCINOMA ARE LATERAL TO THE. MAIN FOCUS AND MEASURE 5 MM (X 2), 4 MM, 3 MM AND 1 MM. LYMPHOVASCULAR INVASION IDENTIFIED. DUCTAL CARCINOMA IN SITU (DCIS), HIGH GRADE, PREDOMINANTLY. CRIBRIFORM AND CLINGING TYPES WITH CANCERIZATION OF LOBULES. AND ASSOCIATED LYMPHOCYTIC INFILTRATE. DCIS EXTENDS IN AN APPARENT IRREGULAR DISTRIBUTION OVER A 4 CM AREA. DCIS EXTENDS TO LESS THAN 1 MM FROM THE ANTERIOR MARGIN, TO 1 MM. FROM THE INFERIOR MARGIN, AND TO 2 MM FROM THE SUPERIOR AND. POSTERIOR MARGINS. INVASIVE CARCINOMA EXTENDS TO 2 MM FROM THE ANTERIOR MARGIN. (SEE. COMMENT). (C) ADDITIONAL CENTRAL ANTERIOR INFERIOR MARGIN, EXCISION: Benign breast tissue, no tumor present. (D) LEFT AXILLARY CONTENTS, DISSECTION: METASTATIC CARCINOMA IN ONE OF THIRTY LYMPH NODES (1/30); METASTASIS. MEASURES 7 MM; NO EXTRANODAL EXTENSION IDENTIFIED. (E) ADDITIONAL LEVEL I LEFT AXILLARY TISSUE, EXCISION: Two lymph nodes, no tumor present (0/2). Entire report and diagnosis completed by. COMMENT. Additional tissue was re-excised, and invasive carcinoma does not approach the final margins. However, I. with involvement of lobules is 1 mm from the final inferior margin and 2 mm from. the final superior and posterior margins. Tumor marker studies will be performed and reported in an addendum. GROSS DESCRIPTION. (A) ADDITIONAL MARGIN OF MOST MEDIAL TUMOR - Received is a piece of fibroadipose. tissue (1.8 x 1.2 x 0.5 cm) with clips on the true margin. The true margin inked black. The. specimen is serially sectioned and entirely submitted in A. (B) LEFT SEGMENTAL MASTECTOMY - A segmental mastectomy specimen (8.0 x 6.5 X 5.5. cm) with a short stitch at the superior aspect, long stitch at the lateral aspect, and multiple clips. on the anterior aspect. The specimen is serially sliced from medial to lateral into 11 slices. A. well-circumscribed tan-pink tumor 1.4 x 1.1 x 1.0 cm, with an associated biopsy clip is identified in. slice #3, which is 0.7 cm from the closest anterior margin. Multiple smaller nodules are identified. lateral to the main tumor. One of these is very close to the anterior margin in the central anterior. inferior aspect of the specimen, and additional tissue is requested from this margin. INK CODE: Anterior - yellow, posterior - black, superior - blue, inferior - green, medial. and lateral - red. SECTION CODE: B1, medial perpendicular margin; B2, tissue adjacent to tumor from. slice #2 ; B3-B7, tumor and margins from slice #3 (B3 and B4, tumor with anterior margin in area. of clip; B5, inferior margin; B6, posterior margin; B7, superior margin); B8, fibrous tissue adjacent. to the tumor from slice #4; B9, one small nodule, 1.2 cm from superior margin and 1.8 from. anterior margin of slice #4; B10, one small nodule 1.0 cm from anterior margin and 1.2 cm from. superior margin of slice #5; B11, one small nodule, 1.5 cm from anterior margin, 2.0 cm from. superior margin of slice #5; B12, B13, one small nodule, 0.1 cm from anterior margin and 1.2 cm. from inferior margin of slices #6 and #7; B14, one small nodule 0.4 cm from posterior margin and. 1.5 cm from inferior margin of slice #4; B15-818, remainder of margins of slice #4, entirely. submitted (B15, anterior margin; B16, superior margin; B17, posterior margin; B18, inferior. margin); B19, representative section from slice #8; B20, lateral perpendicular margin. (C) ADDITIONAL CENTRAL ANTERIOR INFERIOR MARGIN, LEFT BREAST - A portion of. fibroadipose tissue (2.0 x 1.3 x 0.5 cm) with clips on the true margin. The true margin is inked. black. The specimen is serially sectioned and entirely submitted in C1-C2. (D) LEFT AXILLARY CONTENTS - Adipose tissue (11.0 x 7.5 x 3.0 cm). Multiple lymph nodes. are identified ranging from 0.2 x 0.2 x 0.2 cm to 2.5 x 1.5 x 0.8 cm. SECTION CODE: D1-D3, each containing six lymph nodes; D4, four lymph nodes; D5,. four. lymph nodes; D6, one lymph node, trisected; D7, one lymph node, serially sectioned: n8. one lymph node, serially sectioned; D9 and D10, one lymph node, serially sectioned. (E) ADDITIONAL LEVEL I LEFT AXILLARY TISSUE - Two lymph nodes (0.2 x 0.2 x 0.2 cm and. 0.8 x 0.4 x 0.4 cm), entirely submitted. SECTION CODE: E1, one lymph node; E2, one lymph node, trisected. CLINICAL HISTORY. Left breast cancer. SNOMED CODES. T-04050, M-85003, M-85002 T-C4710, M-85006. ""Some tests reported here may have been developed and performance characteristics. determined by. These tests have not been. specifically cleared or approved by the U.S. Food and Drug Administration."". Released by: Start of ADDENDUM #1. ADDENDUM. Addendum completed by. This report is issued to give immunohistochemistry results. Immunohistochemical staining is performed on a representative formalin-fixed, paraffin-. embedded section of INVASIVE DUCTAL CARCINOMA, left breast, block B3. MARKER. % POSITIVE. SCORE. Estrogen Receptor. Negative. 0 %. Progesterone Receptor. Negative. < 1 %. N/A. HER-2/neu. overexpression. Negative. Focal 1+. Due to the above HER-2/neu immunohistochemical staining result, gene. copy level (HER-2/neu: CEP17 signal ratio) will be evaluated by FISH. and a separate report will be issued. FOOTNOTE. Estrogen receptor was assessed by immunohistochemistry using antibody 6F11 (. Progesterone receptor was assessed by immunohistochemistry using antibody PgR1294(. HER-2/neu was assessed by immunohistochemistry using antibody AB8 (I. Released by: Start of ADDENDUM #2. ADDENDUM #2. This modified report is being issued to report the results of HER-2/neu FISH. Addendum completed by. SPECIMEN SOURCE. Left breast. SUMMARY. Tissue section of the invasive carcinoma. B3 was evaluated for HER-2/neu gene. amplification by interphase fluorescence in situ hybridization technique using the -. HER-2/neu DNA Probe Kit (LSI HER-2/neu. /CEP17. Slide adequacy is satisfactory. Sixty tumor nuclei were counted and showed an average of 1.57. copies of LSI HER-2/neu gene per nucleus and an average of 1.40 copies of CEP17 per nucleus. Negative and positive controls (established by. 1 with this batch are. appropriate. Two representative images have been archived. INTERPRETATION. The tumor cells demonstrated no amplification of the HER-2/neu gene copy levels (HER-2/neu: CEP17 signal ratio: 1.12). The following guideline has been established for HER-2/neu testing: Normal HER-2/neu levels: < 1.80; equivocal HER-2/neu levels: 1.80 - 2.20; amplified HER-2/neu. levels: > 2.20. (Ref: Arch Patholo Lab Med. 2007; 131:18-43). NOTES. The LSI HER-2/neu probe is specific for the HER-2/neu gene Locus (17q 11.2-q12) and the CEP. 17 DNA probe is specific for the alpha satellite DNA sequence at the centromeric region of. Chromosome 17 (17 p11.1-q11.2). This test has been cleared and approved for specific uses by the U.S. Food and Drug. Administration. Its system is operating within the performance specifications stated in the product. insert. Released by:",BRCA,1,True,"According to the report, metastatic carcinoma was found in one out of thirty lymph nodes examined, which classifies the N stage as N1 according to the rule: 'N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.'","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but it does not affect the N stage.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.",15.0,1406.0,69.0,False
1116,TCGA-D8-A1J9.D80E9389-AAD8-4EEB-9DE0-5DE57B5E5F6B,0,"page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - left breast with axillary tissues. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the left breast. Results of immunohistochemical examination: Estrogen receptors found in 10-75% of neoplastic cell nuclei. No progesterone receptors found in neoplastic cell nuclei. HER2 protein stained with HercepTestâ„¢M by DAKO. Positive reaction in invasive cancerous cells ( Score = 3+ ). Macroscopic description: Left breast sized 18 x 12.5 x 2.5 cm removed along with axillary tissues sized 9 x 5 x 1 cm and a 14 x 4 cm skin flap. Weight. 350 g. Tumour sized 1.8 x 1.5 x 1.9 cm on the boundary of outer quadrants, 2.0 cm from the lower boundary, 0.3 cm from. the base and 0.7 cm from the skin. Microscopic description: Carcinoma ductale invasivum - NHG2 (2 + 3 +1:4 mitoses/10 HPF, visual area diameter 0.55 mm). Mamilla sine laesionibus. Lesions of the type mastopathia fibrosa et cystic, calcificationes. Invasive lesions situated 7 cm from the base. Axillary lymph nodes: Lymphonodultis chronica et sinus histiocytosis (No. VI). page 2 / 2. Histopathological diagnosis: Carcinoma ductale invasivum mammae sinistrae. Invasive ductal carcinoma of the left breast. (NHG2, pT1c, pNO ). CALL YOUR DOCTOR WITH THIS REPORT!.",BRCA,0,True,"The report states 'pNO', which means no malignancy was found in the regional lymph nodes. According to the rules, if no malignancy is found in regional lymph nodes, the N stage is N0.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.",15.0,1406.0,100.0,True
1378,TCGA-GM-A2DA.F3CD8E6E-B02F-4D5D-B895-6DF063F61603,1,"i.b. FIRAL 114 th: CONSULTANT: TIME KFCn. Photo: VO. 14 CCPY TO:113. CLINIC COPY. (A) RIGHT BREAST AND AXILLARY CONTENTS: l''VASIVE PUCTAL CARCINOMA, BLACK'S NUCLEAR GRACE 11. (SEE COMPENT). Fibrocystic changes. NETASTATIO CARCINOMA IN [10) UF THIRTEFN AXILLARY LYYPH NONES. (SEE CONMENT). fargins of resection free of tumor. CURMMENT: The nain tumor mass measures 2.5 x 2.0 x 1.5 cm in greatest. dimensions and is located in the inner quadrant, A separate microscopic. focus of invasive tunor is located in the upper outer quadrant and neasures. 1.5 x 1.0 x 0.5 mm. The largest lymph node containing netastatic disease. neasures 1.5 x 1.0 x 0.5 cm and shows 50% reolacement by tumor. Une of the. lymoh nodes containing metastatic tumor shows several foci of extracapsular. extension with a cumulative area of 3.0 x 5.5 Tm. GROSS DESCRIPTION. ( A ) RIGHT BREAST AND AXILLAWY CONTENTS - The specimen 125 x 15 x 4 cm). consists of breast (15 x 13 x 2 cm) covered by an unremarkable skin elliose. (3 x 5 cm) with nipple. The axillary contents measure 12 x 5 x "".1 c n . A nass is identified in the inner quadrant and measures 2.5 x ?.0 x. 1.5. Cin. The nass is 0.5 cm from the deep surgical nargin. The nass is 4.5. c.n away from the nedial nargin and 5 cm away from the niopte, 2.5 cm away. from the inferior naryin and 5 cm away from the superior margin. The. o. the breast parenchyma shows fibrosis. No other nass is present. SECTION CUDE: A1, tumor with deep surgical margin; A2-A7, sections of. tumori As, inner woper quadrant periohent; 19, inner lower quartrant central. ILJ. inner lower quartrant perioheral; A11, outer upper quadrant verioheral: 11?, outer upper quadrant centrali A13, Outer lower quadrant central ; ALL,. outer lower juadrunt perioheral ; A15, AlÃ©, nipple; 117, two Lymph nodes; A1. in - lymph node; ii), one lymph node; 120, three lymph nodes; A21, tao lynph. nodes; 122. two lynph notes; A23, one lymph node, bisect a; 124, one lvnnh. REPORT OF TISSUE. DIAGNOSIS. \ rortion of the tumor is submitted for ftow. TECHNICAL CHARGES: REPORT OF TISSUE. DIAGNOSIS.",BRCA,1,True,"The report indicates that there are 10 positive lymph nodes in the axilla, with one of them showing extracapsular extension. This puts the N stage at N2, as per the rule: 'N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.', and the additional rule: 'Extranodal extension of metastatic carcinoma increases the N stage by one level.'","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.",N2,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.",16.0,1487.0,97.0,True
509,TCGA-A2-A0ST.1E8B978E-3D1B-46E8-80EE-3A11EE571CEC,0,"Patient: : Specimen # : Race: WHITE. AMENDED. SPECIMEN: A: RIGHT BREAST BIOPSY B: SENTINEL LYMPH NODE#1. C: SENTINEL LYMPH NODE#2. FINAL DIAGNOSIS: A. BREAST, RIGHT; EXCISION: - INFILTRATING DUCTAL CARCINOMA, POORLY DIFFERENTIATED (MODIFIED. BLOOM-RICHARDSON GRADE 9: MITOSES=3, NUCLEAR PLEOMORPHISM=3, TUBULE. FORMATION=3). -TUMOR SIZE 2.0 CM. - -TUMOR IS LESS THAN 0.1 CM FROM ANTERIOR AND MEDIAL SURGICAL MARGINS. - -ASSOCIATED FINDINGS: FIBROCYSTIC CHANGES INCLUDING STROMAL SCLEROSIS. AND MICROCYSTS. -MICROCALCIFICATIONS IDENTIFIED, ASSOCIATED WITH BENIGN BREAST TISSUE. - IMMUNOHISTOCHEMICAL STAINS FOR ESTROGEN AND PROGESTERONE AS FOLLOWS. ESTROGEN RECEPTOR: NEGATIVE. PROGESTERONE RECEPTOR: POSITIVE. -HER2/NEU (FISH METHODOLOGY) : NOT AMPLIFIED (1.3). B. LYMPH NODE, SENTINEL LYMPH NODE#1, BIOPSY: -ONE (1) LYMPH NODE POSITIVE FOR METASTATIC CARCINOMA ON H AND E AND. IMMUNOHISTOLOGIC SECTIONS. -TUMOR SEEN IS APPROXIMATELY 0.5 CM IN SIZE. C. LYMPH NODE, SENTINEL LYMPH NODE#2, BIOPSY: -ONE (1) LYMPH NODE POSITIVE FOR METASTATIC CARCINOMA ON H AND E AND. IMMUNOHISTOLOGIC SECTIONS. -TUMOR SEEN LESS THAN 0.1 CM IN SIZE. COMMENT: This case is amended to reflect the review of. immunohistochemical stains for estrogen and progesterone receptors and. FISH for Her2/neu amplification. There is no change in diagnosis. COMMENT. ge 1. specimen #: FINAL DIAGNOSIS (continued) : Case amended. to report results of HER2 analysis by. immunohistochemistry (DAKO Hercep Test) : HER2/NEU PROTEIN OVEREXPRESSION: NEGATIVE (SCORE: 1+) . CLINICAL DIAGNOSIS AND HISTORY: -year-old female with palpable mass on right breast with no ultrasound. or mammographic correlation. GROSS DESCRIPTION: A. RIGHT BREAST BIOPSY received in formalin, labeled with the patient's. name, designated ""RIGHT BREAST EXCISIONAL BIOPSY"" is a lumpectomy specimen. measuring 10.2 x 7.0 x 3.0 cm in dimension. The specimen is composed. largely of yellow, lobulated, glistening adipose tissue admixed with white. fibrous areas. The specimen will be inked and oriented as follows: Black=deep, yellow=anterior, blue=medial, green=lateral, and red denotes. superficial and inferior. The specimen is serially sectioned from superior. to inferior revealing a fiarly well-defined, grey/tan nodule, 1.5 cm in. greatest dimension, abutting the anterior margin in the mid portion of the. specimen. Immediately adjacent to this nodule is a 1.5 cm patch of. indurated fibrous tissue involving the anterior and medial margins. The. remaining tissue consists of an admixture of fibrous tissue (approximately. 40%) and fat (approximately 60%) . The fibrous tissue is variably. indurated, particularly in the inferior half of the specimen. Sections of. nodule and fibrous tissue are harvested for the CBCP protocol. Matching. paraffin sections are as follows: A1: Nodule. A2: Indurated fibrous tissue adjacent to A1. A3: Fibrous tissue 3.0 cm inferior to nodule. A4: Fibrous tissue 6.0 cm inferior to nodule at the inferior margin. The remainder of the specimen is serially sectioned and submitted from. superior to inferior as follows: A5-A12: Representative section from each level from superior to inferior. Specimen #: GROSS DESCRIPTION (continued) : A13-A14: Next lower level. A15-A16: Next lower level. A17-A18 Inferior most section. B. SENTINEL LYMPH NODE#1 received in formalin, labeled with the patient'. name, designated ""SUPERIOR LYMPH NODE NUMBER ONE"" is a 1.7 x 1.3 x 0.8 cm. lymph node. A small portion of the node is harvested for the CBCP. protocol. The remaining tissue is entirely submitted in cassette B1. C. SENTINEL LYMPH NODE#2 received in formalin, labeled with the patient' S. name, designated ""SENTINEL LYMPH NODE NUMBER TWO"" is a 1.2 x 0.8 x 0.5 cm. tan/brown lymph node. The tissue is entirely submitted in cassette C1.",BRCA,1,True,"Based on the pathology report, there are two sentinel lymph nodes (#1 and #2) that are positive for metastatic carcinoma. The report does not provide the exact number of lymph nodes examined, but it does mention that two nodes are positive, and no substaging information is given. Therefore, according to the rules, N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes. In this case, since there are two positive lymph nodes, the N stage is N1.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.",15.0,1406.0,97.0,True
1278,TCGA-E9-A1ND.AC26EE69-27D8-4523-917A-68573F5F614E,1,"BREAST TISSUE CHECKLIST. Specimen type: Radical mastectomy. Specimen size: Not specified. Tumor site: Breast. Tumor size: 2.7 x 2.7 X 2.7 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal carcinoma. Histologic grade: Poorly differentiated. Tumor extent: Not specified. Lymph nodes: 1/11 positive for metastasis (Axillary 1/11). Left, upper. Extracapsular invasion of the lymph nodes: Not specified. outer. Margins: Not specified. quadrant. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: None.",BRCA,1,True,"The report indicates that 1 out of 11 lymph nodes is positive for metastasis (Axillary 1/11). This corresponds to the N1 stage, as defined by the rules, which classifies N1 as 1-3 positive nodes.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of metastasis in 1 out of the examined lymph nodes corresponds to the N1 stage.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of metastasis in 1 out of the examined lymph nodes corresponds to the N1 stage.",16.0,1499.0,97.0,True
1277,TCGA-E9-A1NC.AA1B707B-4DE8-4E0D-87CA-601760F4A6CF,1,BREAST TISSUE CHECKLIST. Specimen type: Radical mastectomy. Specimen size: Not specified. Tumor site: Breast. Tumor size: 2.2 x 2.2 x 2.2 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal and lobular carcinoma. Histologic grade: Tumor extent: Not specified. Lymph nodes: 1/9 positive for metastasis (Axillaris 1/9). Right upper. Extracapsular invasion of the lymph nodes: Not specified. inner. Margins: Not specified. quadrant. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: None.,BRCA,1,True,"The report indicates that one out of nine lymph nodes was positive for metastasis (Axillaris 1/9). This corresponds to the N1 stage, as per the rule: 'The presence of metastasis in 1 out of the examined lymph nodes corresponds to the N1 stage.'","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of metastasis in 1 out of the examined lymph nodes corresponds to the N1 stage.
The presence of metastasis in 2-3 out of the examined lymph nodes corresponds to the N1 stage.
The presence of metastasis in 4-9 out of the examined lymph nodes corresponds to the N2 stage.
The presence of metastasis in 10 or more out of the examined lymph nodes corresponds to the N3 stage.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of metastasis in 1 out of the examined lymph nodes corresponds to the N1 stage.
The presence of metastasis in 2-3 out of the examined lymph nodes corresponds to the N1 stage.
The presence of metastasis in 4-9 out of the examined lymph nodes corresponds to the N2 stage.
The presence of metastasis in 10 or more out of the examined lymph nodes corresponds to the N3 stage.",19.0,1791.0,91.0,True
585,TCGA-A7-A26I.CCE33A95-774E-4242-B2A1-05FF002ED1D9,1,"Date Coll: SPECIMEN. A. Left axillary sentinel node. B. Left breast mass. Long stitch anterior, short stitch superior. CLINICAL NOTES. PRE-OP DIAGNOSIS: Left breast cancer. CLINICAL HISTORY: year-old white female with breast cancer. POST-OP DIAGNOSIS: Left breast cancer. GROSS DESCRIPTION. A. Received fresh labeled ""left axillary sentinel nodes"". are two slightly rubbery tan-white-pink tissues in keeping. with lymph nodes measuring 0. and 1.0 cm. in greatest dimension. The specimens are bisected and entirely submitted independently in. two blocks (one bisected tissue per cassette). B. Received fresh within a TranSpec container labeled. 'left breast mass"" is a 7.3 cm. (medial to lateral) x 6.5. cm. (superior to inferior) x 3.7 cm. (anterior to posterior), soft,. lobulated tan gold-white portion of fibroadipose tissue with two. sutures as stated previously. The margins are inked as follows: Anterior - blue, posterior - black, superior - green, and inferior. orange. The specimen is sectioned from medial to lateral. There is. a central, moderately well-circumscribed, 3.2 cm. (medial to. lateral) x 2.5 cm. (superior to inferior) x 2.4 cm. (anterior to. posterior), firm tan white tumor mass with several central. associated cylindrical tan white structures in keeping with cyte of. prior needle core biopsy. A portion of tumor and a portion of. normal parenchyma are submitted for tissue procurement as requested. The tumor appears to focally extend to within 0.3 cm. of both the. anterior and posterior inked margins. The cut surfaces throughout. the remainder of the specimen consist predominantly of glistening. lobulated golden yellow adipose tissue with a minimal amount of. interspersed dense tan-white fibrous tissue. No additional. abnormality is noted. Representative sections are submitted in. a. sequential manner from medial to lateral in 10 blocks as labeled. BLOCK SUMMARY: 1 - Representative perpendicular sections medial. margin cap; 2-9 sequential sections; 10 - representative. perpendicular sections lateral margin cap. MICROSCOPIC DESCRIPTION. A. Microscopic examination involved the evaluation of the. four H&E stained sections of each of the tissue blocks. Also pan cytokeratin AE1/AE3 immunohistochemical stains were. evaluated of each tissue block and no metastatic tumor was. identified in any of the examined sections (0/2) (snpNO). B. Microscopic examination of the left breast lumpectomy. specimen reveals: Invasive Carcinoma: Present. Histologic type: Infiltrating ductal. Histologic grade: Elston's SBR grade 2. Overall grade: 2. Architectural score: 2. Nuclear score: 2. Mitotic score: 2. Greatest dimension (pT) : 3.2 cm. in greatest dimension (pT2). Specimen margins: The resection margins are negative for. carcinoma with the closest resection margins being superior and. anterior where invasive tumor is 2 mm. from the resection. margin. Tumor is 3 mm from the posterior resection margin. Vessel invasion: Not identified. Calcification: Present. Ductal carcinoma in situ: Present. Histologic pattern: Solid with cancerization of lobules. Nuclear grade: High grade. Central necrosis: Absent. % DCIS of total tumor (if mixed) : Less than 10%. Extensive intraductal component (present/absent) : Absent. Specimen margins: DCIS is 2 mm from the anterior and superior. margins and 3 mm from the posterior margin. Calcification: not identified. Description of non-tumorous breast: Fibrosis, apocrine metaplasia. and microcysts with sclerosing adenosis. Prognostic markers, Umpon been reported previously on the core. biopsy see. 4x2, 20x1. DIAGNOSIS. A. Left axillary sentinel lymph nodes, biopsy: Two lymph nodes negative for metastatic tumor (0/2). B. Left) breast, lumpectomy: Invasive ductal carcinoma, Elston's SBR grade 2, tumor size. 3.2 cm. Associated high grade solid ductal carcinoma in-situ. Invasive and in-situ carcinoma are 2 mm from the resection. margins designated superior and anterior and 3 mm from the. resection margin designated posterior. No lymphovascular space invasion identified. See microscopic description. (Electronic Signature). End Of Report ---.",BRCA,0,True,"The pathology report states that the left axillary sentinel lymph nodes, biopsy revealed two lymph nodes negative for metastatic tumor (0/2). This indicates that there is no malignancy found in the regional lymph nodes, which corresponds to an N0 stage.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of metastasis in 1 out of the examined lymph nodes corresponds to the N1 stage.
The presence of metastasis in 2-3 out of the examined lymph nodes corresponds to the N1 stage.
The presence of metastasis in 4-9 out of the examined lymph nodes corresponds to the N2 stage.
The presence of metastasis in 10 or more out of the examined lymph nodes corresponds to the N3 stage.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of metastasis in 1 out of the examined lymph nodes corresponds to the N1 stage.
The presence of metastasis in 2-3 out of the examined lymph nodes corresponds to the N1 stage.
The presence of metastasis in 4-9 out of the examined lymph nodes corresponds to the N2 stage.
The presence of metastasis in 10 or more out of the examined lymph nodes corresponds to the N3 stage.",19.0,1791.0,100.0,True
1304,TCGA-E9-A229.15FA41AE-3A0F-4112-828B-EE8687A6F158,0,"Laterality:Right, lower inner quadrant. Path Report:BREAST TISSUE CHECKLIST. Specimen type: Mastectomy. Specimen size: Not specified. Tumor site: Breast. Tumor size: 2 x 1.5 X 2 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal carcinoma. Histologic grade: Moderately differentiated. Tumor extent: Not specified. Lymph nodes: Not specified. Extracapsular invasion of the lymph nodes: Not specified. Margins: Not specified. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: None.",BRCA,0,True,"The pathology report does not mention any examination or findings related to regional lymph nodes, such as the number of lymph nodes examined, the number of positive lymph nodes, or extranodal extension. Therefore, based on the given rules, the N stage would be N0, indicating no positive lymph nodes.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of metastasis in 1 out of the examined lymph nodes corresponds to the N1 stage.
The presence of metastasis in 2-3 out of the examined lymph nodes corresponds to the N1 stage.
The presence of metastasis in 4-9 out of the examined lymph nodes corresponds to the N2 stage.
The presence of metastasis in 10 or more out of the examined lymph nodes corresponds to the N3 stage.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of metastasis in 1 out of the examined lymph nodes corresponds to the N1 stage.
The presence of metastasis in 2-3 out of the examined lymph nodes corresponds to the N1 stage.
The presence of metastasis in 4-9 out of the examined lymph nodes corresponds to the N2 stage.
The presence of metastasis in 10 or more out of the examined lymph nodes corresponds to the N3 stage.",19.0,1791.0,100.0,True
830,TCGA-AQ-A1H2.1B5FA34B-E3B4-4D4B-AF0A-1C90016CC532,1,"SURGICAL PATHOLOGY REVISED REPORT. Diagnosis: Breast, right, mastectomy. Tumor type: invasive ductal carcinoma with extensive fibrosis (see comment). Nottingham combined histologic grade: 2. Tubule formation score: 2. Nuclear Pleomorphism Score: 3. Mitotic count score: 2. Focality of tumor: single focus. Tumor size (greatest dimension): 3.5 cm (see comment). Lymphovascular invasion: present (A8). In Situ Component: present. In Situ Component type/Architecture pattern: solid and cribriform. In Situ Component nuclear grade: 3. In Situ Component necrosis: none identified. In Situ Component extent/size: DCIS is present with tumor and focally away from tumor. Size is approximately 6 mm. Extensive intraductal component: Absent. The DCIS comprises approximately 2% of total tumor. Nipple involvement: none identified. Skin involvement: none identified. Margin status: nvasive component: >5 mm. in Situ component: >5 mm. Axillary lymph nodes: Total number with metastasis: 7. Total number examined: 10 (1 from part A, 9 from part B below). Size of largest metastasis: 1.3 cm (A14, A15). Extracapsular extension: present and extends into fibrous septae of surrounding fibroadipose tissue. Microcalcifications: associated with invasive carcinoma, ductal carcinoma in situ, and sclerosing adenosis. Other findings: - Fibrocystic changes with ductal epithelial hyperplasia. - Sclerosing adenosis. - Benign skeletal muscle. AJCC PATHOLOGIC TNM STAGE: pT2 pN2a. Note: This pathologic stage assessment is based on information available at the time of this report, and is subject to. change pending clinical review and additional information. B: Soft tissue, axillary contents, removal. - Six of nine lymph nodes with metastatic carcinoma (6/9). - Largest metastatic focus 1.3 cm. - Extracapsular extension is present. Comment: Although two foci of carcinoma were previously identified radiologically (2.0 cm and 1.5 cm) and sampled by core. biopsy, only one large focus of tumor is identified grossly in this mastectomy specimen. Gross examination has. been repeated several times and additional sections submitted with no second tumor nodule identified. A second firm. nodule was identified 3 cm away from the first, but microscopically it appeared to be sclerosing adenosis and this was. confirmed with positive immunostaining with p63 and smooth muscle myosin heavy chain (A17). The current single. focus of tumor is extremely fibrotic and measures 3.5 cm (which is equal to the two previously identified foci combined). Of the two foci initially seen, one was described as superficial and the other deep, but they were very close to each. other (10:00 and 9:00 to 10:00). The current large focus is located at 9:00 to 10:00 and extends from superficial to. deep. Histologically, the tumor demonstrates morphologic features consistent with both of the previous core biopsies. (predominant morphology is that of the ""deep"" core with some areas resembling the ""superficial"" core). The. different-appearing areas merge into each other and are part of the same nodule of tumor. Immunostain for e-cadherin was performed on a couple of areas that have lobular features (similar to the superficial. core biopsy); it is positive, confirming the ductal phenotype of the tumor (A8, B3). Immunostain for AE1/AE3 was. performed on block B8 and confirms no metastatic tumor in that lymph node. Immunohistochemical stains for ER, PR and HER2/Neu were performed with the following results. These stains were. performed on tumor that resembles the deep core biopsy, and results are similar to those from the deep core biopsy. (except HER2 is 1+ instead of 0, but still considered negative). Material from an additional block (with areas resembling. the superficial core) has been submitted to see if it stains similarly to the superficial core; the original superficial. core showed HER2 at 2+ and amplification by FISH. These results will be reported in an addendum. Estrogen receptor (: , clone SP1): Interpretation: Positive. Computer-assisted quantitative score: 100%. Progesterone receptor (. clone 1E2): Interpretation: Positive. Computer-assisted quantitative score: 12%. HER2/neu (Ventana, clone 4B5, FDA-approved): Interpretation: Negative (not overexpressed). Computer-assisted quantitative score: 1+. Site: right breast. Performed on block: A7. Fixation: 10% neutral buffered formalin. Fixation time: 6-48 hours. Reference range: Estrogen receptor and progesterone receptor: <1%=NEGATIVE, 1-10% WEAK POSITIVE, >10% POSITIVE. HER2/neu: 0,1=NEGATIVE FOR OVEREXPRESSION, 2=INDETERMINATE, 3=POSITIVE FOR OVEREXPRESSION. Comment: The quantitative scores reported above were obtained using the FDA-approved. The control slides for this case show appropriate staining. Some of the immunohistochemical reagents used in this case may be classified as analyte specific reagents (ASR) or. research use only (RUO) reagents. These were developed and have performance characteristics determined by the. These reagents have not been cleared or. approved by the US Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not. necessary. These tests are used for clinical purposes. They should not be regarded as investigational or for research. This. laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform. high complexity clinical laboratory testing. Intraoperative Consult Diagnosis: Clinical History: with right breast cancer. Gross Description: Received are two appropriately labeled containers. Container A: Specimen fixation: formalin. Time in fixative: 9 hours. Type of mastectomy: modified radical. Weight of specimen: 970 grams. Size of specimen: 25 cm medial to lateral, 24 cm superior to inferior, and 3.5 cm anterior to posterior. Orientation of specimen: Inking: lateral=yellow, anterior=blue, posterior=black. Skin ellipse dimensions: 21.5 x 16.3 cm. Nipple/areola: 0.6 cm/3.4 cm, respectively. Axillary tail: absent. Biopsy site: not identified. Discrete Mass(es): present; one large firm mass is identified. The cut surface is tan with small areas of hemorrhage and. fat necrosis. The mass is well demarcated and lobular in shape. Number of discrete masses: one. Size of mass (es)/biopsy site: 3.5 x 2.9 x 1.8 cm. Location of mass(es): upper outer quadrant. Distance of mass/biopsy site from surgical margin: 2.4 cm from the black inked posterior margin and 4.5 cm from the. closest blue inked anterior margin. Gross involvement of skin or fascia/muscle by tumor: absent. Description of remaining breast: The remainder of the breast tissue is predominantly yellow lobulated fat which is. interspersed with delicate strands of white fibroconnective tissue. Other remarkable features: There is an arterial graft in the subareolar breast tissue that runs from the superior to. inferior aspects of the specimen. This graft is 11.7 cm long and 1.4 cm in diameter. Tissue submitted for special investigations: tumor and normal tissue are submitted for. Addendum: On further gross examination, a second mass is identified. The second mass is approximately 3 cm medial to. the first mass. The second mass is a well circumscribed, white firm nodule measuring 1.5 x 1.0 x 1.0 cm. This mass is 7.5. cm from the nearest blue inked anterior margin, 3.0 cm from the nearest black inked deep margin, and 3.0 cm from the. skin. There is no evidence of hemorrhage or necrosis associated with this mass. (Histologically, this mass is sclerosing. adenosis.). Block Summary: Inking: lateral=yellow, anterior=blue, posterior=black). A1 - perpendicular sections of nipple. A2 - areola, en face. A3 - representative section of mass with closest black inked posterior margin. A4 - representative section of breast tissue from closest anterior margin. A5-A9 - representative sections of mass. A10 - representative section of breast tissue from upper inner quadrant. A11 - representative section of breast tissue from lower inner quadrant. A12 - representative section of breast tissue from lower outer quadrant. A13 - representative section of breast tissue from upper outer quadrant. A14,A15 - intraparenchymal lymph node, serially sectioned. A16-A18- second mass, submitted entirely from lateral to medial. Container B holds a 9.5 x 5.4 x 3.5 cm mass of yellow/tan lobulated fat with associated connective tissue. This specimen. is unoriented. The specimen is dissected to identified lymph node candidates and multiple lymph node candidates. are identified. The largest candidate measures 3.1 x 1.9 x 1.0 cm. Block summary: 1,B2 - largest lymph node candidates, serially sectioned. B3 - one lymph node candidate, serially sectioned. B4 - one lymph node candidate, serially sectioned. B5 - one lymph node candidate, serially sectioned. B6 - three lymph node candidates. B7 - one lymph node candidate, serially sectioned. B8 - one lymph node candidate, serially sectioned. B9 - two lymph node candidates. B10 - three lymph node candidates. B11 - one lymph node candidate, bisected. B12 - one lymph node candidate. Grossing Pathologist: Light Microscopy: Light microscopic examination is performed by Dr. For cases in which immunostains are performed, the following applies: Appropriate internal and/or external positive and. negative controls have been evaluated. Some of the immunohistochemical reagents used in this case may be classified. as analyte specific reagents (ASR). These were developed and have performance characteristics determined by the. Anatomic Pathology Department,. These reagents have not been cleared or. oproved by the US Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not. necessary. These tests are used for clinical purposes. They should not be regarded as investigational or for research. This. laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform. high complexity clinical laboratory testing. Resident Physician: Attending Pathologist: I have personally conducted the evaluation of the above specimens and have. rendered the above diagnosis(es). Procedures/Addenda: Addendum. Addendum. The following addendum is issued to report the results of estrogen receptor, progesterone receptor, and HER2/neu. immunohistochemical studies. Estrogen receptor (1. 1, clone SP1): Interpretation: Positive. Computer-assisted quantitative score: 94%. Progesterone receptor t. clone 1E2): Interpretation: Negative. Computer-assisted quantitative score: 0%. HER2/neu (. clone 4B5, FDA-approved): Interpretation: Positive (overexpressed). Computer-assisted quantitative score: 3+ (see note). NOTE: This block (A5) includes areas that show morphologies similar to both the superficial and deep cores. ER and PR are. relatively homogeneous throughout the tumor, regardless of morphology. Immunostain for HER2 is heterogeneous, but. staining does not correlate with any particular morphology. There is enough strong complete staining to interpret the. HER2 as 3+ (overexpressed); however, areas in this block range from no staining to strong and complete staining. Site: right breast. Performed on block: A5. Fixation: 10% neutral buffered formalin. Fixation time: 6-48 hours. Reference range: Estrogen receptor and progesterone receptor: <1%=NEGATIVE, 1-10% WEAK POSITIVE, >10% POSITIVE. HER2/neu: 0,1=NEGATIVE FOR OVEREXPRESSION, 2=INDETERMINATE, 3=POSITIVE FOR OVEREXPRESSION. Comment: The quantitative scores reported above were obtained using the FDA-approved. The control slides for this case show appropriate staining. Jome of the immunohistochemical reagents used in this case may be classified as analyte specific reagents (ASR) or. research use only (RUO) reagents. These were developed and have performance characteristics determined by the. These reagents have not. been cleared or approved by the US Food and Drug Administration (FDA). The FDA has determined that such clearance. or approval is not necessary. These tests are used for clinical purposes. They should not be regarded as investigational. or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as. qualified to perform high complexity clinical laboratory testing.",BRCA,2,True,"The report states that 'Axillary lymph nodes: Total number with metastasis: 7. Total number examined: 10'. This means that 7 out of 10 lymph nodes have metastasis. According to the rules provided, N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes. Therefore, the N stage for this patient is N2.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.",N2,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.",15.0,1406.0,88.0,True
679,TCGA-A8-A09R.5E615F92-6FD0-48C7-AC37-78526974BCFC,1,"Concluding diagnosis: Left breast segment at 12 o'clock with a 3 cm moderately differentiated invasive ductal. carcinoma with concomitant low-grade DCIS grade II. The resection margins lie in healthy. tissue on all sides. Two of a total 16 lymph nodes with metastases (2/16). Tumor classification: pT2 (3 cm), pN1a (2/16), MX, R0; G2, L0, V0.",BRCA,1,True,"The report indicates that out of a total of 16 lymph nodes examined, 2 had metastases. This corresponds to the N1 stage, as defined by the rules provided, which states that N1 indicates 1-3 positive nodes.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastases in 1-3 regional lymph nodes corresponds to N1 stage.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastases in 1-3 regional lymph nodes corresponds to N1 stage.",16.0,1470.0,98.0,True
842,TCGA-AR-A0TW.F832C787-3668-475F-8F67-6342DA3777F4,2,"Breast, right, modified radical mastectomy: Multifocal ductal carcinoma of the breast. The largest tumor. is a Nottingham grade III (of III) ductal adenocarcinoma (5.5 cm in greatest dimension). There are. multiple (3) additional tumors (all Nottingham grade II (of III) 2.0 cm 1.5 cm, and 1.0 cm in greatest. dimension. The surgical margins are negative. Metastatic adenocarcinoma is identified in multiple (3 of. 27) right axillary lymph nodes. The largest node of metastasis measures 3.5 cm in greatest dimension. No definite extracapsular extension is identified. Breast, left, simple mastectomy: Nonproliferative fibrocystic changes characterized by dense fibrosis,. cyst formation, and fibroadenomatous change. Nipples, left and right, excision: Negative for malignancy.",BRCA,1,True,The report states that metastatic adenocarcinoma is identified in 3 out of 27 right axillary lymph nodes. This corresponds to N1 stage as per the rule: 'Metastases in 1-3 regional lymph nodes corresponds to N1 stage.',"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.",15.0,1406.0,98.0,True
803,TCGA-AO-A0JI.468411B5-1719-46B4-835D-E469D6AEFF12,0,"Clinical Diagnosis & History: Internal development of enhancing mass on MRI left breast, core biopsy. showed infiltrating ductal carcinoma (IFDC) and DCIS, history of right. infiltrating ductal carcinoma 0.3 cm 0/6 sentinel lymph node, status post. right TM sentinel lymph node biopsy 8/05. Specimens Submitted: 1: SP: Sentinel node #1, level 1, left axilla (fs). 2: SP: Sentinel node #2, level 2, left axilla (fs) (. 3: SP: Left breast. 4: SP: Nonsentinel nous left axilla. DIAGNOSIS: 1). LYMPH NODE, SENTINEL #1 LEVEL I LEFT AXILLA; EXCISION: - METASTATIC CARCINOMA IN THE FORM OF MICROSCOPIC CLUSTERS AND SINGLE. CELLS, MEASURING 0.5 MM (MICROMETASTATIC) IS IDENTIFIED IN ONE LYMPH NODE. (1/1) ON ADDITIONAL H&E STAINED SECTIONS AND CYTOKERATINS. IMMUNOHISTOCHEMCIAL STAINS (AE1:AE3). - THERE IS NO EXTRACAPSULAR EXTENSION OF CARCINOMA. 2). LYMPH NODE, SENTINEL #2 LEVEL II LEFT AXILLA; EXCISION: - ONE BENIGN LYMPH NODE (0/1). - ADDITIONAL HE STAINED SECTIONS AND IMMUNOHISTOCHEMICAL STAINS FOR. CYTOKERATINS AE1:AE3) SHOW NO EVIDENCE OF METASTATIC CARCINOMA. 3). BREAST, LEFT; MASTECTOMY: - INVASIVE DUCTAL CARCINOMA, NOS TYPE, POORLY DIFFERENTIATED,. HISTOLOGIC GRADE III/III (SLIGHT OR NO TUBULE FORMATION), NUCLEAR GRADE. III/III (MARKED VARIATION IN SIZE AND SHAPE). , MEASURING 1.1 CM IN LARGEST. DIMENSION MICROSCOPICALLY. DUCTAL CARCINOMA IN SITU (DCIS) IS ALSO IDENTIFIED, SOLID TYPE, WITH HIGH. NUCLEAR GRADE AND MINIMAL NECROSIS. - THE DCIS CONSTITUTES LESS THAN OR EQUAL TO 25% OF THE TOTAL TUMOR MASS,. AND IS PRESENT ADMIXED WITH THE INVASIVE COMPONENT. - LOBULAR CARCINOMA IN SITU (LCIS) IS ALSO IDENTIFIED, CLASSICAL TYPE (TYPE. A) INVOLVING SCLEROSING ADENOSIS. THE INVASIVE CARCINOMA IS LOCATED IN THE UPPER OUTER QUADRANT. - THE DCIS IS LOCATED IN THE UPPER OUTER QUADRANT. - NO INVOLVEMENT OF THE NIPPLE BY EITHER IN SITU OR INVASIVE CARCINOMA IS. IDENTIFIED. CALCIFICATIONS ARE PRESENT IN THR IN SITU AND INVASIVE CARCINOMA, AND IN. BENIGN BREAST PARENCHYMA. - NO VASCULAR INVASION IS NOTED. - NO INVOLVEMENT OF THE SURGICAL MARGINS BY EITHER INVASIVE OR IN SITU. CARCINOMA IS IDENTIFIED. - NO SKIN INVOLVEMENT BY CARCINOMA IS IDENTIFIED. - THE SKIN SHOWS SEBORRHEIC KERATOSIS. - THE NON-NEOPLASTIC BREAST TISSUE SHOWS BIOPSY SITE CHANGES, EXTENSIVE. SCLEROSING ADENOSIS, RADIAL SCAR, ATYPICAL DUCTAL HYPERPLASIA (ADK),. INTRADUCTAL SCLEROSED PAPILLOMA WITH FOCAL ATYPIA, FIBROADENOMA AND CYST. FORMATION. - RESULTS OF SPECIAL STAINS (ER, PR, HER2-NEU) ARE AS FOLLOW: Immunohistochemical stains were performed on formalin-fixed tissue with the. following results for invasive carcinoma (block 6) : ESTROGEN RECEPTOR. 95% nuclear staining with strong intensity. PROGESTERONE RECEPTOR. 0% nuclear staining. HER2 (HercepTest;. Negative (0 / 1+). (1% of invasive tumor cells exhibit complete membranous staining;. Uniformity of staining: absent;. Homogeneous, dark circumferential pattern: absent). Controls are satisfactory. Comment: HercepTestTM ( 1 is an FDA-approved method for assessment of. HER2 protein overexpression in breast cancer tissue routinely processed for. histological evaluation. The HER2 test results are reported in accordance. with the ASCO/CAP guideline recommendations for HER2 testing in breast. cancer (J Clin Oncol 2007; 25 (1) :1-28) . 4). LYMPH NODE, NON-SENTINEL LEFT AXILLA; EXCISION: - ONE BENIGN LYMPH NODE (0/1) -. I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL), AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. Gross Description: MD. 1). The specimen is received fresh for frozen section consultation, labeled. Sentinel mode #1, level 1, left axilla"" and consists of a single yellow-tan. firm and fatty lymph node measuring 4.7 cm. The node is trisected and two. half are submitted for frozen section in cassettes labeled as A and B. The. remaining fatty portion is bisected and entirely submitted for permanent. section. Summary of sections: FSC-A -- frozen section control-A. FSC-Bfrozen section control B. RLN- remaining lymph node. 2). The specimen is received fresh for frozen section consultation,. labeled ""Sentinel node #2, level 2, left axilla"" and consists of a single. pink-tan - fatty lymph node measuring 1.6 cm in greatest dimension. Bisected. and entirely submitted for frozen section. Summary of sections: FSC -- frozen section control. .D. 3). The specimen is received fresh, labeled ""left breast, stitch marks. axillary tail"" and consists of a breast measuring 25 x 24 x 4 cm with. overlying skin ellipse measuring 24 x 7.5 cm. Situated central/superiorly. on the skin surface is an everted nipple measuring 1.0 x 0.9 x 0.5 cm and. areola measuring 3.0 x 2.7 cm. The skin shows a raised pigmented lesion. measuring 1.0 x 0.5 x 0.2 cm, located 1.8 cm medial to the areola. No scar. is grossly identified on the skin surface. A suture demarcates the axillary. aspect. The posterior surface of the breast is inked black and the radial. margin is inked blue. The specimen is serially sectioned to reveal a firm,. white, well-circumscribed mass measuring 1.0 x 1.0 x 0.9 cm, located within. the upper outer quadrant at the two o'clock aspect, 1.2 cm from the deep. margin. A hemorrhagic biopsy site is associated with the mass. An irregular. area of white fibroglandular tissue is located immediately medial to the. mass and measures approximately 5 x 5 x 3 cm. No additional discrete masses. are grossly identified. Sectioning of the axillary aspect reveals no grossly. identifiable lymph nodes. Representative sections are submitted. TPS is. taken. Summary of sections: N - nipple with nipple base. S - skin with pigmented lesion. D - deep margin. BX - biopay site. T - tumor, entirely submitted. FG - dense fibroglandular tissue medial to the mass. UIQ - upper inner quadrant. LIQ - lower inner quadrant. UOQ - upper outer quadrant. LOQ - lower outer quadrant. M.D. 4). The specimen is received in formalin, labeled ""non-sentinel node left. axilla"" and consists a single lymph node with surrounding fibrofatty tissue. measuring 1.2 x 0.4 cm. The lymph node is bisected and entirely submitted. Summary of sections: U-undesignated. Summary of Sections: Part 1: SP: Sentinel node #1, level 1, left axilla (fs). Block. Sect. Site. PCs. 1. FSC-A. 1. 1. FSC-B. 1. 1. RLN. 3. Part 2: SP: Sentinel node #2, level 2, left axilla (fs). Block. Sect. Site. PCs. 1. FSC. 1. Part 3: SP: Left breast (sr). Block. Sect. Site. PC's. 2. BX. 2. 1. D. 1. 9. FG. 9. 1. LIQ. 1. 1. LOQ. 1. 1. N. 1. 1. s. 1. 2. 2. 1. UIQ. 1. 1. UOQ. 1. Part 4: SP: Nonsentinel node left axilla. Block. Sect. Site. PCs. 1. U. 1. Intraoperative Consultation: Note: The diagnoses given in this section pertain only to the. tissue sample examined at the time of the intraoperative. consultation. 1). FROZEN SECTION DIAGNOSIS: GROSSLY LARGE AND FATTY LYMPH. NODE. REPRESENTATIVE SECTIONS FROZEN AND SHOW NO TUMOR ON FROZEN SECTION. PERMANENT DIAGNOSIS: SAME. ., MD.",BRCA,1,True,"Based on the report, metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.5 mm (micrometastatic) is identified in one sentinel lymph node (1/1) in level I of the left axilla. This indicates that the N stage is N1, as per the rule: 'N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.'","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
N stage is determined by the number of positive lymph nodes, with N0 indicating no positive nodes, N1 indicating 1-3 positive nodes, N2 indicating 4-9 positive nodes, and N3 indicating 10 or more positive nodes.
The N stage is not affected by the presence or absence of estrogen or progesterone receptors.
The N stage is not affected by the HER2/NEU status of the tumor.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
A higher number of positive lymph nodes results in a higher N stage.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.",16.0,1564.0,95.0,True
1283,TCGA-E9-A1NI.3F4F5A98-F6EA-46D5-95E8-6797D419328A,1,Ne. BREAST TISSUE CHECKLIST. Specimen type: Mastectomy. Specimen size: Not specified. Tumor site: Breast. Tumor size: 2.3 x 1.8 x 1.8 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal and lobular carcinoma. Histologic grade: Tumor extent: Not specified. Lymph nodes: 0/4 positive for metastasis (Regional 0/4). Extracapsular invasion of the lymph nodes: Not specified. Left upper. Margins: Not specified. outer. quadrant. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments; None.,BRCA,0,True,"The report indicates that 0 out of 4 regional lymph nodes were positive for metastasis. According to the rules, if no malignancy is found in regional lymph nodes, the N stage is N0.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.",13.0,1193.0,84.0,True
1496,TCGA-PL-A8LY.8C97B391-96B4-468D-AAA3-24E196DE03CA,2,"Sex: Female. Date of Tumour Procurement: 1. GROSS ASSESSMENT: Cut section showed a variegated tumour measuring. 3.4x2.5x1.5cm. 2. MICROSCOPIC ASSESSMENT. Microscopic description: Section shows a malignant tumour in cords, solid nests and. tubular patterns. It is composed of large cells having moderately pleomorphic. hyperchromatic nuclei and amphophilic cytoplasm. The stroma is demoplastic containing. similar tumour cells and aggregates of lymphocytes. Focal areas of necrosis noted. 3. Tumour Type: Malignant. 4. Tumour Site: Right Breast. 5. Distance of invasive carcinoma to closest margin: -5mm. Which margin? Deep resection. 6. HISTOLOGICAL DIAGNOSIS: Invasive Ductal Carcinoma. 7. COMMENTS: Dr. Reporting Pathologist Name.",BRCA,0,True,"The pathology report does not provide information about the regional lymph nodes, including the number of lymph nodes examined, the number of nodes with malignancy, or the presence of extranodal extension. Therefore, based on the given rules, the N stage is N0, which indicates no malignancy in regional lymph nodes.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.",13.0,1193.0,100.0,True
1014,TCGA-BH-A0E7.CE32A294-10FC-4DBA-A779-FAEEBE677D38,1,"FINAL DIAGNOSIS: PART. LEFT BREAST, SEGMENTAL BIOPSY -. A. INVASIVE DUCTAL CARCINOMA, NOTTINGHAM GRADE 7/9 (NUCLEI 3, TUBULES 2, MITOSES 2) WITH FOCI OF. MICRO PAPILLARY FEATURES.( (See comments). B. MICRO PAPILLARY CARCINOMA ACCOUNT TO ABOUT 10 % OF THE TUMOR MASS. C. TUMOR SIZE 2.1 X 1.8 X 1.3 CM. D. DUCTAL CARCINOMA IN-SITU NUCLEAR GRADE 2, SOLID AND MICROPAPIILLARY ACCOUNTING TO. 5% OF THE TUMOR MASS, PRESENT ADJACENT AND ADMIXED WITH THE INVASIVE CARCINOMA. E. NO PROMINENT ANGIOLYMPHATIC INVASION. F. MARGINS ARE FREE OF INVASIVE AND IN SITU CARCINOMA; CLOSEST MARGIN IS POSTERIOR MARGIN. WHICH IS 1MM FROM THE TUMOR. G. FIBROCYSTIC CHANGES WITH DUCTAL EPITHELIAL HYPERPLASIA. H. MICROCALCIFICATIONS PRESENT IN BENIGN EPITHELIUM AND ARTERIAL WALL. 1. ESTROGEN RECEPTOR POSITIVE, PROGESTERONE RECEPTOR POSITIVE AND HER-2.NEU NEGATIVE (1+). PART 2: LEFT AXILLARY DISSECTION CONTENTS, DISSECTION -. A. ONE OF SEVENTEEN LYMPH NODES WITH METASTATIC TUMOR (1/17). B. THE METASTATIC CARCINOMA IN THE LYMPH NODE MEASURED 1.2X0.8 CM WITH EXTRACAPSULAR. SPREAD ABOUT. PART 3: LEFT BREAST, NEW DEEP MARGIN, LEFT. SEGMENTAL MASTECTOMY - carcinoma, infiltrating ductal, NOS. SKELETAL MUSCLE AND FIBROADIPOSE TISSUE, FREE OF TUMOR. CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Segmental. Not specified. SIZE OF TUMOR: Maximum dimension invasive component: 2 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR AGGREGATE SIZE: Sum of the sizes of multiple invasive tumors: 2.1 cm. TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS, Other Type(s): micropapillary. NOTTINGHAM SCORE: Nuclear grade: 3. Tubule formation: 2. Mitotic activity score: 2. Total Nottingham score: 7. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: Not applicable. CALCIFICATION: Yes, benign zones. TUMOR TYPE, IN SITU: Solid, DCIS admixed with invasive carcinoma, Percent of tumor occupied by in situ. component: 5% %. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 3 mm. SURG MARGINS INVOLVED BY IN SITU COMPONENT: Distance of in situ disease to closest margin: 13 mm. PAGET'S DISEASE OF NIPPLE: LYMPH NODES POSITIVE: 1. LYMPH NODES EXAMINED: 17. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SENTINEL NODE METASTASIS: ONLY KERATIN POSITIVE CELLS ARE PRESENT: SIZE OF NODAL METASTASES: Diameter of largest lymph node metastasis: 10 mm. LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: METASTASES TO IPSILATERAL INTERNAL MAMMARY LYMPH NODE (IF APPLICABLE): SKIN INVOLVED (ULCERATION): NON-NEOPLASTIC BREAST TISSUE: FCD. pT2. T STAGE, PATHOLOGIC: N STAGE, PATHOLOGIC: pN1. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTORS: positive. HER2/NEU: zero or 1+.",BRCA,1,True,"The pathology report indicates that one out of seventeen lymph nodes had metastatic tumor (1/17). This is consistent with N1 stage, as a higher number of positive lymph nodes results in a higher N stage. Micrometastasis is considered a positive lymph node and classified as N1, and the method of evaluation of sentinel lymph nodes can affect the N stage. The report mentions that only keratin positive cells are present in the sentinel node, which supports the presence of metastatic carcinoma.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.",13.0,1193.0,100.0,True
1049,TCGA-BH-A18G.7C92F144-4A84-4D9E-8A35-C059FD082150,0,"PATIENT HISTORY: CHIEF COMPLAINT/PRE-OP/POST-OP DIAGNOSIS: Right breast cancer. LMP DATE: PROCEDURE: Right needle localized segmental mastectomy and right axilla sentinel node biopsy. SPECIFIC CLINICAL QUESTION: Not provided. OUTSIDE TISSUE DIAGNOSIS: No. PRIOR MALIGNANCY: No. CHEMORADIATION THERAPY: No. OTHER DISEASES: No. FINAL DIAGNOSIS: PART 1: RIGHT AXILLARY SENTINEL LYMPH NODE #1, BIOPSY -. ONE (1) LYMPH NODE, NEGATIVE FOR NEOPLASM (0/1). PART 2: RIGHT BREAST AT 8 O'CLOCK, NEEDLE LOCALIZED SEGMENTAL MASTECTOMY -. A. INVASIVE DUCIAL CARCINOMA, NOTTINGHAM GRADE 3 (NUCLEAR GRADE 3, TUBULE SCORE 3, MITOTIC. ACTIVITY SCORE 2; TOTAL SCORE: 8/9). B. TUMOR MEASURES 2.7 CM (GROSS MEASUREMENT). C. NO LYMPHOVASCULAR SPACE INVASION IS IDENTIFIED. D. MARGINS ARE NEGATIVE FOR NEOPLASM; TUMOR APPROACHES MOST CLOSELY TO THE SUPERIOR. MARGIN (0/9) CM. E. ATYPICAL DUCTAL HYPERPLASIA, AND RADIAL SCAR. F. SCLEROSING ADENOSIS AND FIBROCYSTIC CHANGES. G. FIBROSIS, SUGGESTIVE OF PREVIOUS BIOPSY. H. SKIN, NEGATIVE FOR TUMOR. TUMOR PREVIOUSLY REPORTED TO BE POSITIVE FOR ER AND PR AND NEGATIVE FOR HER-2/neu. J. PATHOLÃ“GIC STAGE: PT2 pNO pMX. PART 3: RIGHT BREAST, EXCISION (102 GRAMS) -. A. FAT NECROSIS AND FIBROSIS. B. FIBROCYSTIC CHANGES AND COLUMNAR CELL CHANGE. C. SKIN WITH NO SIGNIFICANT PATHOLOGIC DIAGNOSIS. PART 4: LEFT BREAST TISSUE, EXCISION (254 GRAMS) -. A. SCLEROSING ADENOSIS, COLUMNAR CELL CHANGE, AND FIBROCYSTIC CHANGES. 8. SKIN WITH NO SIGNIFICANT PATHOLOGIC DIAGNOSIS. CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Right. PROCEDURE: Segmental. Lower outer quadrant. SIZE OF TUMOR: Maximum dimension invasive component: 27 mm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 3. Tubule formation: 3. Mitotic activity score: 2. Total Nottingham score: 8. Nottingham grade (1, 2. 3): 3. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 9 mm. LYMPH NODES POSITIVE: 0. LYMPH NODES EXAMINED: 1. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. T STAGE, PATHOLOGIC: pT2. N STAGE MODIFIER: (sn). N STAGE, PATHOLOGIC: pNO. M STAGE: Not applicable. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTORS: positive. HER2/NEU: 1+.",BRCA,0,True,"The report states that 1 lymph node was examined and found to be negative for neoplasm (0/1). This indicates that there is no malignancy found in the regional lymph nodes, which according to the first rule, corresponds to an N0 stage.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.",13.0,1193.0,100.0,True
745,TCGA-AN-A04A.6FB7A794-C3E7-4501-A844-CF65B9C3D32C,1,Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Left Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: OCT. Container: block Type of Procurement: Radical mastectomy Grade: 2. T Stage: 2 N Stage: 2 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.,BRCA,2,True,"The N stage is reported as 2, which indicates that there are 1-3 axillary lymph nodes with metastatic carcinoma. This is determined by the statement 'N Stage: 2' in the report.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.
The N stage is a separate entity from the T and M stages, and is determined by the number of positive lymph nodes",N2,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.
The N stage is a separate entity from the T and M stages, and is determined by the number of positive lymph nodes",14.0,1307.0,95.0,True
556,TCGA-A2-A3XX.770EEADF-19CD-4AB9-A7FA-1A05EE17984C,1,"Specimen #: (Age. Race. SPECIMEN: A: SENTINEL NODE #1 B: LEFT BREAST TISSUE. FINAL DIAGNOSIS: A. LYMPH NODE, SENTINEL #1, BIOPSY: - ONE (1) LYMPH NODE NEGATIVE FOR METASTATIC CARCINOMA BY H&E AND. IMMUNOSTAINS. B. BREAST, LEFT, MASTECTOMY: - TUMOR TYPE: INFILTRATING DUCTAL CARCINOMA. - NOTTINGHAM GRADE: 3 OUT OF 3. - NOTTINGHAM SCORE: 8 OUT OF 9 (Tubules= 3, Nuclei= 2, Mitoses= 3. mitotic count 22 per 10 HPF at 40x power). TUMOR SIZE (GREATEST DIMENSION) : 2.2 CM (MEASURED GROSSLY). - TUMOR NECROSIS: PRESENT IN BOTH THE INVASIVE AND IN SITU COMPONENTS. - MICROCALCIFICATIONS: ABSENT. - VENOUS / LYMPHATIC INVASION: ABSENT. - MARGINS NEGATIVE. DISTANCE OF TUMOR FROM NEAREST MARGIN IS 0.1 CM, FROM THE. SUPERFICIAL (GREEN INKED) MARGIN. (MEASURED MICROSCOPICALLY) (SLIDE. B6). - INTRADUCTAL COMPONENT: PRESENT. DUCTAL CARCINOMA; HIGH NUCLEAR GRADE. (GRADE III) SOLID SUBTYPE WITH CENTRAL NECROSIS. - LYMPH NODES: ONE (1) NEGATIVE FOR TUMOR. (SEE PART A). - NIPPLE INVOLVEMENT: ABSENT. - SKIN INVOLVEMENT: ABSENT. - MULTICENTRICITY: ABSENT. - ESTROGEN RECEPTORS: NEGATIVE (SEE CASE. - PROGESTERONE RECEPTORS : NEGATIVE (SEE CASE. - HER 2 NEU by IHC: NEGATIVE (SEE CASE. - PATHOLOGIC STAGE: pT2 NO (i-) MX. - ADDITIONAL PATHOLOGIC CHANGES. INTRADUCTAL PAPILLOMA. FIBROADENOMATOUS CHANGES. FIBROCYSTIC CHANGES. COMMENT: Cytokeratin staining of part A supports the above diagnosis. This case received prospective intradepartmental peer review. FOR OFFICIAL USE ONLY - PERSONAL DATA - PRIVACY ACT OF. FOR OFFICIAL US ONLY - PERSONAL DATA - PRIVACY ACT or. Specimen #. FINAL DIAGNOSIS (continued). CLINICAL DIAGNOSIS AND HISTORY: yr old. with left breast cancer. PRE-OPERATIVE DIAGNOSIS: none provided. POST-OPERATIVE DIAGNOSIS: none provided. GROSS DESCRIPTION: A: Received fresh, labeled with the patient's name,. Id. designated ""Sentinel Node #1 with markings; suture marks hottest point at. 1152 hours"" is a 2.5 x 2.5 x 0.7 cm irregular portion of soft tissue. Sectioning reveals a 2.5 x 1.5 x 0,5 cm pink-tan lymph node with attached. adipose tissue. The specimen is entirely submitted as follows: Cassette Summary: A1- sentinel lymph node; A2- adipose tissue. At the time of submission the specimen will have been in formalin for. approximately 23 hours Matched sections of cassette A1 are. submitted in OCT for. Protocol. B: Received fresh, labeled with the patient's name,. and. designated ""Left Breast Tissue, long-lateral, short-superior 1 pm' is. a. 468 gm left mastectomy specimen oriented with a short stitch at the. superior aspect and long stitch at the lateral aspect. The specimen. measures 20.0 cm from superior to inferior by 18.0 cm from medial to. lateral by 3.0 cm from anterior to posterior. The darkly pigmented skin. ellipse measures 9.5 x 3.5 cm and displays a 1.5 cm centrally located,. everted nipple free of discharge. The deep margin is inked in black, and. the left outer quadrant superficial margin is inked in green. Serial. sectioning reveals a 11-circumscribed 2.2 x 2. x 1.8 cm mass in the. lower outer quadrant located 0.3 cm from the superficial margin and 0. cm. from the deep margin. The cut surface is firm gritty pink-red and focally. congested. The remainder of the specimen is composed of evenly. distributed pink-tan fibrous tissue admixed adipose tissue. No additional. lesions are identified. No lymph nodes are identified within the specimen. FOR OFFICIAL USE ONLY - PERSONAL DATA - PRIVACY ACT OF. FOR OFFICIAL USE ONLY - PERSONAL DATA - PRIVACY ACT or. specimen #: GROSS DESCRIPTION (continued) : Representative sections are submitted. At the time of submission the. specimen has fixed in formalin for approximately 21 hours. Cassette Summary: B1- - skin; B2-B3 - lower outer quadrant deep margin;. B4-B6- mass with superficial margin; B7 - representative section of grossly. normal breast parenchyma from the upper outer quadrant; B8- representative. section of grossly normal breast parenchyma from the upper inner quadrant;. B9 representative section of grossly normal breast parenchyma from the. lower inner quadrant; B10- representative section of grossly normal breast. parenchyma from the lower outer quadrant; B11- - representative section of. grossly normal breast parenchyma from the central area; B12-. representative section of nipple with associated subcutaneous tissue. Matched sections of cassette B1, B4-B5, B7-B11 are submitted in OCT for. ) Protocol. FOR OFFICIAL USE ONLY - PERSONAL DATA - PRIVACY.",BRCA,0,True,"The report states that one sentinel lymph node was examined and found to be negative for metastatic carcinoma. According to the rules, if no malignancy is found in regional lymph nodes, the N stage is N0.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.",13.0,1193.0,95.0,True
632,TCGA-A8-A07R.FD75D315-EED7-4350-A890-8FB94648E9FC,1,"Diagnosis: 1. Left breast segment at 2 o'clock with a poorly differentiated invasive ductal carcinoma,. max. 4.6 cm in size, with concomitant high-grade DCIS III with comedo necroses. Tumor classification based on the preliminary findings: pT2 (4.6 cm), pN3a (15/22), MX, R1. (peripheral invasive carcinoma), G3, (L1, V1).",BRCA,3,True,The report indicates that the tumor is a poorly differentiated invasive ductal carcinoma with a size of 4.6 cm (pT2) and that it has metastasized to 15 out of 22 examined lymph nodes (pN3a). This information supports the N3 stage.,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.",N3,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.",13.0,1193.0,100.0,True
1510,TCGA-V7-A7HQ.82B46073-10CE-4D05-9421-6308E3FAD1AD,0,"SurgicalFinal Report. l'emporary. orderediby. Final Pathologic Diagnosis. CORRECTED REPORT: A) SENTINEL NODE #1 (EXCISION): One lymph node involved by metastatic carcinoma (1/1). B) SENTINEL NODE #2 (EXCISION): One out of two lymph nodes, involved by metastatic carcinoma. (micrometastases) (1/2). C) SENTINEL LYMPH NODE #3 (EXCISION): One out of two lymph nodes, involved by metastatic carcinoma. (micrometastases) (1/2). D) RIGHT BREAST (MASTECTOMY): Invasive ductal carcinoma, Nottingham grade 2. See synoptic report. E) NEW INFERIOR MARGIN (EXCISION): Breast tissue with benign fibrocystic changes, including ductal. hyperplasia and apocrine metaplasia. Negative for malignancy. NOTE: This corrected report is being issued due to a typographical error In the original report. The initial diagnosis rendered by. remains unchanged. I attest I have personally reviewed the specimen/slides and agree with the above findings. Synoptic Report. D: BREAST, MASTECTOMY -. SPECIMEN TYPE: Mastectomy. LYMPH NODE SAMPLING: Sentinel lymph node with axillary dissection. SPECIMEN SIZE: Surgical Final Report. Temporary Copy. case. Greatest dimension: 30 cm. Additional dimensions: 7.0 x 2.5. LATERALITY: Right. TUMOR SITE: Lower outer quadrant. SIZE OF INVASIVE COMPONENT: Greatest dimension: 2.0 cm. Additional dimensions: 1.5 x 1.0 cm. Two separate lesions were present, each one measuring 2.0 x 1.5 x 1.0 cm. HISTOLOGIC TYPE: Ductal carcinoma in situ. Invasive ductal carcinoma. HISTOLOGIC GRADE: Tubule formation: Moderate 10% to 75% (score = 2). Nuclear pleomorphism: Marked variation in size, nucleoli, chromatin clumping, etc. (score =. 3). 0 to 5 mitoses per 10 HPF (score = 1). Nottingham Grade II: 6-7 points. PRIMARY TUMOR (pT): pT1c: Tumor more than 1.0 cm but not more than 2.0 cm in greatest dimension. REGIONAL LYMPH NODES (pN): pN2a: Metastasis in 4 to 9 axillary lymph nodes (at least 1 tumor deposit greater than 2.0. mm). Number examined: 18. Number involved: 5. DISTANT METASTASIS (M): pMX: Cannot be assessed. MARGINS: Margin(s) involved by invasive carcinoma. Specify which margin(s): Inferior margin at mastectomy (specimen D). See comment. EXTENT OF MARGIN INVOLVEMENT FOR INVASIVE CARCINOMA. VENOUS/LYMPHATIC (LARGE/SMALL VESSEL) INVASION (V/L): Present. MICROCALCIFICATIONS: Present in DCIS. ADDITIONAL PATHOLOGIC FINDINGS: Fibrocystic changes, biopsy site related changes, and columnar cell hyperplasia. COMMENT(S): The inferior margin is invovled by carcinoma in the mastectomy specimen (specimen D),. however, additionally submitted inferior resection margin is not involved (specimen E). Clinical. correlation is necessary for interpretation of these findings. Diagnostic Comment. According to previous biopsy, 65% of tumor cells show moderate to strong nuclear staining. for estrogen receptors, 80% of tumor cells show nuclear staining show strong nuclear staining. for progesterone receptors, and Her2-neu gene is not amplified by FISH (please see report. Surgical Final Report. emporary Copy. Intraonerative Diagnosis. TP A1: Touch prep positive for carcinoma. No frozen done. TP B1: No touch preps done because first sentinel lymph node is positive. TP C1: No touch preps done because first sentinei lymph node is positive. Clinical History. year old female with breast cancer. Pre/Post-operative Diagnosis. Breast cancer. Gross Anatomic Description. (SPECIMEN D: Dictated by. (SPECIMENS A-C and E: Dictated by. Specimens received in five containers. Snecimen A: Designated ""sentinel node #1"" is received fresh for intraoperative consultation on. labeled with the patient's name and ""sentinel node #1"". Specimen consists one piece of. yellow tissue measuring 1.2 x 1.0 x 0.6 cm. The lymph node is bisected. Touch prep is done. No. frozen section is performed. Section code: A1 - two pieces, one lymph node, entire specimen. Specimen B: Designated ""sentinel node #2"" is received fresh for intraoperative consultation on. labeled with the patient's name and ""sentinel node #2"". Specimen consists of one yellow/tan. irregular fragment of tissue measuring 0.8 x 0.6 x 0.3 cm. No intraoperative procedure performed. Entirely submitted for permanent sections. Section code: B1 - entire specimen. Specimen C: Designated ""sentinel node #3"" is received fresh for intraoperative consultation on. labeled with the patient's name and ""sentinel node #3"". Specimen consists of one yellow/tan. fatty fragment of tissue measuring 0.8 x 0.4 x 0.4 cm. The specimen is bisected revealing one lymph. node. No intraoperative procedure performed. Entirely submitted for permanent sections. Section code: C1 - two pieces, one lymph node, entire specimen. Specimen D: Designated ""right mastectomy (stitch on lateral margin, clip on apex of dissection)"" is. received fresh for Tumor Bank on. labeled with the patient's name, MRN and ""right. mastectomy (stitch on lateral margin, clip on apex of dissection). Specimen consists of one right. radical mastectomy with attached axillary tail weighing 220.8 g. The specimen measures 30.0 x 7.0. x. 2.5 cm. The axillary tail measures 13.0 x 3.5 x 2.0 cm. The breast measures 17.0 x 6.0 x 2.5 cm. There is an overlying ellipse of tan wrinkled skin measuring 15.0 x 6.0 cm. There is an unremarkable. nipple measuring 1.5 cm in diameter and 0.5 cm in thickness. The areola measures 4.0 x 3.5 cm and. is unremarkable. The external palpation of skin reveals two firm masses which are inferior lateral to. the nipple, at the outer lower quadrant. One is at 3.5 cm from the nipple and the other is at 2.0 cm. from the nipple. The suture is identified which denotes the lateral margin. Cut surface reveals two. white/tan spiculated tumors. The medial tumor measures 2.0 x 1.5 x 1.0 cm with what appears to be. a. previous biopsy site. The more lateral tumor mass measures 2.0 x 1.5 x 1.0 cm and also appears to. have a previous biopsy site. The tumor masses appear to be connected by a white/tan tract of tumor. Surgica Final Report. Temporary.Copy. Collectedal. D. orderediby. measuring 0.5 x 0.2 x 0.2 cm. The lateral tumor comes within <0.1 cm of the inferior margin and 0.2. cm of the deep margin. The medial tumor comes within 0.1 cm of the inferior margin and appears to. abut the deep margin. Both tumors are >3.0 cm from the superior and medial margins. The. remainder of the cut sections are grossly unremarkable as yellow/tan fatty fibrous tissue. There is a. free floating fragment of breast tissue measuring 8.5 x 1.5 x 0.5 cm with a staple denoting the medial. position. The fragment weighs 3.9 g. This fragment is oriented with the assistance of. and. according to him, it represents the deep margin. The fragment is oriented regarding lateral and medial. aspects. The axillary tail is dissected and eleven lymph nodes are identified. The lateral tumor comes. within -0.2 cm of skin and the medial tumor comes within 1.0 cm of skin. Inking code - breast: Green - superior portion of breast; Blue - inferior portion of breast; Black - deep. portion of breast; Orange - area of further resection, inferiorly, adjacent to additional inferior margin. (specimen E). Inking code - additional fragment of tissue (deep margin): Black - entire external surface of free deep. fragment; Green - medial tip of free deep fragment. Section code: D1 - representative section of tumor closest to nipple; D2 - representative section of. tumor farthest from nipple; D3 - tip of nipple, serially sectioned; D4 - remainder of nipple, en face; D5. - section of medial tumor with skin and orange margin; D6 - representative section of medial tumor. with skin and orange margin; D7 - representative portion of tissue between described tumors to. contain described tumor tract; D8 - representative section of lateral tumor with skin; D9-D10 -. representative sections of lateral tumor with skin (sections through tumor were made from medial. to. lateral); D11-D12 - two representative sections of unremarkable breast tissue from medial inferior. quadrant; D13-D14 - representative sections of unremarkable breast tissue from superior medial. quadrant; D15-D16 - representative portions of unremarkable breast tissue from superior lateral. quadrant; D17-D18 - representative sections of unremarkable breast tissue and lateral inferior. quadrant; D19 - one lymph node, bisected; D20 - one lymph node, bisected; D21 - two lymph nodes. submitted wholly with the more proximal node inked in black; D22 - two lymph nodes submitted wholly. with the more proximal lymph node inked in black; D23 - one lymph node, bisected; D24 - two lymph. nodes submitted wholly with the more proximal lymph node inked in black; D25 - two lymph nodes. with the more proximal node inked in black (the lymph nodes were submitted from proximal to distal);. D26 - inferior margin; D27 - lateral margin; D28 - medial margin; D29 - superior margin; D30 - deep. posterior margin; D31-D36 - deep free fragments of breast tissue serially sectioned from medial to. lateral. Specimen E: Designated ""new inferior margin"" is received in formalin labeled with the patient's name. and ""new inferior margin"". Specimen consists of one yellow/tan fatty fragment of tissue weighing 10.6. g and measuring 5.5 x 2.5 x 1.0 cm. The new inferior margin is inked in blue and the specimen is. serially sectioned. Cut sections reveal a yellow/tan fatty interior that is grossly unremarkable. Section code: E1-E6 - entire specimen.",BRCA,2,True,"Based on the pathology report, there are 5 positive lymph nodes out of 18 examined, with at least one tumor deposit greater than 2.0 mm in size. This meets the criteria for pN2a, which corresponds to N2 stage.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.",N2,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.",13.0,1193.0,100.0,True
1177,TCGA-D8-A3Z5.B16B3335-492B-471B-AEFE-2350EA558BFC,1,"page 1 / 1. Examination: Histopathological examination. KXX. Material: 1. Total organ resection - right breast and axillary lymph nodes. Unit in charge: : Material collected or. Material received or. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the right breast. Macroscopic description: Right breast, sized 27.8 x 17.2 x 6.8 cm, removed along with axillary tissues sized 13 x 9 x 4 cm and a skin flap of 21.8 x. 10.3 cm. Weight 940 g. Tumour sized 4.2 x 2.4 x 1.4 cm found on the boundary of outer quadrants, placed 2.2 cm from the outer boundary, 1.6 cm from the. base and 2.6 cm from the skin. Lymph nodes of 1 cm in length. Microscopic description: Carcinoma lobulare invasivum (classical type) - NHG1 (3 + 1 + 1/0 mitoses/ 10 HPF - visual area 0,55 mm). Infiltratio carcinomatosa mamillae. Lesions in situ of the type: carcinoma lobulare in situ (LCIS). Glandular tissue showing parenchyma atrophy. AXILLAR. LYMPH NODES: Metastases carcinomatosae in lymphonodis (No XIX/XXI). Infiltratio telae perinodalis. Histopathological Diagnosis. Carcinoma lobulare invasivum mammae dextrae. Lubular invasive carcinoma of the right breast. Metastases carcinomatosae in lymphonodis axillae (No XIX/XXI) (NHG1, pT2, pN3a). Cancer metastases in the axillary. lymph nodes No XIX/XXI. Result of immunohistochemical examination. Estrogen receptors found in 75% of neoplastic cell nuclei. Progesterone receptors found in 75% of neoplastic cell. nuclei. HER2 protein stained with. ). Negative reaction in invasive cancerous cells ( Score =1+).",BRCA,3,True,"The report states 'Metastases carcinomatosae in lymphonodis axillae (No XIX/XXI)', which means that out of the 21 lymph nodes examined, 19 had cancer metastases. This indicates a high number of positive lymph nodes, which corresponds to a higher N stage. According to the rules, 'A higher number of positive lymph nodes results in a higher N stage' and 'Micrometastasis is considered a positive lymph node and classified as N1', we can conclude that the N stage is higher than N1. The rule 'The presence of lymphovascular invasion does not affect the N stage' also supports this conclusion. The report does not provide information about extranodal extension, but the high number of positive lymph nodes already indicates a high N stage.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.
The presence of cancer metastases in a high number of lymph nodes corresponds to a higher N stage.",N3,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.
The presence of cancer metastases in a high number of lymph nodes corresponds to a higher N stage.",14.0,1292.0,96.0,True
653,TCGA-A8-A08P.7DB1F816-A55F-449A-8DF9-6724B5100CA1,1,"Diagnosis: 1. Invasive ductal breast carcinoma (maximum diameter 3 cm, conclusive malignancy grade. III) with invasion of the lymph vessels in the tumor periphery and an invasive satellite node,. as macroscopically documented. Remaining glandular body, which is rich in fatty tissue, is in. involution. No calcification here and no DCIS formation. Tumor-free nipple. Wide safety. margins. Tumor classification: pT2m pN2a (4/15), MX, R0; G3 (L1, V0).",BRCA,2,True,The report states that the patient has 4 out of 15 lymph nodes with malignancy (pN2a). This indicates a positive lymph node metastasis and classifies the N stage as N2.,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.",N2,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.",13.0,1193.0,96.0,True
1276,TCGA-E9-A1NA.595BB256-2F3D-493A-AA90-022BE0CC995F,1,"BREAST TISSUE CHECKLIST. Specimen type: Radical mastectomy. Specimen size: Not specified. Tumor site: Breast. Tumor size: 2.4 X 2.4 X 2.4 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal and lobular carcinoma. Histologic grade: Tumor extent: Not specified. Lymph nodes: 0/11 positive for metastasis ( 0/11). Extracapsular invasion of the lymph nodes: Not specified. Left,lower. outer. Margins: Not specified. quadrant. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments; None.",BRCA,0,True,"The report indicates that 0 out of 11 lymph nodes were positive for metastasis (0/11). According to the rule 'If no malignancy is found in regional lymph nodes, the N stage is N0', the N stage for this patient is N0.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.",13.0,1193.0,100.0,True
889,TCGA-AR-A255.492DDF00-858B-4420-A43F-4FED2DF61C15,0,"Final Diagnosis. east, right, wide local excision: Infiltrating ductal carcinoma, Nottingham grade II (of III) [tubules 3/3, nuclei 3/3, mitoses 1/3;. Nottingham score 7/9], forming a mass (1.3 x 1.3 x 1.2 cm) [AJCC pTlc]. Ductal carcinoma in situ, intermediate nuclear grade,. comprises <5% of the tumor volume. Angiolymphatic invasion is absent. Biopsy site changes are present. All surgical resection. margins are negative for tumor (minimum tumor free margin, 0.7 cm, inferior margin). Lymph nodes, right axillary sentinel, excision: Multiple (2) right axillary sentinel lymph nodes are negative for metastatic. carcinoma. [AJCC pNO (i-) (sn)]. Blue dye is identified in right axillary sentinel lymph node No. 1. Blue dye is not identified in. right axillary sentinel lymph node No. 2. Immunohistochemical cytokeratin stain was performed on the paraffin embedded sentinel lymph node tissue and confirms the. H&E impression. Faxitron done.",BRCA,0,True,"The report states that multiple right axillary sentinel lymph nodes were excised and were negative for metastatic carcinoma (pNO(i-)(sn)). This indicates that there is no malignancy found in the regional lymph nodes, which according to the rules corresponds to an N0 stage.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.
Absence of malignancy in regional lymph nodes corresponds to an N0 stage.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.
Absence of malignancy in regional lymph nodes corresponds to an N0 stage.",14.0,1267.0,97.0,True
721,TCGA-AC-A3YI.52CEF542-0F5B-4660-8746-2CF4A27B214E,0,"Provider Group : Date of Service: Date Received: Room. A copy of this report will be faxed to: FINAL SURGICAL PATHOLOGY REPORT. Diagnosis: A. - D.) RIGHT BREAST AND AXILLARY LYMPH NODES, LUMPECTOMY, SENTINEL. LYMPH NODE BIOPSY FOLLOWED BY LYMPH NODE DISSECTION: - Invasive lobular carcinoma, Nottingham grade 1-2. - Focal atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH). Metastatic carcinoma in twelve of thirteen axillary lymph nodes (12/13, including. all three sentinel lymph nodes). - Largest metastatic focus measures 1.1 cm in diameter. - Extranodal extension is identified in at least five lymph nodes,. with the largest focus of extranodal extension measuring up to. 0.5 cm. - One sentinel lymph node (specimen B) shows evidence of having been. previously biopsied. - The lumpectomy margins are free of tumor. - Invasive carcinoma is 0.5 cm from the inferior margin, 0.8 cm from medial,. and is at least 1 cm from all other margins. PATHOLOGIC TUMOR STAGING SYNOPSIS: Type and grade (invasive): Invasive lobular carcinoma, Nottingham grade 1. Primary tumor: pT1c. Regional lymph nodes: pN3a. Distant metastasis: Not applicable. Stage: IIIC. Lymphovascular invasion: Indeterminate. Margin status: Negative. Breast Invasive Tumor Stagina Information. (AJCC Cancer Staging Handbook,. and CAP protocol,. This staging also incorporates: Previous biopsy. Breast profile: This report continues (FINAL). Printed: Acct No. -. Pathology Report - Page 110. Partial breast. Specimen type: Lumpectomy. Specimen procedure: Sentinet lymph node biopsies followed by axillary. Lymph node sampling: lymph node dissection. Intact specimen. Specimen integrity: Right. Specimen laterality: 5.4 x 4.3 x 2.3 cm. Specimen size: INVASIVE TUMOR FEATURES: 1.8 cm. Invasive tumor size: 12: :00. Invasive tumor site: Single focus invasive carcinoma. Invasive tumor focality: Invasive lobular carcinoma. Histologic type: 1 of 3. Total Nottingham Grade: 3 of 3. Tubule formation: 1-2 of 3. Nuclear Pleomorphism: 1 of 3. Mitotic count for Nottingham: One mitosis in ten high power fields. Mitotic count: Indeterminate. Lymphatic invasion: MARGIN STATUS FOR INVASIVE COMPONENT: Negative. 0.5 cm. Distance of tumor from margins: Inferior. Closest margin: See diagnosis section. Other margins: Not identified. DUCTAL CARCINOMA IN-SITU (DCIS): Not identified. LOBULAR CARCINOMA IN-SITU (LCIS): Not applicable. Skin: Not applicable. Nipple: Not applicable. Skeletal Muscle: INVASIVE PATHOLOGIC TUMOR STAGING (pTNM). pTic. Primary tumor (pT): Regional lymph nodes (pN): pN3a. Not applicable. Distant metastasis (pM): IIIC. Pathologic stage: RECEPTOR STATUS AND HER2/NEU: 98% positive cells. Estrogen receptors: 25% positive. Progesterone receptors: IHC 1+,. Her2/neu: 15% positive cells. Ki-67 proliferative index: This report continues (FINAL). Printed. Acct No. rage 2. Pathology Report - Page 2/5. FINAL SURGICAL PATHOLOGY REPORT. athologist. Source of Specimen: A. Breast lumpectomy,righ. B. Sentinel lymph node;right axillary. C. Sentinel lymph node;right axillary. D. Right axillary dissection. Clinical History/Operative Dx: Malignant neoplasm of right breast. Intraoperative Diagnosis: B. Right axillary sentinel node. (with wire): Two lymph nodes, positive for metastasis. C. Right axillary sentinel node. One lymph node, positive for metastasis (Dr.'. ). The. intraoperative interpretation(s) was/were performed and rendered at. Gross Description: A. Specimen A is labeled right breast lumpectomy. Initially received in the fresh state for Oncogenotyping. studies is a 42 gram yellow-tan portion of fibrofatty soft tissue, 5.4 cm anterior-posterior, 4.3 cm. medial-lateral, 2.3 cm inferior-superior. A localizing guidewire impales the specimen through the. superior-lateral periphery. Three sets of sutures are present designated as follows: two short - anterior, one. long - medial, and two long - superior. The surgical margins are now differentially inked as follows: SUPERIOR: BLUE. I. This report continues. Printed: Acct No. -. - Page 3. Pathology Report - Page 3/5. F. FINAL SURGICAL PATHOLOGY REPORT. MEDIAL: RED. ANTERIOR: YELLOW. INFERIOR: GREEN. LATERAL: ORANGE. POSTERIOR: BLACK. The specimen is serially sectioned perpendicularly through the anterior-posterior long axis to reveal a. partially demarcated, to ill-defined, dense, light gray tumor mass measuring up to 1.8 x 1.3 x 1.2 cm. The. lesion is grossly within 0.5 cm of the nearest inferior, 0.7 cm of the superior, 0.9 cm of the medial, 1.3 cm. of the lateral, 0.9 cm of the posterior, and 1.7 cm of the anterior surgical margins. Representative portion. of the tumor is submitted for Oncogenotyping studies. No biopsy site clips are appreciated. The remaining. cut sections demonstrate soft to rubbery admixed, yellow-tan fibrofatty soft tissue without additional. discrete nodularity. Representative sections are submitted in a sequential fashion, posterior to anterior. Cassette summary: A1-A3) siab 1, posterior,. A4-A7) slab 2,. A8-A10) slab 3,. A11-A13) slab 4,. A14-A16) slab 5,. A17-A19) slab 6,. A20-A21) slab 7, margins trimmed and submitted,. A22-A23) slab 8, margins, trimmed and submitted. A24-A25) slab 9, anterior margin represented. B. Specimen B is labeled right axillary sentinel lymph node. (with hookwire). Initially received in the. fresh state for frozen section analysis is a 4.7 x 4.2 x 1.5 cm portion of soft tissue. A localizing guidewire is. present. Examination of the tissue reveals two lymph node candidates, 1.5 and 1.0 cm each. Both lymph. nodes are serially sectioned and two touch preparation slides are forwarded for microscopic evaluation. The lymph node tissue is entirely submitted for microscopic evaluation in B1-B3. Cassette summary: B1-B2) largest lymph node, sentinel node protocol performed, B2) smaller lymph node,. sentinel lymph node protocol performed. C. Specimen C is labeled right axillary sentinel lymph node. Initially received in the fresh state for. frozen section analysis is a 3.5 x 3.0 x 0.5 cm portion of yellow-tan fatty soft tissue. Examination reveais a. single 1.5 cm lymph node candidate. The cut surfaces are rubbery light pink to dense nodular light gray. A. single touch preparation slide is forwarded for microscopic evaluation. The lymph node is entirely. submitted for routine histology in C1. D. Specimen D is labeled right axillary dissection. Received in formalin are two tattered pieces of. fibrofatty soft tissue which measure in aggregate 14 grams and 6.4 x 4.7 x 1.7 cm. Examination reveals. twelve lymph node candidates ranging from 0.2-0.9 cm. The larger lymph nodes demonstrate a palpable. firm-nodular architectures. Lymph node tissue candidacy is entirely submitted for microscopic evaluation. Printed: This report continues (FINAL). Pathology Report - Page 4/5. FINAL SURGICAL PATHOLOGY REPORT. Cassette summary: D1) four lymph node candidates, D2) two lymph node candidates, D3) two lymph node. candidates, D4) four lymph node candidates. Microscopic Description: A. Immunohistochemical stain: invasive lobular carcinoma. Appropriate positive and negative. controls reviewed. B. Immunohistochemical stains: highlighting metastatic carcinoma and extranodal extension. Appropriate positive and negative controls reviewed. C. Immunohistochemical stains: highlighting metastatic carcinoma and extranodal extension. Appropriate positive and negative controls reviewed. D. Microscopic sections have been examined. The microscopic findings are reflected in the diagnosis. rendered. Printed: END OF REPORT (FINAL). Phon. Patholoav Report - Page 5/5. 1.",BRCA,3,True,"The report states that metastatic carcinoma is found in twelve out of thirteen axillary lymph nodes, including all three sentinel lymph nodes. This indicates that the N stage is N3, as a higher number of positive lymph nodes results in a higher N stage. The largest metastatic focus measures 1.1 cm in diameter and extranodal extension of metastatic carcinoma is identified in at least five lymph nodes, but these factors do not affect the N stage.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.",N3,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
Metastatic carcinoma in the form of microscopic clusters and single cells, measuring 0.2 mm or more is considered a positive lymph node and classified as N1.",13.0,1193.0,97.0,True
591,TCGA-A7-A3J1.D8EFFB62-6A23-4033-8144-24B751DECB08,0,"Final Surgical Pathology Report. Procedure: Diagnosis. A. Sentinel lymph node, left axilla, biopsy: A single lymph node is. negative for malignancy. B. Breast, left, excisional biopsy: Invasive lobular carcinoma,. Nottingham grade 2. Note: The margins are negative for malignancy. C. Breast, posterior lateral margin, biopsy: Focal lobular carcinoma. in situ, negative for invasive carcinoma. Microscopic Description: A. A single lymph node is negative for malignancy. [At the request of some staff oncologists and in keeping with the. opinion of some experts in breast pathology, immunohistochemical stains. for keratin were not used on the sentinel lymph node sections in this. case. These stains can be obtained if desired. Our paraffin blocks. are retained for 10 years. (Weaver DL et al. New Engl J Med 364:412,. 2011. Schwartz GF et al. Cancer 94(10):2542,. B. Invasive carcinoma: Histologic type: Invasive lobular carcinoma. Nottingham grade: 2. Architectural score: 3. Nuclear score: 2. Mitotic score: 1. Mitotic index: 0 mitoses/ 10 HPFs (1 HPF = 1.96 sq. mm). Tumor size: 1.7 cm. Specimen margins: Negative for malignancy. Carcinoma is 1.2 mm. from the red (anterior) inked margin in block B15. Vessel invasion: Absent. Calcification: Absent. Non-tumorous breast: Fat necrosis, compatible with prior biopsy site. pTNM stage: Tlc NO. Prognostic markers: No previous biopsy here. Markers are available if. needed. Antibody Results Comment. CK5/6. Positive. E-cadherin. Positive. C. Lobular carcinoma in situ is present. Antibody Results Comment. E-cadherin. Negative. Paraffin sections; 10% neutral buffered formalin; Controls stain. appropriately. (A few of the antibodies used in our laboratory may be classified as. analyte specific reagents. These antibodies are monitored and controlled in our laboratory and. their performance for. in vitro diagnosis is well described in the medical literature. They have not been cleared. or approved by the FDA.]. Specimen. A. Left axillary sentinel node. B. Left breast biopsy long anterior short superior. C. Posterior lateral margin long anterior short superior. Clinical Information. Cancer diagnosed in. Gross Description. A. Specimen A. is received unfixed labeled axillary sentinel node and. consists of 3 pieces of yellow soft tissue measuring 2.5 x 2 x 1 2.5. x. 1.7 x 1.4 and 2.2 x 1 x 0.5 cm. Sections after fixation. AS-6. B. The specimen is received unfixed in the Transpec container labeled. left breast biopsy and consists of yellow and red piece of soft tissue. measuring 8.5 by 6 by approximately 2.5 cm. The external surface the. specimen is inked as indicated below. Anterior: Red. Posterior Orange. Lateral: Blue. Medial: Green. Superior: Yellow. Inferior: Black. There is a firm area near one end of the specimen measuring 1.5 by 1.7. cm in greatest dimension. A small portion of the tumor is taken for. research purposes. Sections after fixation. RS-16. Specimen C. is received unfixed labeled posterior lateral margin and. consists of a yellow piece of soft tissue measuring 3.4 x 2.5 x 1.5 cm. There is along the short suture on the specimen. The external surface. of the specimen is inked as indicated below. Anterior: Red. Posterior: Orange. Lateral: Blue. Medial: Green. Superior: Yellow. Inferior: Black. Sections after fixation.",BRCA,0,True,"The report states that the sentinel lymph node biopsy from the left axilla is negative for malignancy. This indicates that there is no evidence of cancer in the regional lymph nodes, which corresponds to an N0 stage according to the rules.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.",12.0,1081.0,91.0,True
943,TCGA-B6-A0X1.D792031E-2CCE-4341-B3B3-C7D1D84F8F6B,1,"furgical Path. CLINICAL HISTORY: Large primary tumor left breast. GROSS EXAMINATION: A. ""Left breast biopsy"", received fresh. Fibroadipose tissue 5.4 x 4 cm. containing a central infiltrative yellow white stellate tumor 3 cm. in. diameter. A1- AF1. Representative sections in Block A2-A4. B. ""Left breast"", fresh. A breast measuring 23 x 15 x 6 cm with an overlying. skin ellipse 17 x 9 cm. There is a retracted nipple toward the medial aspect. A sutured incision 6 cm across is present towards the lateral aspect. Numerous. slightly elevated brown warty lesions are present on the skin adjacent to the. nipple. Attached axillary tissue is present measuring 13 x 3 x 5 cm and this. contains numerous enlarged lymph nodes, the largest of which measures 2.5 cm. across. The largest three nodes have been marked with a suture and bisected. Sectioning the breast shows a cavity beneath located in the upper outer. quadrant the incision measuring 5 cm in diameter. The deep margin is 0.5 cm. from the deep edge of the cavity. None of these tumor tissues is present. within wall. The remaining breast tissue is irregular fibrous but shows no. suspicious lesions. Block Summary: B1- nipple and adjacent skin lesions. B2- nipple. B3- deep margin. B4, B5- cavity wall. B6- lower outer quadrant. B7- lower outer quadrant. B8- upper inner quadrant. B9- upper outer quadrant. B10- one lymph node lower axilla. B11, B12- one lymph node. B13- fibrous tissue mid axilla. B14, B15- two lymph nodes. B16- three lymph nodes. B17- four lymph nodes. B18- four lymph nodes upper axilla. B19- four lymph nodes. B20- two lymph nodes. INTRA OPERATIVE CONSULTATION: AF1 ""Invasive ductal carcinoma"". Tissue sent for ER/PR. MICROSCOPIC EXAMINATION: Sections show poorly differentiated invasive ductal carcinoma of no special. type invading breast tissue. The tumor is composed of highly atypical. pleomorphic epithelial cells forming sheets, cords, and columns with minimal. attempt at the gland formation. There is extensive lymphatic channel invasion. by tumor, and extensive tumor necrosis is present. DIAGNOSIS: A. ""LEFT BREAST BIOPSY"": INVASIVE DUCTAL CARCINOMA OF NO SPECIAL TYPE MEASURING 3 CM ACROSS. NSABP NUCLEAR GRADE 3, HISTOLOGIC GRADE 3. EXTENSIVE LYMPHATIC CHANNEL INVASION AND TUMOR NECROSIS IS PRESENT. NO ADJACENT IN SITU CARCINOMA PRESENT. B. ""LEFT BREAST BIOPSY"", LEFT RADICAL MASTECTOMY. : BIOPSY CAVITY WALL CONTAINS RESIDUAL HIGH GRADE INVASIVE DUCTAL CARCINOMA. OF NO SPECIAL TYPE SIMILAR TO THE ABOVE TUMOR. DEEP MARGIN IS FREE OF TUMOR. NIPPLE AND NIPPLE DUCT ARE FREE OF TUMOR. SEPARATE FOCI OF TUMOR IS IDENTIFIED IN THE UPPER INNER QUADRANT,. REPRESENTING MULTIFOCAL TUMOR. METASTATIC TUMOR PRESENT IN 16 OF 21 LYMPH NODES WITH EXTRACAPSULAR. INVASION OF TUMOR PRESENT. (3 OUT OF 4 LOWER AXILLA, 9 OUT OF 11 MID AXILLA, 4 OUT 6 UPPER AXILLA). MULTIPLE SEBORRHEIC KERATOSIS ON SKIN ADJACENT TO NIPPLE. (Electronic Signature).",BRCA,1,True,"The report states that metastatic tumor is present in 16 out of 21 lymph nodes, which indicates a high number of positive lymph nodes. This corresponds to an N3 stage according to the AJCC staging system.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.",N3,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.",13.0,1172.0,96.0,True
1473,TCGA-OL-A5RU.7507AC79-4C8E-4393-92B9-BFA6BEB492D0,0,"FINAL PATHOLOGIC DIAGNOSIS. A. Breast, left; modified radical mastectomy: - Invasive ductal carcinoma, SBR grade 2, see parameters. - Ductal carcinoma in situ, intermediate grade, solid and cribriform types. with associated necrosis. - Surgical margins free of tumor. - Biopsy site changes. - Fourteen nodes, negative for carcinoma (0/14). - Nipple, areola, and skin without diagnostic abnormality. B. Breast, right; simple mastectomy: - Invasive ductal carcinoma, SBR grade 2, inferior-anterior of hematoma. cavity, see parameters. - Extensive ductal carcinoma in situ, intermediate grade, solid type, with. associated central necrosis. - Anterior-inferior margin positive for invasive carcinoma. - Attached skeletal muscle focally infiltrated by invasive carcinoma. (anterior-inferior). - Columnar cell change and adenosis. - Intraductal papilloma. - Nipple, areola, and skin without diagnostic abnormality. Breast Pathologic Parameters (Part A Left Breast). 1. Invasive carcinoma: A. Gross measurement: 1.9 X 1.5 X 1.5 cm. B. Composite histologic (modified SBR) grade: II. - Architecture: 2. - Nuclear grade: 3. - Mitotic count: 1. C. Associated intraductal carcinoma in situ (DCIS): - Within main mass (forming 10 % of tumor volume). - Extending away from main lesion. 2. Intraductal carcinoma: A. Gross or microscopic (specify) measurement: (5.2 cm, spanning 4 slices). B. Type: Cribriform and Solid. C. Nuclear grade: Intermediate. D. Associated features: Necrosis. 3. Excisional biopsy margins: Free of tumor. - DCIS 4 mm from posterior margin. - Invasive carcinoma 5 mm from posterior (closest) margin. 4. Blood vessel and lymphatic invasion: Not identified. 5. Nipple: unremarkable. 6. Skin: uninvolved. 7. Skeletal muscle: Focally present, negative for tumor. 8. Axillary lymph nodes: In combination with previous sentinel lymph node biopsy. (see. One of fifteen nodes positive for carcinoma (1/15). - Size of largest metastatic deposit: 18 mm. - Extranodal extension: present (2 mm; largest focus). 9. Special studies (see. - ER: Positive expression in >95% of invasive tumor nuclei. - PR: Positive expression in 80% of invasive tumor nuclei. - Her2/neu antigen (FISH): Non-amplified (1.02). 10. pTNM (AJCC, 7th edition, 2010): pT1cN1MX. Effective. this Checklist utilizes the 7th edition TNM staging. system for breast of the American Joint Committee on Cancer (AJCC) and the. International Union Against Cancer (UICC). Breast Pathologic Parameters (Part B Right Breast). 1. Invasive carcinoma: A. Microscopic measurement: 1.5 cm. B. Composite histologic (modified SBR) grade: II. - Architecture: 3. - Nuclear grade: 2. - Mitotic count: 1. C. Associated intraductal carcinoma in situ (DCIS): - Within main mass (forming 50 % of tumor volume). - Extending away from main mass. 2. Intraductal carcinoma: A. Microscopic measurement: 6.1 cm, spanning over 5 slices, involving lower. inner and upper inner quadrants and extending anteriorly towards nipple. B. Type: Solid. C. Nuclear grade: Intermediate. D. Associated features: Necrosis and cancerization of lobules. 3. Excisional biopsy margins: Positive. - DCIS >3 mm from posterior and inferior (closest) margins. - Invasive carcinoma at inferior-anterior margin with infiltration of. attached skeletal muscle. 4. Blood vessel and lymphatic invasion: Suspicious. 5. Nipple: unremarkable;DCIS noted 5 mm from areolar complex. 6. Skin: uninvolved. 7. Skeletal muscle: Focus attached inferior-anterior infiltrated by carcinoma. 8. Axillary lymph nodes: Negative (Two sentinel nodes, negative for carcinoma. (0/2), see. 9. Special studies (see. - ER: Strong expression in >90% of invasive tumor nuclei. - PR: Strong expression in >90% of invasive tumor nuclei. - Her2/neu antigen (FISH): Non-amplified (1.04). 10. pTNM (AJCC, 7th edition, 2010): pT1cNO(sn)MX (pending review of imaging). Effective. this Checklist utilizes the 7th edition TNM staging. system for breast of the American Joint Committee on Cancer (AJCC) and the. International Union Against Cancer (UICC). Clinical History: The patient is a. 'ear old female with malignant neoplasm of the breast. undergoing left modified radical mastectomy and right simple mastectomy. Comment. B. Stains for CKAE1/AE3 and myosin-heavy chain support extension of invasive. carcinoma into skeletal muscle at the inferior-anterior aspect of the breast. Findings were discussed with. Specimens Received: A: Left modified radicalmastectomy; mastectomy. B: Right simple mastectomy; partial mastectomy. Gross Description: Received are two containers, each labeled with the patient's name and medical. record number. A. Container A is further designated '1. Left modified radicalmastectomy;. mastectomy. The radiographic findings for this breast include an irreglarly. shaped mass measuring 1.4 X 1.2 X 1.9 cm and areas of heterogenous kinetics with. washout. The total extent of the abnormal enhancing is 2.8 X 2.3 X 1.9 cm. Received fresh and placed in formalin is a 468 gram mastectomy specimen. measuring 14.5 cm from medial to lateral, 17.5 cm from superior to inferior and. 3.7 cm from anterior to posterior. It has an axillary tail measuring 11 X 6.5. X. 1.5 cm. The skin measures 13.2 X 5 cm and an nipple areola complex measuring 3 X. 2.7 cm and a nipple measuring 1 X 1 cm. The specimen is inked as follows: posterior black, anterior-superior yellow, anterior-inferior green. It is. sliced into 11 slices to reveal a lesion that is present from slices 6 to 8 and. the lesion measures 1.9 X 1.5 cm and has a medial to lateral dimension of 1.5. cm. It focally abuts the deep margin and is 3 cm from the inferior margin and 9. cm from the superior margin. No other lesions or masses are identified. A. number of lymph node candidates are identified in the axillary tail, the largest. of which measures 2.5 X 2 X 1.8 cm. This large lymph node is sectioned to. reveal a central area of necrosis. Block Summary: A1-A3: lesion from slice 6. A2: superior to lesion. A3: inferior to lesion. A4: lesion in slice 7. A5: lesion in slice 8. A6: slice 5 next to lesion. A7: slice 9 next to lesion. A8: skin and nipple. A9: areola. A10: upper-inner quadrant from slice 2. A11: lower-inner quadrant from slice 4. A12: upper-outer quadrant from slice 7. A13: lower-outer quadrant from slice 7. A14: three lymph node candidates. A15: three lymph node candidates. A16: three lymph node candidates. A17: three lymph node candidates. A18: one lymph node candidate. A19: one lymph node candidate. A20-A21: largest lymph node candidate bisected. A22-A25: additional representative sections of axillary fat. B. Container B is further designated '2. Right simple mastectomy;. partial mastectomy. Received fresh and placed in formalin is a 350 gram. mastectomy specimen measuring 17 cm from medial to lateral, 13.5 from superior. to inferior, and 2.5 cm from anterior to posterior. There is a skin ellipse. measuring3 X 3.5 cm and an areola measuring 2.5 X 2.7 cm and a nipple measuring. 1 x 1 cm. It is sliced into 14 slices in which there is a hematoma cavity. measuring 1.5 X 1.5 x 3.1 cm found in slices 3, 4, 5 and 6. The cavity has a rim. of white-tan, firm tissue around it and the cavity is 1.1 cm from the deep. margin and 0.6 cm from the inferior margin. Also note that the deep margin is. inked red, the anterior-superior margin is inked blue and the anterior-inferior. margin is inked green. No other lesions or masses are identified. Block Summary: B1: lesion in slice 3. B2: superior to B1. B3: lesion in slice 4. B4: superior to B3. B5: lesion in slice 5. B6: superior to B5. B7: lesion in slice 6. B8: superior to B7. B9: slice 7 adjacent to lesion. B10: slice 2 adjacent to lesion. B11: upper-outer quadrant in slice 12. B12: lower-outer quadrant in slice 11. B13: upper-inner quadrant in slice 5. B14: lower-inner quadrant in slice 6. B15: skin and nipple. B16: areola. The specimen is inked as follows: posterior red, anterior-superior blue,. anterior inferior green. The tissue is fixed for at least six hours in NBF and no more than 72 hours.",BRCA,1,True,"The report indicates that there is no malignancy found in the regional lymph nodes for both the left and right breasts (0/14 and 0/2, respectively). Therefore, the N stage is N0.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.",13.0,1172.0,100.0,True
486,TCGA-A2-A0CV.FBDDD9EE-0A5C-4CAB-9EB3-48B6431A9A84,1,"Specimen #: F. Race: ASIAN - PACIFIC ISLANDERTaken: Physician (s) : SPECIMEN: A: SENTINEL LYMPH NODE #1 LEFT. B: NON SENTINEL LYMPH NODE LEFT. C: LEFT BREAST AND AXILLARY CONTENT. FINAL DIAGNOSIS: A-C. TUMOR BREAST, TYPE: LEFT, MASTECTOMY WITH AXILLARY AND SENTINEL LYMPH NODES. INVASIVE (70-80% intraductal DUCTAL CARCINOMA WITH AN EXTENSIVE INTRADUCTAL COMPONENT. NOTTINGHAM SCORE: 6. NOTTINGHAM GRADE: GRADE tumor II (MODERATELY largely intermixed DIFFERENTIATED) with invasive). TUMOR TUMOR (Tubules= NECROSIS: SIZE (GREATEST 2, Nuclei= NOT IDENTIFIED. DIMENSION) 3, Mitoses= : 4.1 1; CM mitotic (MEASURED count GROSSLY) <1 per 10 HPF). MICROCALCIFICATIONS. MARGINS LYMPHATIC INVASION: PRESENT. VENOUS PRESENT / IN INVASIVE AND IN SITU TUMOR AND IN BENIGN DUCTS. NEGATIVE. NEAREST NEAREST MARGIN, MARGIN, IN-SITU INVASIVE TUMOR: TUMOR: 2.5 MM (DEEP, SLIDE C6). INTRADUCTAL NUCLEAR GRADE: COMPONENT: 3 DUCTAL CARCINOMA 3 MM (DEEP, IN SITU, SLIDE CRIBRIFORM C6) TYPE. LYMPH ONE - NODES: (1) SENTINEL METASTASIS LYMPH IN NODE TWO (SPECIMEN OF EIGHTEEN A) : (2/18) POSITIVE EXAMINED LYMPH NODES. EXTRANODAL EXTENSION: PRESENT, 4 MM. ONE (1) LYMPH NODE (SPECIMEN C, LOW, C12) : POSITIVE. NIPPLE IDENTIFIED. - EXTENSION: PRESENT, 1 MM. SKIN IDENTIFIED. MULTICENTRICITY: NOT. EXTRANODAL INVOLVEMENT: INVOLVEMENT: NOT NOT PRESENT. ESTROGEN, PREVIOUSLY PROGESTERONE RECEPTOR STATUS AND HER 2 NEU WERE REPORTED. IN SURGICAL. ADDITIONAL PATHOLOGIC COLUMNAR pT2N1aMX CHANGES: CASE. STAGE: PATHOLOGIC. SCLEROSING ADENOSIS. CELL CHANGE WITH ATYPIA. FIBROCYSTIC CHANGES, USUAL DUCTAL HYPERPLASIA, FIBROADENOMA. MMENT. Specimen #: FINAL DIAGNOSIS (continued) : The earlier report,. of a core biopsy indicates hormone receptors. are POSITIVE (100% strong staining for both estrogen and progesterone. receptors) and Her2 by immunihistochemistry is NEGATIVE (1+). CLINICAL DIAGNOSIS AND HISTORY: year old with left breast 4 X 4 cm mass in left upper outer quadrant. detected with 1cm lymph node. PRE-OPERATIVE DIAGNOSIS: left breast cancer. POST-OPERATIVE DIAGNOSIS: same. FROZEN SECTION DIAGNOSIS: SPECIMEN TYPE: LYMPH NODE. REPORTED TO: DR. REPORTED BY: DR. # BLOCKS: 2. # SCRAPE PREPS 2. FROZEN SECTION DIAGNOSIS : POSITIVE FOR METASTATIC CARCINOMA. GROSS DESCRIPTION: A. Received fresh for intraoperative consultation labeled with patient's. designated ""SENTINEL NODE #1 COUNT 104"" consists of a 1.0 x. 0. 8 x 0.5 cm very firm lymph node with homogeneous yellow tan cut surface. Touch preps are prepared. Half of node submitted for CBCP protocol and. remaining half submitted for paraffin section. B. Received fresh labeled with the patient's name. designated. NON-SENTINEL LYMPH NODE LEFT"" is tan pink soft tissue measuring 0.7 x 0.5. x. 0.2 cm. The presumed lymph node is bisected and submitted entirely. Received fresh labeled with patient's name. designated ""BREAST. Specimen #: GROSS DESCRIPTION (continued) : AND AXILLARY CONTENTS"" consists of 380 gram left mastectomy oriented with. single stitch medial, two stitches superior, stitch on highest axillary. portion. Specimen measures 23 cm medial to lateral 15 cm superior to. inferior, 3 cm anterior to posterior. Attached skin ellipse displays a. centrally located everted nipple measuring 1 cm. No discharge is. identified. No scars are identified. There is a well-defined pink white firm gritty mass in the left outer. quadrant measuring 4.1 x 3.5 x 1.5 cm. Tissue surrounding the mass is. remarkably nodular and firm with possible superior extension of primary. lesion to approximately 5 cm (C4) Focal hemorrhage consistent with. previous biopsy is also noted. Remaining quadrants are also composed of. remarkably nodular focally indurated dense fibrous tissue. No additional. masses identified. Fatty tissue comprises 20% of specimen and is. unremarkable. The attached axillary tail measures 9 x 3.5 x 1.5 cm. Sectioning reveals. sixteen lymph nodes ranging from 0.5 x 0.7 cm in greatest dimension. Sectioning of lowest lymph node shows a firm pink white cut surface with. possible involvement by lesion. INK KEY. blue superficial. black: deep. SUMMARY OF SECTIONS: C1: skin. C2: lower outer quadrant mass. C3: margin of C2. C4: possible extension of tumor. C5 : margin of C4. C6: mass with deep margin. C7: additional mass. C8: lower outer quadrant. C9: upper outer quadrant. C10: upper inner quadrant. C11: lower inner quadrant. C12: one low lymph node. C13: two low bisected lymph nodes, one inked blue. C14: three low lymph nodes. C15: one high lymph node. C16: two high lymph nodes bisected, one blue. C17: one high lymph node intact. Matched sections of C1 C7-C12 and C15 are submitted in OCT for CBCP. rotocol. Specimen #: GROSS DESCRIPTION (continued) : C18 : nipple. C19: mass with deep margin. C20 : : mass with deep and superficial margin. C21: six additional lymph nodes. 21CF.",BRCA,1,True,"Based on the pathology report, there are 18 lymph nodes examined, out of which 2 are positive for metastatic carcinoma. This indicates an N1 stage according to the rules provided.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.",14.0,1261.0,96.0,True
1417,TCGA-LD-A74U.CA6A13D4-DD80-4424-B5F3-654EE31263AE,2,"DATE OBTAINED: DATE RECEIVED: DIAGNOSIS. 1. RIGHT BREAST, PARTIAL MASTECTOMY: INVASIVE LOBULAR CARCINOMA mixed. SIZE (INVASIVE): Approximately 70 mm; see comment. LATERALITY: Right. TUMOR FOCALITY: Unifocal. LESIONAL SITE: 9:00 (according to operative report). HISTOLOGIC TYPE: Invasive lobular carcinoma, classical type, focal pleomorphic type. NUCLEAR GRADE: I of III (classical type) and II-III of III (pleomorphic type). HISTOLOGIC GRADE: N/A. (invasive lobular carcinoma). IN-SITU COMPONENT: Not present. LYMPH NODE SAMPLING: Positive (11/12), (largest 45mm; with extranodal Involvement); see specimen #2. AJCC CATEGORIES: Stage IIIC. (assuming cM0"" status). pTNM: pT3. pN3a. cTNM: cT2. cN1. cMO. INTEGRITY/ORIENTATION: Intact specimen with designated margins. MARGINS (Invasive lobular): Negative. <0.1mm superior margin (1P, highlighted by CK7 Immunostain); 0.2mm medial margin. (1EE) and 1mm posterior margin (1N); other margins >3mm. LYMPHOVASCULAR INVASION: Focal suspicious for LVI. MICROCALCIFICATIONS: Not identified. NIPPLE/SKIN: (if applicable). Negative skin. SKELETAL MUSCLE: Not present. OTHER: Focal atypical lobular hyperplasia, sclerosing adenosis, usual ductal hyperplasia,. apocrine metaplasia and prior blopsy site changes. 2. RIGHT AXILLARY NODE CONTENTS, DISSECTION: ELEVEN OUT OF TWELVE LYMPH NODES TOTALLY. REPLACED BY METASTATIC LOBULAR CARCINOMA (11/12), LARGEST TUMOR 4.5 CM, EXTRANODAL. EXTENSION PRESENT; ADDITIONAL INVASIVE LOBULAR CARCINOMA WITHIN THE FAT (ABOUT 2CM). 3. OMENTUM, RESECTION: ADIPOSE TISSUE; NEGATIVE FOR TUMOR. COMMENT. Tumor grossly is 5.3 cm. In the axillary contents (#2), sizeable tumor mass within the fat is also present in multiple blocks, which. most likely represents a direct extension from the lumpectomy, and thus the tumor size is estimated to be 7cm. 88307x2, 88305, 88329, 88342. Clinical Diagnosis and History: Right breast cancer, gastric cancer. cT2,cN1,cM0 clinical stage Il. Tissue(s) Submitted: 1: RIGHT BREAST MASS SHORT SUTURE SUPERIOR LONG SUTURE LATERAL. 2: RIGHT AXILLARY NODE CONTENTS. 3: OMENTUM. Gross Description: Specimen #1 is received fresh for intraoperative consultation, labeled with the patient's name and right breast mass, and consists. of an 11.3 cm (medial to lateral) X 8.5 cm (superior to inferior) x 4.5 cm (anterior to posterior) product of partial mastectomy which. is surfaced by a 6.9 x 2.2 x 0.2 cm ellipse of unremarkable white tan skin. No nipple is identified. A short suture designating. superior and a long suture designating lateral are present. Two needle localization wires are entering the specimen in the superior. and inferior aspects. The specimen is radiographed and differentially inked as follows: superior-blue, inferior-green, lateral-yellow,. medial-red, posterior/deep-black and serially sectioned from lateral to medial into 10 slices. No biopsy clip is identified. An ill-. defined, rubbery to firm, white-tan area measuring 5.3 x 5.0 x 3.5 cm is identified in slices 4 to 10. This area of fibrous tissue. shows. some. extensions to the posterior, inferior, superior, and medial margins. This fibrous area is also 2.0 cm from the overlying. skin. other. lesions are grossly identified. The breast parenchyma consists of tan-yellow, lobulated adipose tissue (60%) and. fibrous tissue (40%). Time in formalin: Some tumor and normal tissue is frozen for TCGA studies. Representative sections of all slices (with the exception of slices 2 and 3) are submitted as follows: 1A-1B: slice #1, lateral margin, perpendicular (representative). 1C-1D: slice #4, irregular fibrous area. 1E: slice #4, fibrous area to posterior margin. 1F: slice #4, fibrous area to superior margin. 1G-1H: slice #5, fibrous area contiguous section. 11: slice #5, posterior margin. 1J: slice #5, inferior and posterior margins. 1K: overlying skin. 1L-1M: slice #6, contiguous section of fibrous area to inferior margin. 1N-10: posterior margin. 1P: superior margin. 1Q-1T: slice #7, contiguous section from superior to inferior (orange ink denotes contiguous section). 1U: overlying skin. 1V: slice #8, fibrous area. 1W: superior margin. 1X: inferior margin. 1Y: posterior margin. 1Z: slice #9, inferior margin. 1AA: slice #9, irregular fibrous area. 1BB: superior margin. 1CC: posterior margin. 1DD-1GG: slice #10, medial margin, perpendicular (representative). Specimen #2 is received in formalin labeled right axillary dissection, and consists of 11.0 x 10.0 x 2.5 cm yellow adipose tissue. The specimen was serially sectioned to reveal 16 lymph nodes ranging in size from 1.5 to 4.5 cm. The lymph nodes are entirely. submitted and labeled as follows: 2A: Two lymph nodes intact. 2B: Two lymph nodes intact. 2C: Four lymph nodes intact. 2D: One lymph node, bisected. 2E: One lymph node, bisected. 2F: One lymph node, bisected. 2G: One lymph node, bisected. 2H: One lymph node, representative section. 21: One lymph node, representative section. 2J: One lymph node, representative section. 2K-2L: One lymph node, representative section. Specimen #3 is received fresh labeled omentum, and consists of a 20 x 20 x 5.0 yellow lobulated adipose tissue. The specimen is. serially sectioned and no lesion is grossly identified. Representative sections are submitted labeled 3A-3B. Intraoperative Consult Diagnosis. 1A/GDX: NEEDLE LOC WIRE ENTERS SUPERIORLY AND ONE OTHER ENTERS INFERIORLY. VAGUE AREA, NO. DISCRETE MASS; MARGINS HARD TO DETERMINE; QUESTION POSTERIOR, INFERIOR, AND MEDIAL MARGIN.",BRCA,3,True,"The report states that 11 out of 12 lymph nodes were totally replaced by metastatic lobular carcinoma, with the largest tumor being 4.5 cm and extranodal extension present. This information indicates an N3a stage according to the AJCC categories provided in the report.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.",N3,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.",15.0,1353.0,96.0,True
881,TCGA-AR-A24V.468CD293-C9F7-43C6-A40A-18FCDD22F6AA,1,"Final Diagnosis. Feast, right, wide local excision: Infiltrating ductal carcinoma, Nottingham grade II (of III) [tubules 2/3, nuclei 2/3, mitoses 2/3;. Nottingham score 7/9], forming a mass (2.4 x 1.7 x 1.6 cm) [AJCC pT2]. Biopsy site changes are present. Ductal carcinoma in. situ, solid and micropapillary type, intermediate nuclear grade, comprising 5-25% of the tumor mass. Angiolymphatic invasion. is. identified. All surgical resection margins, after re-excision of the medial margin, are negative for tumor (minimum tumor free. margin, 1.0 cm, inferior margin). Lymph nodes, right axillary sentinel Nos. 1 and 2, sentinel biopsy: A single (1 of 2) axillary sentinel lymph node is positive (for. micrometastasis [AJCC pN1mi(sn)]), with 2 metastases, the largest measuring 1.0 mm and smallest 0.5 mm. Immunohistochemical cytokeratin stain was performed on the paraffin embedded sentinel lymph node tissue and confirms the. H&E impression.",BRCA,1,True,"The report states that a single out of two sentinel lymph nodes is positive for micrometastasis, which is considered a positive lymph node and classified as N1. The size of the metastases (1.0 mm and 0.5 mm) does not affect the N stage.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.",17.0,1546.0,93.0,True
861,TCGA-AR-A1AR.747FB91B-F523-4FA0-91DD-6014EF55643D,0,"Final Diagnosis. Breast, left, lumpectomy: Infiltrating ductal carcinoma, Nottingham grade III (of III), [tubules. 3/3, nuclei 3/3, mitoses 2/3; Nottingham score 8/9], forming a 1.8 x 1.5 x 1.5 cm mass [AJCC. pT1c]. Angiolymphatic invasion is present. The non-neoplastic breast parenchyma shows. nonproliferative fibrocystic changes. Changes consistent with prior core biopsy site. All surgical. resection margins, after re-excision of the superior margin, are negative for tumor (minimum. tumor free margin, 0.5 cm, deep margin). Lymph nodes, left axilla, axillary dissection: Multiple 5 (of 14) left axillary lymph nodes are. positive for metastatic carcinoma with extranodal extension (AJCC pN2).",BRCA,2,True,The report states that there are multiple (5 out of 14) positive lymph nodes with extranodal extension in the left axilla. This corresponds to the N2 stage according to the AJCC staging system.,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.",N2,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.",15.0,1353.0,93.0,True
886,TCGA-AR-A251.F5B17108-8904-48E7-9B3D-182F0EA388B7,1,"Final Diagnosis. Yeast, left/wide local excision: Infiltrating ductal carcinoma, Nottingham grade III (of III), forming a 2.7 x 2.4 x 2.0 cm bilobed. mass. [AJCC pT2]. Extensive ductal carcinoma in situ, high nuclear grade, present within (>25%) and outside the invasive. component. Angiolymphatic invasion is present. The non-neoplastic breast parenchyma shows proliferative fibrocystic changes. Calcifications present in malignant ducts. Biopsy site changes present. The tumor does not involve overlying skin. The. medial/inferior margin is positive for ductal carcinoma in-situ. Left breast, new inferomedial margin, re-excision: Focally positive for ductal carcinoma in- situ. Left breast, new deep margin, re-excision: Negative for tumor. Lymph nodes, left axillary, dissection: Multiple (3 of 7) left axillary lymph nodes are positive for metastatic carcinoma. The. largest metastatic focus measures 2.2 x 1.9 x 1.5 cm. Extranodal extension is present. Lymph nodes, additional left axillary, excision: A single (of 3) left axillary lymph node is positive for metastatic carcinoma. [Total 4 positive lymph nodes; AJCCpN2]. Breast, left, total mastectomy: No residual carcinoma identified. Biopsy site changes are present in the outer quadrant. The. adjacent breast parenchyma shows proliferative fibrocystic changes. Surgical margins are negative for tumor. The nipple is. without diagnostic abnormality.",BRCA,2,True,"The report indicates that there are 4 positive lymph nodes (three from the left axillary lymph node dissection and one from the additional left axillary excision) with the largest metastatic focus measuring 2.2 x 1.9 x 1.5 cm. The presence of extranodal extension also upgrades the N stage by one level. Therefore, the N stage is N2.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.",N2,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.",16.0,1468.0,96.0,True
1425,TCGA-LL-A5YL.17B51CA5-E325-4EA0-AFED-C6D0FD5A40EF,1,"AGE/SX: ROOM. REG DR: BED: DIS: TLOC: COLL. TIME IN FORMALIN: 4:16. hrs. CLINICAL INFORMATION: Pre-Op Diagnosis: Right breast CA. Remarks: Specimen (s) : A. Right breast tissue stitch axillary tail. B. Right axillary node x2. C. #1 sentinel node right breast. D. IS level 3 node stitch marks highest level node. E. Axillary contents. MICROSCOPI DIAGNOSIS. A. RIGHT BREAST, TOTAL MASTECTOMY: INVASIVE LOBULAR CARCINOMA. INVASIVE CARCINOMA MEASURES AT LEAST 4.5 CM IN GREATEST DIMENSION (pT2). NOTTINGHAM COMBINED HISTOLOGIC GRADE 2 OF 3. TUBULE FORMATION SCORE 3 OF 3. NUCLEAR PLEOMORPHISM SCORE 2 OF 3. MITOTIC COUNT SCORE 1 OF 3. SURGICAL MARGINS OF RESECTION FREE OF INVASIVE LOBULAR CARCINOMA. FOCI OF LOBULAR CARCINOMA IN SITU. FOCI OF DUCT CARCINOMA IN SITU. INTERMEDIATE NUCLEAR GRADE, NOT EXTENSIVE. SEE COMMENT FOR SURGICAL PATHOLOGY CANCER CASE SUMMARY CHECKLIST. B. RIGHT AXILLARY LYMPH NODES X2, EXCISION: METASTATIC BREAST CARCINOMA IN TWO OF TWO LYMPH NODES. C. SENTINEL LYMPH NODE #1, EXCISION: NEGATIVE. NO EVIDENCE OF METASTATIC CARCINOMA IN THIS SPECIMEN. D. LEVEL 3 AXILLARY LYMPH NODES, REGIONAL RESECTION. NEGATIVE. NO EVIDENCE OF METASTATIC CARCINOMA IN SIX HIGHEST LEVEL 3 LYMPH NODES. E. RIGHT AXILLARY LYMPH NODES, REGIONAL RESECTION: METASTATIC BREAST CARCINOMA IN ONE OF 14 AXILLARY LYMPH NODES. COMMENT(S). SURGICAL PATHOLOGY CANCER CASE SUMMARY CHECKLIST - CAP APPROVED. Procedure: Total mastectomy. RUN DATE. RUN TIME. RUN USER: SPEC #: COMMENT (S). Lymph Node Sampling : Sentinel lymph node(s). axillary dissection. Specimen Laterality: Right. Histologic Type of Invasive Carcinoma : Invasive lobular carcinoma. Tumor Size: Greatest dimension of largest focus of invasion : 45. mm. Histologic Grade (Nottingham) : Glandular/Tubular Differentiation: Score 3. Nuclear Pleomorphism: Score 2. Mitotic Rate: Scors 1. Overall Grade Grade 2. Ductal Carcinoma In Situ: DCIS is present; negative for extensive intraductal. component (EIC). Architectural Patterns: Cribriform, solid. Nuclear Grade Grade II. Necrosis: Present, focal. Lobular Carcinoma In Situ: Present. Invasive Carcinoma: Margins uninvolved by invasive. Margins: carcinoma. Distance from closest margin : 1 0mm. DCIS: Margins uninvolved by DCIS. Distance from closest margin > 10 mm. Lymph Nodes: Number of sentinel lymph nodes examined: 1. Total number of lymph nodes examined (sentinel and. nonsentinel) : 23. Number of lymph nodes with macrometastases (>2 mm) : 3. Number of lymph nodes with micrometastases (>0.2 mm. to 2 mm and/or 200 cells) : 0. Number of lymph nodes with isolated tumor cells. (50.2 mm and <200 cells) : 0. Number of lymph nodes without tumor cells. identified 20. Extranodal Extension : Not identified. Method of Evaluation : Hematolxylin and eosin, level 1. Lymph-Vascular Invasion. Not identified. Dermal Lymph-Vascular Invasion. Not identified. Pathologic Staging: Primary Tumor: pT2. Regional Lymph Nodes: pN1a. Distant Metastasis: Not applicable. Ancillary Studies: ER: Positive (92% of tumor cells with nuclear. positivity); strong. PR: Negative. HER2: Positive (score 3+). In Situ Hybridization for HER2 Not amplified. RUN DATE : RUN TIME: Specimen Inquiry. RUN USER: SPEC #: GROSS DESCRIPTION: The specimen is submitted in five containers. A. The first specimen submitted in the fresh state is labeled ""right breast tissue"" The. specimen is the right breast, total mastectomy specimen Suture marks the axillary tail of. the breast. There is an ellipse of white skin containing the nipple. This measures 9 x 4.5. cm The breast itself measures 23 x 22.5 x 6.5 cm. There is a firm mass palpable beneath. the surface at approximately the 11 o'clock position The overlying superficial margin. adjacent to the skin is marked with black ink and the deep margin beneath this is marked. with blue ink. On cut section the mass measures approximately 4.5 x 3 x 3 cm. The edges. are quite difficult to discern and are more easily palpated than visualized In the center. of the specimen there is a small focus of hemorrhage consistent with previous biopsy. Ã€. portion of this mass is set aside for tissue banking per protocol. The mass extends to. within approximately 1 cm of the overlying superficial margin at approximately 11 O'clock. at its closest point. It is located well above the deep margin which is approximately 7 cm. beneath the mass. Cut sections through the remainder of the breast tissue reveals some. rubbery white parenchymal breast tissue and abundant yellow fat. There. are. other. nodules or mass is identified. Sections are submitted as follows: A1. nipple. A2-5 -. mass in breast. A6. mass in breast with adjacent tissue. A7-9 -. non-neoplastic appearing breast tissue. B. The. second specimen is received in the fresh state in the operating room and represents. two axillary lymph nodes, one measuring 2 x 1.5 x 1 cm and the other measuring 1 x 0.7 x. 0.7. cm. The cut sections are hard. A section of each is examined by frozen section. These are submitted in block B1, frozen section control. Additional section of each is. submitted in block B2. C. The. third specimen initially in the fresh state is labeled ""sentinel node #1"" and is a. piece of yellow fat measuring 2.5 x 2 x 1 cm with a 1 cm round moderately firm lymph node. which is bisected and submitted in toto in block C1. D. The fourth specimen is labeled ""level 3 axillary nodes"" The specimen is a piece of. yellow fatty tissue measuring 9 x 3 x 1.! cm with a suture marking the highest level 3. lymph node. There are five additional small lymph nodes. The highest node is submitted in. block D1 and the other five lymph nodes are submitted in block D2. E. The fifth container is labeled ""right axillary contents"" The specimen is yellow fatty. tissue measuring 10 x 9 x 2.5 cm. Within the fatty tissue are several nodules consistent. with. lymph nodes. The largest of these measures 2 cm in diameter and on cut section is. partially replaced by very hard white tissue. A section of each node is. submitted. in. blocks E1 through E4. MICROSCOPIC DESCRIPTION. The slides are examined and evaluated. RUN DATE. RUN TIME. Specimen Inquiry. RUN USER. SPEC #: INTRAOPERATIVE CONSULTATION. OPERATING ROOM CONSULTATIONS : Ã€. Portions of the breast mass are processed for tumor tissue banking per protocol. B. FROZEN SECTION DIAGNOSIS OF RIGHT AXILLARY LYMPH NODES X2: METASTATIC CARCINOMA IN TWO LYMPH NODES. PHOTO DOCUMENTATION. Image. Image. Image. Image. Image. Image. (signature on file).",BRCA,1,True,"Based on the pathology report, there are metastatic carcinoma deposits found in 1 out of 14 axillary lymph nodes examined (excluding sentinel lymph nodes), which falls under the N1 category. The report does not mention extranodal extension, and the method of evaluation is hematoxylin and eosin, which is consistent with the AJCC staging system for breast cancer.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
A higher number of positive lymph nodes results in a higher N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.",18.0,1626.0,95.0,True
1043,TCGA-BH-A0W3.801A4E2F-E26E-424F-BF42-CD0D9CD62BCE,0,"PATIENT HISTORY: CHIEF COMPLAINT/PRE-OP/POST-OP DIAGNOSIS: 1.2-cm mass upper inner quadrant left breast, core blopsy Invasive ductal. carcinoma. LMP DATE: Not provided. PROCEDURE: Left segmental mastectomy, sentinel lymph node biopsy. SPECIFIC CLINICAL QUESTION: Not provided. OUTSIDE TISSUE DIAGNOSIS: No. PRIOR MALIGNANCY: No. CHEMORADIATION THERAPY: No. OTHER DISEASES: No. ADDENDA: Addendum. Immunostains for HER-2/neu were performed on block 1B. HER2 IMNUNOHISTOCHEMISTRY: Using appropriate formalin fixed (8 - 96 hours), controls and tissue. test block, 4B5 antibody clone is used as part of FDA approved Pathway on the. and interpreted as follows: 2+. A weak to moderate complete membrane staining is. (Equivocal). observed in more than 10% of the tumor cells). NOTE: Her-2/Neu FISH was ordered and will be subsequently reported. CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Segmental. Upper inner quadrant. SIZE OF TUMOR: Maximum dimension invasive component: 15 mm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 3. Mitotic activity score: 1. Total Nottingham score: 6. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: Not applicable. CALCIFICATION: TUMOR TYPE, IN SITU: Cribriform. Micropapillary. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: LYMPH NODES EXAMINED: 4. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SENTINEL NODE METASTASIS: T STAGE, PATHOLOGIC: pT1c. N STAGE, PATHOLOGIC: pN1a. M STAGE: Not applicable. ESTROGEN RECEPTORS: positive, H-score: 300. PROGESTERONE RECEPTORS: positive, H-score: 225. HER2/NEU: 2+. INTERPRETATION. nuc ish(D17Z1,ERBB2)x2-6[80]. No amplification of the HER-2/NEU gene was seen by interphase FISH analysis. Fluorescence in situ hybridization (FISH) analysis was performed on a formalin-fixed Block 1B (Left segmental mastectomy 10:00). using the DNA probe for the HER-2/NEU gene. An adequate number of invasive tumor cells were. present and evaluated by four independent observers. The ratio of HER-Z/NEU signals (ERBB2) to chromosome 17 centromere. signals (. was determined to be 1.69. A ratio of greater than 2.2 is considered to be amplified with ratios of 1.80 to 2.20 in. the equivocal range; therefore, this specimen is not amplified. The average number of HER-2/NEU signals per cell was 4.10. The average number of signals for the chromosome 17 centromere was 2.43. Many of the cells exhibited 3 or more signals for. both the HER-2/NEU gene and for the chromosome 17 centromere. This may be indicative of either polyploidy or aneuploidy. for chromosome 17. Concurrent positive and negative control specimens showed the expected results. This FISH test is performed using a modification of the Vysis FDA approved PathVysion HER-2 DNA Probe Kit (1:2 LSI HER-2/neu. / CEP17 probe : T-denhyb-2 buffer). This FISH test was developed and Its performance determined by the. Pursuant to the requirements of CLIA '88, this laboratory has established and vermed the test's. accuracy and precision. FINAL DIAGNOSIS: PART 1: BREAST, LEFT, SEGMENTAL MASTECTOMY AT 10:00-. A. INVASIVE DUCTAL CARCINOMA, NOTTINGHAM GRADE 2 (TUBULAR FORMATION 3, NUCLEAR GRADE 2,. MITOTIC ACTIVITY 1; TOTAL SCORE 6/9). B. THE INVASIVE TUMOR MEASURES 1.5 CM IN LARGEST DIMENSION (GROSS MEASUREMENT). C. DUCTAL CARCINOMA IN SITU (DCIS), MICROPAPILLARY AND CRIBRIFORM PATTERNS, NUCLEAR GRADE. 2. D. DCIS ACCOUNTS FOR 6% OF TOTAL TUMOR VOLUME, ADMIXED WITH OR CLOSE TO INVASIVE. COMPONENT. E. INVASIVE TUMOR IS 2.5 MM FROM ANTERIOR MARGIN AND 4 MM FROM POSTERIOR MARGIN; DCIS IS. LESS THAN 0.2 MM FROM THE ANTERIOR MARGIN. F. NO LYMPHOVASCULAR INVASION IDENTIFIED. G. ATYPICAL DUCTAL HYPERPLASIA. H. NON-NEOPLASTIC BREAST TISSUE SHOWING PAPILLOMA, FIBROCYSTIC CHANGE AND DUCTAL. EPITHELIAL HYPERPLASIA. I. BIOPSY SITE CHANGES. J. TUMOR IS POSITIVE FOR ER AND PR, HER-2/NEU SCORE 2+ (. PART 2: ADDITIONAL ANTERIOR MARGIN, NEW ANTERIOR MARGIN, EXCISION -. BENIGN BREAST FIBROADIPOSE TISSUE. PART 3: LEFT AXILLARY SENTINEL LYMPH NODE #1, BIOPSY -. A. ONE OF TWO (1/2) LYMPH NODES, POSITIVE FOR METASTATIC CARCINOMA (SEE COMMENT). B. THE TUMOR MEASURES 1 CM. PART 4: LEFT SENTINEL LYMPH NODE #2, BIOPSY -. ONE LYMPH NODE NEGATIVE FOR METASTATIC CARCINOMA (0/1). PART 5: LEFT SENTINEL LYMPH NODE #3, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR METASTATIC CARCINOMA (0/1).",BRCA,1,True,"The N stage is determined by the examination of lymph nodes for malignancy. In this report, 3 lymph nodes were examined, and 1 of them was found to be positive for metastatic carcinoma. This information satisfies the rule 'A higher number of positive lymph nodes results in a higher N stage' and places the patient in the N1 category.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in a single axillary lymph node is also classified as N1.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in a single axillary lymph node is also classified as N1.",19.0,1738.0,93.0,True
961,TCGA-BH-A0AV.6DFA6F0F-09BC-4246-87B9-247207B74A39,0,"FINAL DIAGNOSIS: PART 1: BREAST, LEFT. 11 O'CLOCK SEGMENTAL MASTECTOMY -. A. INFILTRATING DUCTAL CARCINOMA. B. NEOPLASM MEASURES 1.5 CM ON SLIDE 1F. C. NOTTINGHAM SCORE 8/9, GRADE 3 (TUBULES 3, NUCLEI 3, MITOSES 2). D. MARGINS OF RESECTION FREE OF NEOPLASM, CLOSEST POSTERIOR AT 0.6 CM. E. NO LYMPHOVASCULAR INVASION IDENTIFIED. F. ER NEGATIVE, PR NEGATIVE, HER-2/NEU NOT AMPLIFIED PER PREVIOUS REPORTS. G. PATHOLOGIC STAGE pT1C, pNo, pMX. H. DUCTAL CARCINOMA IN SITU, SOLID TYPE, NUCLEAR GRADE 3 WITH COMEDONECROSIS AND. CALCIFICATION. I. DUCTAL CARCINOMA IN SITU IS IDENTIFIED IN FOUR OF FIFTEEN (4/15) SECTIONS, OUTSIDE OF INVASIVE. COMPONENT. J. MARGINS OF RESECTION FREE OF IN SITU CARCINOMA BY GREATER THAN 1.0 CM (see comment). K. UNREMARKABLE SKIN. L. FIBROCYSTIC CHANGES. PART 2: LYMPH NODE, LEFT AXILLARY, SENTINEL NUMBER 1, BIOPSY -. ONE LYMPH NODE NEGATIVE FOR METASTATIC CARCINOMA (0/1). PART 3: LYMPH NODE, LEFT AXILLARY, NONSENTINEL, BIOPSY -. ONE LYMPH NODE NEGATIVE FOR METASTATIC CARCINOMA (0/1). CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Segmental. Upper inner quadrant. SIZE OF TUMOR: Maximum dimension invasive component: 1.5 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 3. Tubule formation: 3. Mitotic activity score: 2. Total Nottingham score: 8. Nottingham grade (1, 2, 3): 3. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: Yes, malignant zones. TUMOR TYPE, IN SITU: Solid. DCIS present outside of invasive carcinoma component. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 6.0 mm. SURG MARGINS INVOLVED BY IN SITU COMPONENT: LYMPH NODES POSITIVE: o. LYMPH NODES EXAMINED: 2. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SENTINEL NODE METASTASIS: NON-NEOPLASTIC BREAST TISSUE: FCD. T STAGE, PATHOLOGIC: pT1c. N STAGE, PATHOLOGIC: pNO. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: previously performed. PROGESTERONE RECEPTORS: previously performed. HER2/NEU: zero or 1+.",BRCA,0,True,"The report states that two lymph nodes were examined and both were negative for metastatic carcinoma (0/2). According to the rules, if no malignancy is found in regional lymph nodes, the N stage is N0.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in a single axillary lymph node is also classified as N1.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in a single axillary lymph node is also classified as N1.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.",20.0,1830.0,97.0,True
753,TCGA-AN-A0AS.0D1ACC76-910E-4243-A229-5F76B5A3299A,1,JB: Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Left Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: Frozen. Container: cryomold Type of Procurement: Radical mastectomy Grade: 2. T Stage: 2 N Stage: 2a M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.,BRCA,2,True,"The N stage is 2a, which corresponds to the presence of metastatic carcinoma in 1-3 axillary lymph nodes. This is stated explicitly in the report.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in a single axillary lymph node is also classified as N1.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in a single axillary lymph node is also classified as N1.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",20.0,1860.0,95.0,True
1161,TCGA-D8-A1Y2.4ACD42D6-9520-4DC6-BB40-9187A4D49981,1,"page 1 / 2. Examination: Histopathological examination (cito). Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - right breas with axillary tissues. Unit in charge: : Expected time of examination: 5 working days. Clinical diagnosis: Macroscopic description: Right breast, sized 24.8 x 19.3 x 5.2 cm, removed with axillary tissues sized 8.0 x 7.5 x 3.0 cm and a skin flap of 28.6 x 14.6 cm. Tumour sized 2.2 x 1.7 x 2.4 found in the lower outer quadrant, located 5.2 cm from the lower boundary, 1.7 cm from the base. and 0 cm from the skin. Microscopic description: Carcinoma ductale invasivum NHG3 (3+3+2: 10 mitoses/10 HPF - visual area 0.55 mm). Mamillae sine laesionibus. Glandular tissue showing parenchymal atrophy. Axillary lymph nodes: Lymphonodulitis chronica (No VII). Histopathological diagnosis: Carcinoma ductale invasivum mammae dextrae. Invasive ductal carcinoma of the right breast. (NHG3, pT2, pNO). Results of immunohistochemical examination: Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in less than 10% of neoplastic cell. nuclei. HER2 protein stained with Ventana's Pathway HER-2/neu (4B5) rabbit antibody. Score=2+, FISH verification. recommended. Examination: Histopathological examination (cito). page 2 / 2. Gender: F. Result of immunohistochemical examination: RESULT OF HER2/neu GENE AMPLIFICATION with the FISH method by Path Vysion HER2 DNA Probe Kit. HER-2 GENE AMPLIFICATION NOT FOUND.",BRCA,0,True,"The report states 'pNO' which means no malignancy was found in the regional lymph nodes. This aligns with the rule 'If no malignancy is found in regional lymph nodes, the N stage is N0.'","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3, but this rule is not applicable in this case.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage, but this rule is not applicable in this case.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage, but this information is not provided in the report.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1, but this rule is not applicable in this case.
The presence of metastatic carcinoma in a single axillary lymph node is also classified as N1, but this rule is not applicable in this case.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage, but this information is not provided in the report.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3, but this rule is not applicable in this case.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage, but this rule is not applicable in this case.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage, but this information is not provided in the report.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1, but this rule is not applicable in this case.
The presence of metastatic carcinoma in a single axillary lymph node is also classified as N1, but this rule is not applicable in this case.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage, but this information is not provided in the report.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",20.0,2148.0,93.0,True
1150,TCGA-D8-A1XQ.33B6269D-1D59-4184-A786-2BEB73F6D3A8,1,"page 1 / 1. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - right breast with axillary tissues. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the right breast. Specimen from a modified radical mastectomy using. technique. Macroscopic description: Right breast sized 20 x 16 x 5 cm removed along with axillary tissues sized 9 x 11 x 3 cm and a skin flap of 20 x 8 cm. Weight 880. g. Tumour sized 2.2 x 2.0 x 1.5 cm on the border of the outer quadrants, located 3.0 cm from the lower boundary, 1.2 cm from the. base and 1.6 cm from the skin. Lymph nodes of 1.0 cm in length. Microscopic description: Carcinoma ductale invasivum, basal-like NHG3 (3 + 3 +2/15 mitoses/10 HPF - visual area 0.55 mm). Reactio lymphocytaria peritumoralis. Mamilla sine laesionibus. Axillary lymph nodes: Lymphonodulitis reactiva No VII. Histopathological diagnosis: Invasive ductal carcinoma of the right breas)(NHG3, pT2, pNO). Results of immunohistochemical examination: No estrogen receptors found in neoplastic cell nuclei. Progesterone receptors found in less than 10% of neoplastic cell nuclei. HER2 protein stained with HercepTestâ„¢M by DAKO. Negative reaction in invasive cancerous cells ( Score = 1+). Tests performed. twice. Compliance vali.",BRCA,0,True,"The report states 'pNO', which indicates that no malignancy was found in the regional lymph nodes. According to the rules, if no malignancy is found in regional lymph nodes, the N stage is N0.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3, but this rule is not applicable in this case.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage, but this rule is not applicable in this case.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage, but this information is not provided in the report.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1, but this rule is not applicable in this case.
The presence of metastatic carcinoma in a single axillary lymph node is also classified as N1, but this rule is not applicable in this case.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage, but this information is not provided in the report.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3, but this rule is not applicable in this case.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage, but this rule is not applicable in this case.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage, but this information is not provided in the report.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1, but this rule is not applicable in this case.
The presence of metastatic carcinoma in a single axillary lymph node is also classified as N1, but this rule is not applicable in this case.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage, but this information is not provided in the report.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",20.0,2148.0,100.0,True
983,TCGA-BH-A0BP.2444E1FE-E0AB-4AA0-9081-967426B90EE6,0,"FINAL DIAGNOSIS: PART 1: LEFI BREASI, SEGMENTAL MASTECTOMY AT 3 O'CLOCK -. A. TWO FOCI OF INFILTRATING DUCTAL CARCINOMA, 0.7 AND 1.5 CM, NOTTHINGHAM SCORE 6/9 (TUBULES. 3, NUCLEAR 2, MITOSES 1). B. TUMOR AGGREGATE 2.2 CM. C. DUCTAL CARCINOMA IN SITU WITH COMEDO NECROSIS ASSOCIATED WITH MICROCALCIFICATION. PRESENT IN BOTH FOCI OF TUMOR AND REPRESENTING 10% OF THE TUMOR VOLUME. D. LYMPHOVASCULAR SPACE INVOLVEMENT IS NOT PROMINENT. E. 1ND INVASIVE TUMOR IS 0.2 CM FROM THE ANTERIOR MARGIN AND DCIS IS 0.1 CM FROM ANTERIOR. MARGIN. F. 2ND INVASIVE TUMOR IS 0.1 CM FROM THE POSTERIOR MARGIN. G. MARGINS FREE OF TUMOR. H. FIBROCYSTIC CHANGES WITH ATYPICAL DUCTAL EPITHELIAL HYPERPLASIA, SCLEROSING ADENOSIS. ASSOCIATED WITH MICROCALCIFICATION. I. MICROSCOPIC RADIAL SCAR, CONFIRMED BY POSITIVE P63 AND SMOOTH MUSCLE MYOSIN HEAVY. CHAIN IMMUNOSTAIN. PART 2: LEFT AXILLA, SENTINEL LYMPH NODE #1, BIOPSY -. TWO LYMPH NODES NEGATIVE FOR TUMOR. PART 3: LEFT AXILLA, SENTINEL LYMPH NODE #2, BIOPSY -. ONE LYMPH NODE NEGATIVE FOR TUMOR. CASE STNUPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Segmental. Upper outer quadrant. SIZE OF TUMOR: Maximum dimension invasive component: 1.5 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR AGGREGATE SIZE: Sum of the sizes of multiple invasive tumors: 2.2 cm. TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 3. Mitotic activity score: 1. Total Nottingham score: 6. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: Not applicable. CALCIFICATION: Yes, benign zones. Yes, malignant zones. TUMOR TYPE, IN SITU: Solid. Comedo. DCIS admixed with invasive carcinoma. Percent of tumor occupied by in situ component: 10 %. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 1 mm. SURG MARGINS INVOLVED BY IN SITU COMPONENT: Distance of in situ disease to closest margin: 1 mm. LYMPH NODES POSITIVE: 0. LYMPH NODES EXAMINED: 3. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SENTINEL NODE METASTASIS: NON-NEOPLASTIC BREAST TISSUE: ADH, Radical scar, FCD. T STAGE, PATHOLOGIC: pT1c. N STAGE, PATHOLOGIC: pNO. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: previously performed. PROGESTERONE RECEPTORS: previously performed. HER2/NEU: zero or 1+.",BRCA,0,True,"The pathology report indicates that 3 sentinel lymph nodes were examined and all were negative for malignancy. According to the rules, if no malignancy is found in regional lymph nodes, the N stage is N0. The number of lymph nodes examined and the number of nodes with malignancy, the size and extent of the primary tumor, the presence of lymphovascular invasion, and the histologic type and grade of the tumor do not affect the N stage.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3, but this rule is not applicable in this case.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage, but this rule is not applicable in this case.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage, but this information is not provided in the report.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1, but this rule is not applicable in this case.
The presence of metastatic carcinoma in a single axillary lymph node is also classified as N1, but this rule is not applicable in this case.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage, but this information is not provided in the report.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",20.0,2148.0,69.0,False
477,TCGA-A2-A0CL.17950062-E052-4FC2-A437-A17669B4DD01,2,"Specimen #: (Age: F Race: BLACK. Physician (s) : SPECIMEN: RIGHT BREAST AND AXILLARY CONTENT. FINAL DIAGNOSIS: BREAST, RIGHT, MASTECTOMY WITH AXILLARY LYMPH NODES : TUMOR TYPE: INFILTRATING DUCTAL CARCINOMA. NOTTINGHAM GRADE: POORLY DIFFERENTIATED. NOTTINGHAM SCORE: 9 OF 9. (Tubules= 3, Nuclei= 3, Mitoses= 3). TUMOR SIZE (GREATEST DIMENSION) : 5.6 CM (MEASURED GROSSLY). TUMOR NECROSIS: PRESENT IN INFILTRATING COMPONENT. MICROCALCIFICATIONS: PRESENT IN TUMOR. VENOUS / LYMPHATIC INVASION: PRESENT (EXTENSIVE). MARGINS : DEEP MARGIN IS INVOLVED BY INFILTRATING TUMOR. -DISTANCE OF TUMOR FROM NEAREST MARGIN IS 0 CM, FROM DEEP MARGIN. INTRADUCTAL COMPONENT: PRESENT. LYMPH NODES: 9 OF 12 POSITIVE FOR TUMOR; LARGEST METASTATIC FOCUS IS. 1.5 CM. ESTROGEN RECEPTORS: POSITIVE (20%) (PERFORMED ON. PROGESTERONE RECEPTORS: NEGATIVE (less than 5%) (PERFORMED ON. HER 2 NEU by IHC: NEGATIVE (1%) (PERFORMED ON. PATHOLOGIC STAGE: pT3 N2a M# (AJCC Stage IIIA). CLINICAL DIAGNOSIS AND HISTORY: year old female with right breast cancer. PRE-OPERATIVE DIAGNOSIS: Right breast cancer. Specimen #: GROSS DESCRIPTION: A. Received fresh and consists of 553 gram right mastectomy specimen with. axillary tail. Specimen measures 22 cm medial to lateral, 18 cm superior. to inferior, 3 cm anterior to posterior. Superficial skin ellipse is. darkly pigmented and measures 18 x 7 cm. Centrally everted nipple is. surrounded by nodular areolar. No scar or discharge is noted. Deep. resection margin is inked black. Specimen serially sectioned to reveal. 6. x 3.5 x 1.5 cm poorly circumscribed firm gritty mass within the lateral. outer quadrant. Located 5 cm from this mass at the mid inner aspect at. 3:00 there is a second similar appearing mass measuring 2.5 x 2.5 x 1. o. cm. The surrounding tissue shows marked hemorrhage consistent with. previous biopsy located within lateral inner quadrant is a 1 x 0.8 x 0.5. cm similar mass located 5 cm from 3:00 mass. Also within lateral inner. quadrant is a 1.5 X 0. x 0.5 cm similar mass abutting deep margin. Remainder of breast parenchyma is composed of 40% dense slightly nodular. fibrous tissue. Fatty tissue is unremarkable. Attached axillary tail measures 8 x 5 x 1 cm and contains twelve lymph. nodes ranging from 0. to 2 cm in greatest dimension. Upon sectioning the. cut surfaces are predominantly firm, pink white and appear involved by. lesion. Cassette key: A1: skin. A2: nipple. A3: LOQ mass inferior portion. A4: LOQ mass superior portion. A5: mid inner quadrant 3:00 mas. A6: LIQ mass. A7: LIQ mass at margin. A8: LOQ. A9: LIQ. A10: UIQ. All: UOQ. A12: largest lymph node, low axillary. A13: low axillary lymph node. A14: low axillary lymph node. A15: high axillary lymph node. A15-A18: two lymph nodes bisected in each cassette. A19-A20: one bisected lymph node in each cassette. Matched sections of A1-A6 and A8-A15 placed in. for CBCP protocol.",BRCA,2,True,"The report states that 9 out of 12 lymph nodes are positive for tumor, with the largest metastatic focus being 1.5 cm. This meets the criteria for N2a (i+/ii+/iii+, where i, ii, and iii represent the number of positive lymph nodes in different locations).","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3, but this rule is not applicable in this case.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage, but this rule is not applicable in this case.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage, but this information is not provided in the report.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1, but this rule is not applicable in this case.
The presence of metastatic carcinoma in a single axillary lymph node is also classified as N1, but this rule is not applicable in this case.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage, but this information is not provided in the report.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",N2,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3, but this rule is not applicable in this case.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage, but this rule is not applicable in this case.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage, but this information is not provided in the report.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1, but this rule is not applicable in this case.
The presence of metastatic carcinoma in a single axillary lymph node is also classified as N1, but this rule is not applicable in this case.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage, but this information is not provided in the report.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",20.0,2148.0,100.0,True
1266,TCGA-E2-A573.14EB270E-0AAB-4C12-8D71-ED79076C2E93,0,"SPECIMEN(S): A. RIGHT BREAST PARTIAL MASTECTOMY. B. SLN #1 RIGHT AXILLA. C. ADDITIONAL AXILLARY TISSUE RIGHT AXILLA. CLINICAL HISTORY: This is a. year old female with a 1.4 cm tumor in the right breast, IDC at 11:00. S/P. benign MRI biopsy inferior and lateral to this index lesion, not clipped. Here for N/L. lumpectomy with SLN biopsy. INTRAOPERATIVE CONSULTATION DIAGNOSIS: A. Right breast, partial mastectomy: Tumor is 0.3 cm from anterior margin. TPB1-TPB4: SLN#1, right axilla, excision: Four lymph nodes, negative for carcinoma. Diagnosis called to Dr. at by Dr. PRE-OPERATIVE DIAGNOSIS: Right breast cancer. GROSS DESCRIPTION: A. RIGHT BREAST PARTIAL MASTECTOMY. Received fresh in a container labeled with the patients name and ""right breast partial. mastectomy"" is an oriented (straight: superior= 1 clip, long: lateral = 2 clips, double: deep, air knot in axillary tail), previously inked, 130g, 11 x 9 x 3.5 cm partial mastectomy. with accompanying radiograph. Ink code: anterior-yellow, posterior-black, medial-green,. lateral-red, superior-blue, inferior-orange. The specimen is serially sectioned from. superior to inferior into 8 slices revealing a 1.6 x 1.4 x 0.8 cm firm, circumscribed, tan. mass that is closest to the anterior margin at 0.3 cm. Tissue is procured. Representatively. submitted: A1: slice 1, superior margin. A2-A3: slice 4, mass with skin and anterior margin, bisected. A4-A5: slice 4, posterior margin underlying mass, bisected. A6-A7: slice 4, anterior and posterior margins, bisected. A8-A9: slice 4, lateral and posterior margins, bisected. A10-A11: slice 4, anterior and medial margins, bisected. A12-A13: slice 4, medial and posterior margins, bisected. A14: slice 5, mass with skin and anterior margin. A15-A16: slice 8, inferior margin. B. SLN #1 RIGHT AXILLA. Received fresh labeled with the patients name and ""SLN #1 right axilla"" is a 5 x 2 x 0.7. cm aggregate of fatty tissue within which four lymph nodes, 2 X 0.6 x 0.6 cm, 2 X 1 x 0.6. cm, 2 x 1.1 x 0.4 cm, 1.2 x 1 x 0.6 cm are identified. Touch preps are performed. Lymph. nodes are entirely submitted: B1-B2; one lymph node. B3: one lymph node. B4: one lymph node. B5: one lymph node. C. ADDITIONAL AXILLARY TISSUE RIGHT AXILLA. Received in formalin in a container labeled with the patients name and designated. ""additional axillary tissue"" is a 1.7 x 1 x 0.2 cm fragment of soft fatty tissue. The. specimen is bisected and entirely submitted. DIAGNOSIS: A. BREAST, RIGHT, PARTIAL MASTECTOMY: - INVASIVE DUCTAL CARCINOMA WITH LYMPHOPLASMACYTIC. INFILTRATE AND GEOGRAPHIC NECROSIS, SBR GRADE 3,. MEASURING 1.1-CM. - SURGICAL RESECTION MARGINS NEGATIVE FOR TUMOR. - BIOPSY SITE CHANGES WITH FIBROSIS AND FAT NECROSIS. - SEE SYNOPTIC REPORT. B. LYMPH NODE, SENTINEL #1, RIGHT AXILLA, EXCISION: - FOUR LYMPH NODES, NEGATIVE FOR METASTASES (0/4). C. ADDITIONAL AXILLARY TISSUE, RIGHT, AXILLARY DISSECTION: - FIBROADIPOSE TISSUE, NO TUMOR OR LYMPHOID TISSUE. IDENTIFIED. SYNOPTIC REPORT - BREAST. Specimen Type: Partial mastectomy. Needle Localization: Laterality: Right. Invasive Tumor: Present. Multifocality: WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 1.1cm. Tumor Site: Upper outer quadrant. Margins: Negative. Distance from closest margin: 0.3cm. anterior. Tubular Score: 3. Nuclear Grade: 3. Mitotic Score: 2. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Present. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node. Lymph node status: Negative 0/4. DCIS not present. ER/PR/HER2 Results. ER: Pending. PR: Pending. HER2: Pending. Pathological staging (pTN): pT 1c N 0. Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition. ADDENDUM: SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimen: Surgical Excision. Block Number: A2. ER: Negative. Allred Score: 0 = Proportion Score 0 + Intensity Score 0. PR: Negative. Allred Score: 0 = Proportion Score 0 + Intensity Score 0. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the. proportion score (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-. 30% of cells staining, 4 = 31-60% of cells staining, 5 = >60% of cells staining) to the intensity score. (1 = weak intensity of staining, 2 = intermediate intensity of staining, 3 = strong intensity of. staining), with a scoring range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score. of less than or equal to 2. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Immunohistochemistry was performed using the mouse anti-human ER (ER 1D5, 1:100) and PR. (PGR 136, 1:100) provided by. following the manufacturer S. instructions. This assay was not modified. Interpretation of the ER/PR immunohistochemical stain. is guided by published results in the medical literature, information provided by the reagent. manufacturer and by internal review of staining performance. SYNOPTIC REPORT - BREAST HER-2 RESULTS. Specimen: Surgical Excision. Block Number: A2. Interpretation: EQUIVOCAL. Intensity: 2+. % Tumor Staining: 10%. Fish Ordered: METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Her2 analysis was performed using the FDA approved. ) HercepTes (TM) test kit. ising rabbit anti-human HER2. This assay was not modified. External kit-slides. provided by the manufacturer (cell lines with high, low and negative HER2 protein expression) and. in-house known HER2 amplified control tissue were evaluated along with the test tissue. Adequate,. well preserved, clear-cut invasive carcinoma was identified for HER2 evaluation. Interpretation of. the HER2 immunohistochemical stain is guided by published results in the medical literature,. information provided by the reagent manufacturer and by internal review of staining performance. This assay has been validated according to the. joint recommendations and guidelines from. ASCO and CAP and from the NCCN HER2 testing in Breast Cancer Task Force. The. Pathology Department takes full responsibility for this test's performance. ADDENDUM: FISH/ISH ANALYSIS REPORT 3. Specimens Involved. Specimens: A: RIGHT BREAST PARTIAL MASTECTOMY. HER2/NEU RESULTS. ANALYTICAL INTERPRETATION OF RESULTS. HER-2 NOT AMPLIFIED. Clinical interpretation of the results. A majority of tumors cells displayed 2 chromosome 17 centimeter signals and 2 HER2. signals, with a HER2/CEP 17 Ratio 1.3, consistent with no amplification of the HER2/neu. gene. Probes identification. LSI Her-2/neu 17q11.2-12, spectrumorange. CEP 17, 17 p11.1-q11.1 alpha satellite DNA, spectrumgreen. Image analysis method - Manual. Results interpreted. ISCN. nuc ish: (CEP17,HER2)x2[200]. Number of invasive tumor cells counted. 200. Number of observers. 1. Number of Her2 signals/nucleus. 2.3. Number of CEP 17 signals/nucleus. 1.8. Her2/CEP 17 ratio. 1.3. TEST CHARACTERISTICS: PathVysion HER-2 DNA Probe Kit is FDA approved for. selection of patients for whom Herceptin therapy is being considered. These tests were. performed in the Pathology Core Facility, Department of Pathology,. under the direction of Dr.. The results of these studies should always be. interpreted in the context of the clinical, morphological, and immunophenotypic diagnosis. The. PathVysion Kit is not intended for use to screen for or diagnose breast cancer. It. is intended to be used as an adjunct to other prognostic factors currently used to predict. disease-free and overall survival in stage II, node-positive breast cancer patients. In. making decisions regarding adjuvant CAF treatment, all other available clinical. information should also be taken into consideration, such as tumor size, number of. involved lymph nodes, and steroid receptor status. No treatment decision for stage II,. node-positive breast cancer patients should be based on HER-2/neu gene amplification. status alone. Specimen information. RPCI surgical pathology/cytology case number. Source of case. RPCI. Block number used A2. Specimen site. Breast. Female breast right. Specimen type. Complete excision (less total mastectomy). Specimen fixative type. Formalin. Duration of fixation (hrs). 6 48 hrs. Comment: Controls: The FISH study was performed with appropriately stained positive and negative. controls.",BRCA,0,True,"The report states that four lymph nodes were examined and all were negative for metastases (0/4). This indicates that the N stage is N0, as there is no malignancy found in regional lymph nodes.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3, but this rule is not applicable in this case.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage, but this rule is not applicable in this case.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage, but this information is not provided in the report.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1, but this rule is not applicable in this case.
The presence of metastatic carcinoma in a single axillary lymph node is also classified as N1, but this rule is not applicable in this case.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage, but this information is not provided in the report.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",20.0,2148.0,69.0,False
1141,TCGA-D8-A1XC.E5D2E429-C41C-47E2-96CB-F3B6F412499B,3,"page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - right breast. Expected time of examination: 5 working days. Clinical diagnosis: Right breast - advanced cancer of both breasts, toilet mastectomy of both breasts. Results of immunohistochemical examination: Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in over 75% of neoplastic cell. nuclei. HER2 protein stained with HercepTestâ„¢M by DAKO. Negative reaction in invasive carcinoma cells ( Score = 1+. Macroscopic description: Right breast sized 19 x 9 x 6 cm removed along with axillary tissues sized 7 x 3 x 2 cm and a skin flap of 13 x 9.5 cm. Weight 370. g. Tumour sized 7 x 4 x 8 cm found in the central part. Margin to the lower boundary - uncertain, margin to the base - uncertain,. margin to the skin 0.1 cm. Histopathological diagnosis: Carcinoma mucinosum invasivum - NHG2 (3+2+1/5 mitoses/10 HPF - visual area 0.55mm). Invasive mucinous carcinoma of the right breast. Numerous foci of carcinoma ductale found outside the tumour (cribrate type, with medium nuclear atypia, without. necrosis) and lesions of the type mastopathia fibrosa et cystica, hyperplasia ductalis simplex (UDH) AXILLARY LYMPH. NODES: Micrometastases carcinomatosae in lymphonodo (No I/XX). Examination: Histopathological examination. page 2 / 2. cxamination No.: Gender: F. Complementary diagnosis: Complementary macroscopic description: Extensive skin proliferation. Minor ulceration in the skin. Skin proliferation confirmed microscopically. Focal. tumour pattern along the incision line at the side of the base and lower boundary. Test result: Carcinoma mucinosum invasivum with a neuroendocrinic component mammae dextrae. Micrometastasis. carcinomatosa in lymphonodo axillae (No 1/XX) (NHG2, pT4b, pNIa mi). Immunophenotype: CK7+/- (Only part of the. cells exhibit positive reaction, CK5/6 p63-, calponin ambiguous reaction, synaptophysin +, chromogranin -/+). Compliance validated k,.",BRCA,1,True,"The report mentions the presence of micrometastases carcinomatosae in a lymph node (No I/XX) of the axillae, which is classified as N1 according to the rules provided. The number of lymph nodes examined or the presence of extracapsular extension is not specified, but the rule states that the N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3, but this rule is not applicable in this case.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage, but this rule is not applicable in this case.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage, but this information is not provided in the report.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1, but this rule is not applicable in this case.
The presence of metastatic carcinoma in a single axillary lymph node is also classified as N1, but this rule is not applicable in this case.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage, but this information is not provided in the report.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",20.0,2148.0,69.0,False
763,TCGA-AN-A0FV.5AEE90E0-A9A1-4944-AD6A-2675764D869D,1,Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Right Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: Frozen. Container: cryomold Type of Procurement: Radical mastectomy Grade: 2. T Stage: 2 N Stage: 0 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.,BRCA,0,True,"The N stage in this report is N0, as there is no malignancy found in the regional lymph nodes.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in a single axillary lymph node is also classified as N1.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in a single axillary lymph node is also classified as N1.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",20.0,1860.0,93.0,True
1296,TCGA-E9-A1RE.80831A1A-95BD-4ECD-B7D9-6DDCD5313B25,1,"OC ID: Gross Description: Breast with the tumor of 3.5 x 3 cm in size; fatty tissue lymph nodes are dense, hyperemic, up to 1 cm in their diameter. Microscopic Description: Infiltrating duct carcinoma; G2. Ten lymph nodes were examined, nine lymph nodes demonstrated metastases. Diagnosis Details: Tumor Features: Unknown,Tumor Extent: T2tumorsizemore than 2cmnot more than 5 cm, Venous Invasion: Absent,. Margins: Absent, Treatment Effect: Comments: BREAST TISSUE CHECKLIST. Specimen type: Radical mastectomy. Specimen size: Not specified. Tumor site: Upper outer quadrant. Tumor size: 3 x 0x3.5 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal carcinoma. Histologic grade: Moderately differentiated. Tumor extent: Not specified. Lymph nodes: 9/10 positive for metastasis (Axillary 9/10). Extracapsular invasion of the lymph nodes: Not specified. Margins: Uninvolved. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: None. Laterality: Left, upper outer quadrant.",BRCA,2,True,"The report states that 9 out of 10 examined lymph nodes demonstrated metastases. According to the rules, the presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",N3,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",19.0,1765.0,97.0,True
646,TCGA-A8-A08F.683AAF99-3B91-4501-B701-C3A4E8439647,1,"Diagnosis: 1. Ablated (right) breast sample with a multifocal invasive ductal carcinoma with. intraductal components and focal angioinvasion (focus of a poorly differentiated. invasive ductal carcinoma with a tumor diameter of 2.8 cm and two further foci of. a. moderately invasive ductal carcinoma with tumor diameters of 3.0 cm and 1 cm). Dorsal resection margin tumor-free with minimum margin of 0.5 cm with the first. tumor focus, 1.5 cm with the second and 0.7 cm with the third, other margins are. free. Tumor classification: NOS, G III, pT2(mult)N3aL1V0R0. NÂ°. Site. Prior Prigian Noted QUALIFIED. is. (circle): Die.",BRCA,3,True,"The report indicates that the tumor has metastasized to 4 or more axillary lymph nodes (N3a), as evidenced by the TNM classification 'pT2(mult)N3aL1V0R0'.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",N3,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",19.0,1765.0,100.0,True
858,TCGA-AR-A1AO.37EF1828-0A53-4358-97C7-A7849EC653AF,0,"Final diagnosis. Breast, left wide local excision: Infiltrating ductal carcinoma, Nottingham grade III (of III). [tubules 3/3, nuclei 3/3, mitoses 2/3, Nottingham score 8/9], forming a 1.7 x 1.6 x 1.2 cm mass. [AJCC pTlc]. Ductal carcinoma in situ, intermediate nuclear grade, comprising less than 5% of. tumor volume. Angiolymphatic invasion is absent. Biopsy site changes present. All surgical. resection margins, after re-excisions of the medial and superior margins, are negative for tumor. (minimum tumor free margin, 0.9 cm, superior margin). A single intramammary lymph node,. present at the medial margin, is positive for metastatic carcinoma. The involved lymph node. measures 1.5 mm in maximum dimension. Lymph nodes, left axillary sentinel, excision: A single (of 2) left axillary lymph node is positive. for metastatic carcinoma [AJCC pN1]. Blue dye is identified in both left axillary sentinel lymph. nodes. Immunohistochemical cytokeratin stain was performed on the paraffin embedded sentinel. lymph node tissue and confirms the H&E impression. Lymph nodes, left axillary, dissection: Multiple (36) left axillary lymph nodes are negative for. tumor. Faxitron done. Estrogen and progesterone receptor analysis and Her-2/NEU have been ordered on paraffin. embedded tissue.",BRCA,1,True,"The report states that a single intramammary lymph node is positive for metastatic carcinoma, and a single (of 2) left axillary lymph node is positive for metastatic carcinoma. This indicates that there is cancer in at least one lymph node, but not in 4 or more axillary lymph nodes. Therefore, the N stage is N1.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",19.0,1765.0,100.0,True
674,TCGA-A8-A09I.AF12859A-D67A-488D-8BC2-ED28698F2ACA,1,"Diagnosis. 1. and 2. Poorly differentiated invasive ductal right breast carcinoma measuring up to 4.4 cm. with a minimum dorsal margin of 2.9 cm in the ablated breast tissue. Circumscribed ductal. carcinoma in situ (high-grade DCIS with comedo necrosis) in the tumor center, about 0.2 cm. in diameter. Lipomatous atrophy of the remaining breast tissue. Regular nipple. Regular skin. Sixteen right axillary lymph nodes free of metastases (0/16). Tumor classification: M-8500/3, G 3, pT2, pNO (0/16), pMX, stage II A.",BRCA,0,True,"The report states that sixteen right axillary lymph nodes were free of metastases (0/16). According to the rules, if no malignancy is found in regional lymph nodes, the N stage is N0.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N3.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",19.0,1765.0,100.0,True
915,TCGA-B6-A0IG.4379DEE0-F7CB-4A73-8828-21EA0AA830F5,1,"Fatient. Surgical Pathology: Final. CLINICAL HISTORY: Breast cancer. GROSS EXAMINATION: A. ""Left breast and axilla"", received fresh. The specimen is a 22.7 x 11.5. x. 2.5 cm mastectomy specimen. The overlying skin ellipse measures 17.0 x 11.0. cm, and includes a 5.5 cm areola and 1.0 cm nipple. A well-healed 3.0 cm scar. is noted just superior to the areola in the upper inner quadrant. The. specimen includes an axillary tail which measures 11.0 cm x 7.0 cm. The. margins of the specimen are inked in blue, and the specimen is serially. sectioned to reveal a 3.5 x 3.5 x 3.0 cm tumor in the upper inner quadrant,. extending medially to the upper outer quadrant. The tumor is firm,. tannish-white, with a gritty consistency. It appears to be infiltrating. adjacent tissue. Tissue has been sent for estrogen and progesterone receptor. assays. The tumor approaches to 1 cm of the deep margin. It approaches to. 1.0 cm to the lateral margins. The remainder of the breast tissue is composed. of lobular adipose tissue intermixed with reddish pink fibrous tissue. There. is an area of dense white fibrous breast tissue in the upper outer quadrant. The axillary tail measures 13.5 x 8.0 cm. It is composed of yellow lobular. adipose tissue. Several nodes are identified grossly. A 3.1 x 1.0 cm node is. sectioned to reveal a firm 2.0 x 1.0 cm tan-white mass. The axillary tail is. amputated, divided into three sections and searched for lymph nodes which are. submitted as described below. Block Summary: A1- section of skin through nipple and areola. A2- section of breast through overlying skin with scar. A3- section of deep margin of tumor. A4- section of deep margin of tumor. A5- section of lateral margin of tumor. A6- section of tumor. A7- section of tumor. A8- section of tumor, with possible biopsy cavity. A9- tissue from the upper inner quadrant. A10- tissue from the lower inner quadrant. A11- tissue from lower outer quadrant. A12- tissue from upper outer quadrant. A13-one grossly positive lymph node, section I. A14-one lymph node, sectioned, section I. A15- six lymph nodes, section II. A16- three lymph nodes, section II. A17 one lymph node , sectioned, section II. A18- three lymph nodes, section III. A19- one lymph node, sectioned, section III. A20- three lymph nodes, section III. MICROSCOPIC EXAMINATION: The previous biopsy site is located in the center of a large tumor mass. consisting of infiltrating ductal carcinoma. Positive lymph nodes are. identified in the axillary tail in the following distribution: low axillary. tail, 2/2 (one macroscopically positive with extracapsular extension) ; mid. axillary tail, 2/8; high axillary tail, 0/6. DIAGNOSIS: A. ""LEFT BREAST AND AXILLA""; MODIFIED RADICAL MASTECTOMY: 1. RESIDUAL INFILTRATING DUCTAL CARCINOMA, NSABP NUCLEAR GRADE 2/3,. eBrowser Result for. 1 of 2. HISTOLOGIC GRADE 3/3. 2. RESIDUAL TUMOR SIZE 3.5 x 3.5 x 3.0 CM. 3. FOCAL DUCTAL CARCINOMA IN SITU, COMEDO TYPE. 4. FOCAL VASCULAR INVASION IS IDENTIFIED. 5. NIPPLE, NO PAGET'S DISEASE IDENTIFIED. 6. SKIN WITH HEALING SCAR. NO DERMAL LYMPHATIC INVASION IDENTIFIED. 7. ALL SURGICAL MARGINS ARE FREE OF TUMOR. 8. REMAINING BREAST WITH PAPILLARY APOCRINE METAPLASIA, CYSTIC CHANGE, AND. INTER- AND INTRALOBULAR FIBROSIS. 9. METASTATIC ADENOCARCINOMA INVOLVING 4 OF 16 TOTAL AXILLARY LYMPH NODES. ONE LYMPH NODE IN THE LOW AXILLA IS MACROSCOPICALLY POSITIVE AND. EXHIBITS EXTRACAPSULAR INVASION BY TUMOR. 2 of 2.",BRCA,1,True,"The report states that metastatic adenocarcinoma is present in 4 out of 16 total axillary lymph nodes, and one of these nodes exhibits extracapsular invasion by tumor. This meets the criteria for N2 staging according to the rules provided.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",N2,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",18.0,1679.0,97.0,True
609,TCGA-A8-A06N.2F0333BC-E9BB-4903-B3E2-8AE241DDDF84,3,"Diagnosis: Poorly differentiated invasive ductal carcinoma (tumor diameter: 17 cm; minimum. distance from preparation margins less than 0.1 cm) with multiple ulcerations of the. skin. Together with the preliminary finding, this gives rise to the following tumor. classification: NOS, G III, pT4bpNOLOVORO.",BRCA,0,True,"The report does not mention any malignancy found in regional lymph nodes (N0), and it only describes the primary tumor characteristics. The absence of malignancy in regional lymph nodes, regardless of the number of lymph nodes examined, leads to the N0 stage.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",18.0,1679.0,100.0,True
1506,TCGA-S3-AA15.DD2B9E47-8C67-4599-B0B6-0D30DE727B55,1,"Female. Admission Date: Discharge Date: Collected Date/Time: Received Date/Time: Final Diagnosis. A. RIGHT SENTINEL LYMPH NODE, EXCISION: - METASTATIC CARCINOMA TO ONE LYMPH NODE (1/1). - THE FROZEN SECTION DIAGNOSIS IS CONFIRMED. SEE SPECIAL STAINS AND SYNOPTIC REPORT. B. RIGHT BREAST, MASTECTOMY WITH AXILLARY LYMPH NODES DISSECTION: - INVASIVE DUCTAL CARCINOMA, GRADE 3, MEASURING 1.1 CM, EXTENDING TO 5 MM FROM THE CLOSEST. POSTERIOR RESECTION MARGIN, WITH ILYMPHOVASCULAR INVASION. - DUCTAL CARCINOMA IN-SITU, NUCLEAR GRADE 3, WITH FOCAL NECROSIS, EXTENDING TO MORE THAN 5. MM FROM THE CLOSEST POSTERIOR RESECTION MARGIN. - MICROMETASTATIC CARCINOMA (0.21 MM) TO 1 OF 12 AXILLARY LYMPH NODES (1/12). - HEALING BIOPSY SITE WITH ORGANIZING HEMATOMA. - SKIN AND NIPPLE WITH SCLEROSING ADENOSIS. - SEE SYNOPTIC REPORT AND SPECIAL STAINS. (Electronic signature). Verified: Synoptic Report. SPECIMEN: Total breast (including nipple and skin). PROCEDURE: Total mastectomy (including nipple and skin). LYMPH NODE SAMPLING: Axillary dissection (partial or complete dissection). SPECIMEN INTEGRITY: Single intact specimen (margins can be evaluated). SPECIMEN SIZE: Greatest dimension: 30 cm. Print Date/Time: Distribute to: Patient Locations: surgical Pathology Report. Collected Date/Time: Received Date/Time: Additional dimensions: 22 X 7 cm. SPECIMEN LATERALITY: Right. TUMOR SITE: INVASIVE CARCINOMA: Upper inner quadrant. TUMOR SIZE: SIZE OF LARGEST INVASIVE CARCINOMA: Microinvasion only (<=0.1 cm). Greatest dimension of largest focus of invasion over 0.1 cm: 1.1 cm. TUMOR FOCALITY: Single focus of invasive carcinoma. MACROSCOPIC AND MICROSCOPIC EXTENT OF TUMOR: Skin: Invasive carcinoma does not invade into the dermis or epidermis. DUCTAL CARCINOMA IN SITU (DCIS): DCIS is present. Extensive intraductal component (EIC) negative. NUCLEAR GRADE: Grade III (high). NECROSIS: Present, focal (small foci or single cell necrosis). HISTOLOGIC TYPE OF INVASIVE CARCINOMA: Invasive ductal carcinoma (no special type or not otherwise specified). GLANDULAR (ACINAR)/TUBULAR DIFFERENTIATION: Score- 3: <10% of tumor area forming glandular/tubular structures. NUCLEAR PLEOMORPHISM: Score 3: Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in size and shape, occasionally with very. large and bizarre forms. MITOTIC COUNT: Score 2. Number of mitoses per 10 high-power fields: 17. Diameter of microscope field: 0.55 mm. OVERALL GRADE: Grade 3: scores of 8 or 9. MARGINS: Margins uninvolved by invasive carcinoma. Distance from closest margin: POSTERIOR 5 mm. Distance from anterior margin: >5 mm. Margins uninvolved by DCIS (if present). Distance from anterior margin: >5 mm. Distance from posterior margin: >5 mm. TREATMENT EFFECT: RESPONSE TO PRESURGICAL THERAPY: IN THE BREAST: No known presurgical therapy. TREATMENT EFFECT: RESPONSE TO PRESURGICAL THERAPY: IN THE LYMPH NODES: No known presurgical therapy. LYMPH-VASCULAR INVASION: Present. Print Date/Time: Collected Date/Time: Received Date/Time: DERMAL LYMPH-VASCULAR INVASION: Not identified. LYMPH NODES: Number of sentinel lymph nodes examined: 1. Total number of lymph nodes examined (sentinel and nonsentinel): 13. Number of lymph nodes with macrometastases (>0.2 cm): 1. Number of lymph nodes with micrometastases (>0.2 mm to 0.2 cm and/or >200 cells): 1. Number of lymph nodes with isolated tumor cells (less than or equal to 0.2 mm and less than or equal to 200 cells): 0. Size of largest metastatic deposit: 0.9 CM. EXTRANODAL EXTENSION: Not identified. METHOD OF EVALUATION OF SENTINAL LYMPH NODES: Hematoxylin and eosin (H&E), one level. PRIMARY TUMOR (INVASIVE CARCINOMA (pT): pT1c: Tumor >10 mm but less than or equal to 20 mm in greatest dimension. REGIONAL LYMPH NODES (pN): pN1a: Metastases in 1 to 3 axillary lymph nodes, at least 1 metastasis greater than 2.0 mm. DISTANT METASTASIS (M): Not applicable. ESTROGEN RECEPTOR: Performed on another specimen. Specimen (accession number): PROGESTERONE RECEPTOR: Performed on another specimen. Specimen (accession number): HER2/NEU IMMUNOPEROXIDASE STUDIES: Performed on another specimen. Specimen (accession number): MICROCALCIFICATIONS. Not identified. CLINICAL HISTORY: Mass or architectural distortion. Source of Specimen. A. Lymph Nodes, Rt. Sentinel. B. RT Breast and Axillary Nodes I & II. Clinical Information. African American female with right breast cancer, silk marks axilla upper inner quadrant. PRE-OP DIAGNOSIS: Right breast cancer. POST-OP DIAGNOSIS: Same. TYPE OF PROCEDURE: Right breast mastectomy and Sentinel node biopsy. Gross Description. Print Date/Time: Female. Collected Date/Time: Received Date/Time: Specimen is received in 2 parts: A. The specimen is labeled ""RIGHT SENTINEL NODE"" and is received unfixed for frozen section diagnosis. (The specimen is in the. formalin. more. than 6 hours and less than 48 hours). It consists of a large lymph node measuring 3.5 x 2 x 2 cm. Sectioned and. entirely submitted in cassettes FSA 1-FSA3. Time specimen was removed from the patient: Time specimen was placed in formalin : Ischemic time: 27 minutes. B. The specimen is labeled ""RIGHT BREAST AND AXILLARY NODES I AND II"" and is received in formalin. (The specimen is. in the formalin more than 6 hours and less than 48 hours). It consist of mastectomy specimen with lymph nodes weighing 1150. grams and measuring 30 x 22 x 7 cm with brown skin ellipse measuring 21 x 10 cm, containing grossly unremarkable 2.0 cm in. diameter nipple. The skin is tagged with a black stitch designating the axilla The posterior margin is composed of smooth fascia. which is inked black. The breast is sliced in sagittal planes revealing a 5 x 5 x 4 cm hemorrhagic cavity within the upper inner-central. quadrants which is 0.7 cm away from the closest deep fascial margin of resection. The remaining parenchyma reveals unremarkable. yellow mammary fat with streaks of white-gray mammary parenchyma. Representative sections are submitted as follows: B1 = one lymph node, bisected. B2 = one lymph node, bisected. B3 = one lymph node, bisected. B4 = 5 lymph nodes. B5 = 2 lymph nodes, one bisected. B6 = one lymph node, bisected. B7 = one lymph node, bisected. B8 = one lymph node, bisected. B9-E = upper inner quadrant-central mass. B13 = mass closest to deep fascial margin of resection. B14 = nipple. B15 = upper inner quadrant. B16 = upper outer quadrant. B17 = lower outer quadrant. B18 = lower inner quadrant. B19-28= additional sections from biopsy cavity. Time specimen was removed from the patient: Time specimen was placed in formalin : Ischemic time: 18 minutes. Intra Operative Consultation. Right sentinel lymph node: one lymph node, positive for carcinoma (1/1). Special Stains/Slides. Immunohistochemical studies were performed on formalin fixed, paraffin-embedded tissue (Block B2, B5, B6) with adequate positive. and negative control sections. Immunostains for keratins AE1/AE3 are negative for carcinoma. Print Date/Time: Collected Date/Time: Received Date/Time: The performance characteristics of these antibodies were determined by the. They have not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such. clearance or approval is not necessary. These tests are used for clinical purposes. They should not be regarded as investigational or for research. This laboratory is. certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high-complexity clinical laboratory testing. Tissue Code.",BRCA,1,True,"The report states that there is metastatic carcinoma present in 1 out of 12 axillary lymph nodes (1/12). This meets the criteria for N1 stage, as the presence of metastatic carcinoma in 1 to 3 axillary lymph nodes is classified as N1.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",18.0,1679.0,100.0,True
1269,TCGA-E2-A9RU.E28607CD-0847-46F4-8E69-2D1DC80DE56F,1,"SPECIMENS: A. RIGHT AXILLARY CONTENTS. B. RIGHT BREAST WIDE EXCISION. C. RIGHT POSTERIOR MARGIN. SPECIMEN(S): A. RIGHT AXILLARY CONTENTS. B. RIGHT BREAST WIDE EXCISION. C. RIGHT POSTERIOR MARGIN. INTRAOPERATIVE CONSULTATION DIAGNOSIS: A.-excision right breast: Mass/lesinn identified 1 cm to the superior margin. Diagnosis called by Dr. to Dr. at. DIAGNOSIS: A.RIGHT AXILLARY CONTENTS: -12. OF 22 LYMPH NODES ARE POSITIVE FOR METASTATIC CARCINOMA (12/22). -FOCAL EXTRANODAL INVOLVEMENT IS IDENTIFIED. B. RIGHT BREAST WIDE EXCISION: - INVASIVE DUCTAL CARCINOMA (IDC), SBR GRADE 3, MEASURING 3.5 CM. - DUCTAL CARCINOMA IN -SITU, INTERMEDIATE NUCLEAR GRADE, SOLID AND CRIBRIFORM. TYPES (MINOR COMPONENT). - SURGICAL RESECTION MARGINS ARE NEGATIVE FOR TUMOR. BIOPSY SITE CHANGES WITH FIBROSIS, GRANULATION TISSUE, FOREIGN BODY GIANT CELL. REACTION AND FAT NECROSIS. - SEE SYNOPTIC REPORT AND SEE NOTE. C. RIGHT POSTERIOR MARGIN: - MAINLY ADIPOSE TISSUE WITH CALCIFICATION OF VESSEL WALL. (MONCKEBERGS CALCIFIC SCLEROSIS). - NO TUMOR IS IDENTIFIED,. SYNOPTIC REPORT - BREAST. Specimens Involved. Specimens: A: RIGHT AXILLARY CONTENTS. B: RIGHT BREAST WIDE EXCISION. Specimen Type: Excision. Localization: Needle. Laterality: Right. Multifocality: No. WHO CLASSIFICATION. Invasive carcinoma of no special type (NST) 8500/3. Tumor size: 35mm. Additional dimensions: 30mm X 30mm. Tumor Site: Not specified. Margins: Negative. distance from (in mm): anterior margin: 6. Tubular Score: 3. Nuclear Grade: 3. Mitotic Score: 3. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Present. Vascular/Lymphatic Invasion: Present. Lymph nodes: Non-sentinel lymph node. Lymph node status: Positive 12/22. Size of largest metastasis: 20mm. Micrometasteses: Extranodal extension: Yes. DCIS PRESENT. Margins: Margins uninvolved by DCIS Specify: 1.5 mm to superior resection margin. DCIS Quantity: Estimate % 2. DCIS Type: Solid. Cribriform. DCIS Location: Separate from invasive tumor mass. Nuclear Grade: Intermediate. Necrosis: Absent. ER/PR/HER2 Results. Estrogen Receptor: Positive. Allred Score: 6. Progesterone Receptor: Negative. Allred Score: 0. Her2: Interpretation: Negative. Methodology: FISH. Performed on Case: (outside slides0. Pathological staging (pTN): pT 2 N 3a. Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition. GROSS DESCRIPTION: A. RIGHT AXILLARY CONTENTS. Received fresh labeled with the patient's identification and ""right axillary contents "" are piece of yellow-. tan adipose tissue, 14 x 10 x 2 cm, containing lymph nodes ranging from 0.2 cm to 2 cm; lymph nodes. are sectioned and submitted entirely: A1: 6 possible lymph nodes. A2: 2 lymph nodes, bisected (one inked green). A3-A5: 1 lymph node, bisected, each block. A6: 1 lymph node. A7: 2 lymph nodes, bisected (one inked green). A8: 1 lymph node, bisected. A9:2 lymph nodes. A10: 1 lymph node. A11: 3 lymph nodes. A12-13:1 lymph node. A14-A17: 1 lymph node. A18-A19: 1 lymph node. B. RIGHT BREAST EXCISION. Received fresh labeled with the patient's identification and ""right breast excision"" is an previously inked,. 177 g, 11.5 cm medial to lateral x 7.5 cm superior to inferior x 3.5 cm anterior to posterior, excision. The. overlying skin measuring 9.5x 7 cm in diameter. There are multiple brown papules on the skin. Ink. code: anterior-yellow, posterior-black, medial-green, lateral-red, superior-blue, inferior-orange. The. specimen is serially sectioned from medial to lateral into 7 slices revealing a 3.5 x 3 x 3 cm, white, firm. mass that is closest to the superior and anterior margins at 1 cm. The clip was retrieved in slice 4. Representatively submitted as per the attached diagram: B1: medial margin. B2: slice 2, anterior margin with tumor. B3: slice 2, superior margin with tumor. B4: slice 3, skin with tumor. B5-B6: slice 3, anterior margin with tumor. B7: slice 3, superior margin with tumor. B8: slice 3, posterior margin with tumor. B9: slice 3, inferior margin. B10: slice 4, tumor around clip. B11: slice 4, skin with tumor. B12: Slice 5, superior and anterior margins. B13: slice 7, lateral margin. C. RIGHT POSTERIOR MARGIN. Received fresh labeled with the patient's identification and ""right posterior margin"" is a yellow-tan. adipose tissue, 10 x 2 x 1.3 cm. One surface has been marked with clips indicating new margin. This. surface is inked black. Serial sectioning does not reveal any abnormality. Representative sections. submitted in 4 cassettes. CLINICAL HISTORY: None Given. PRE-OPERATIVE DIAGNOSIS: None Given. Final Review: Final: M.D.,.",BRCA,3,True,"The report states that 12 out of 22 lymph nodes are positive for metastatic carcinoma (12/22). This indicates that the patient has metastatic carcinoma in 4 or more axillary lymph nodes, which is classified as N2 according to the AJCC Cancer Staging Manual, 7th Edition.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",N2,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information (e.g. 'a', 'b', 'c') can provide additional details about the N stage but does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",18.0,1679.0,100.0,True
841,TCGA-AR-A0TV.7594A7F8-1806-4B74-99EF-4E4C889E7BEA,1,"Breast, left, simple mastectomy: Infiltrating Nottingham grade III (of III) ductal carcinoma forming a 2.6. x 2.4 x 2.0 cm (AJCC pT2) mass located in the outer quadrant. No angiolymphatic invasion identified. No significant ductal carcinoma in situ component identified. A separate hyalinized fibroadenoma (1.2 x. 1.0 x 1.0 cm) is present superior to the tumor mass. The nipple and skin are unremarkable. Lymph nodes, left axillary sentinel, excision: Multiple (3) left axillary sentinel lymph nodes are negative. for tumor. Blue dye is identified in left axillary sentinel lymph node No. 1. Blue dye is not identified in. left axillary sentinel lymph nodes No. 2 and No. 3. Immunohistochemical cytokeratin stain was. performed on the paraffin embedded sentinel lymph node tissue and confirms the H&E impression. [AJCCpN0(i-)]. Her-2/NEU has been ordered on paraffin embedded tissue.",BRCA,0,True,"The report states that multiple (3) left axillary sentinel lymph nodes were negative for tumor, as confirmed by immunohistochemical cytokeratin stain. No substaging information is provided, and there is no mention of extracapsular extension or metastatic carcinoma in internal mammary or supraclavicular lymph nodes. Therefore, the N stage is N0.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",18.0,1605.0,98.0,True
1138,TCGA-D8-A1X9.E69CF3E3-4799-4892-87E9-4291B14A1B9C,1,"page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Total organ resection - left breast with axillary tissues. Material collected on: : Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the left breast. Results of immunohistochemical examination: Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in over 75% of neoplastic cell. nuclei. HER2 protein stained with HercepTestâ„¢ by DAKO. Score = 2+, FISH verification recommended. Macroscopic description: Left breast sized 22 x 15 x 5 cm removed along with axillary tissues sized 13 x 7.5 x 1.5 cm and a skin flap of 19 x 11 cm. Retracted nipple. Tumour sized 2.5 x 2 x 2.8 cm found on the boundary of lower quadrants, located 3.5 cm from the lower. boundary, 0.4 cm from the base and 3 cm from the skin. Microscopic description: Carcinoma ductale invasivum - NHG2 (2+2+3/21 mitoses/10 HPF - visual area 0.57mm). Glandular tissue showing. lesions of the type mastopathia fibrosa et cystica, hyperplasia ductalis simplex (UDH 1. AXILLARY LYMPH NODES: Metastases carcinomatosae in lymphonodis (No III/XXIII). Infiltratio capsulae lymphonodorum. Histopathological diagnosis: Carcinoma ductale invasivum mammae sinistrae. Invasive ductal carcinoma of the left breast. Metastases carcinomatosae in lymphonodosi axillae (No III/XXIII) (NHG2, pT2, pNIa). Cancer metasta Â° of axillary lymph nodes (No III/XXIII) (NHG2, pT2, pNIa). S. Examination: Histopathological examination. page 2 / 2. Gender: F. Results of immunohistochemical examination: RESULT OF HER2/neu GENE AMPLIFICATION with the FISH method by Path Vysion HER2 DNA Probe Kit. HER-2 GENE AMPLIFICATION NOT FOUND.",BRCA,1,True,"The report mentions metastases carcinomatosae in 3 out of 23 axillary lymph nodes (No III/XXIII). This indicates that there are positive lymph nodes, and the number of positive lymph nodes is less than 4. According to the rules, this is classified as N1.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.",18.0,1605.0,100.0,True
1252,TCGA-E2-A1LB.A868EC86-9CB6-445E-B961-5D4C57263548,1,"SPECIMENS: A. WLE RIGHT BREAST. B. RIGHT AXILLARY CONTENTS. SPECIMEN(S): A. WLE RIGHT BREAST. B. RIGHT AXILLARY CONTENTS. INTRAOPERATIVE CONSULTATION DIAGNOSIS: Part A, WLE Right breast, gross examination: Tumor 0.2-cm from posterior margin. Called to Dr. at. by Dr. GROSS DESCRIPTION: A. WLE RIGHT BREAST. Received fresh labeled with matching patient identifiers is an oriented (short-superior, long-lateral) 124. g, 9.7 (medial to lateral) x 9 x 3 cm lumpectomy with a slender fragment of tan skin 2.8 x 0.3 cm. The. specimen is inked as follows: anterior - blue, posterior - black, superior - red, inferior - orange, medial. green, lateral - yellow. The specimen is serially sectioned from medial to lateral into 7 slices revealing. a 2.8 x 2.5 x 1.4 cm ill defined firm tan mass approaching the closest posterior margin at 0.2 cm, and. superior margin at 0.5 cm. A portion of the specimen is submitted for tissue procurement. Representative sections are submitted as follows: A1-A2: Perpendicular sections medial margin. A3-A4: Section 2 anterior. A5: Section 2 posterior. A6: Section 3 inferior. A7: Section 3 anterior/superior. A8-A9: Section 3 superior. A10-A11: Section 4 lesion and posterior. A12: Section 4 anterior/inferior. A13-A16: Section 5, lesion and nearest posterior. A17-A18: Section 6, lesion and posterior/anterior. A19-A20: Section 6, lesion and superior. A21-A22: Perpendicular sections lateral margin. A23-A26: Medial margin. A27: Section 6, inferior aspect. A28: Lateral margin. A29: Lateral margin. A30: Section 5, superior margin. A31: Section 2, superior aspect. A32: Section 2, inferior aspect. A33: Section 5, inferior margin. A34: Section 2, superior aspect. B. RIGHT AXILLARY CONTENTS. Received in formalin in a container labeled with matching patient identifiers is a portion of red yellow. fibroadipose tissue measuring 10.7 x 5.9 x 2.5 cm. Multiple possible lymph nodes are identified ranging. in size from 0.3 x 0.3 x 0.3 up to 4 x 3.5 x 2 cm. Cassette summary: B1-B3: Representative sections, largest lymph node. B4: Two possible lymph nodes. B5: Two possible lymph nodes. B6: Four possible lymph nodes. B7: Four possible lymph nodes. B8: Two possible lymph nodes. B9: Two possible lymph nodes. B10: Three possible lymph nodes. B11-B15: Additional possible lymph nodes. DIAGNOSIS: A. BREAST, RIGHT, WIDE LOCAL EXCISION: - INVASIVE DUCTAL CARCINOMA, POORLY DIFFERENTIATED. (SBR GRADE 3), WITH APOCRINE FEATURES, AND SEVERAL FOCI OF. MICROINVASION ASSOCIATED WITH DCIS. - TUMOR MEASURES AT LEAST 3 CM IN GREATEST DIMENSION. INVASIVE CARCINOMA IS 2 MM FROM THE DEEP MARGIN. - EXTENSIVE LYMPHVASCULAR INVASION IS PRESENT. DUCTAL CARCINOMA IN SITU (DCIS), SOLID TYPE, NUCLEAR GRADE 3,. WITH NECROSIS AND ASSOCIATED LYMPHOID INFILTRATE, INVOLVING. LOBULES. DCIS IS PRESENT AT THE LATERAL MARGIN, IS WITHIN 1 MM OF THE. ANTERIOR/MEDIAL AND ANTERIOR MARGIN, AND IS WITHIN 2 MM. OF THE DEEP MARGIN. B. AXILLARY CONTENTS, RIGHT, DISSECTION: - METASTATIC CARCINOMA TO 2 OF 25 LYMPH NODES WITH LARGEST. METASTASIS MEASURING 4 CM (2/25). - NO EXTRACAPSULAR EXTENSION IS SEEN. SYNOPTIC REPORT - BREAST. Specimen Type: Excision. Needle Localization: Laterality: Right. Invasive Tumor. Present. Multifocality: Yes. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 3cm. Tumor Site: Upper outer quadrant. Margins: Negative. Distance from closest margin: deep. Tubular Score: 3. Nuclear Grade: 3. Mitotic Score: 2. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Absent. Vascular/Lymphatic Invasion: Present. Lobular neoplasia: None. Lymph nodes: Axillary dissection. Lymph node status: Positive 2/25. DCIS present. Margins involved by DCIS: lateral margin. DCIS Quantity: Estimate 25%. DCIS Type: Solid. DCIS Location: Both associated and separate from invasive tumor mass. Nuclear grade: High. Necrosis: Present. ER/PR/HER2 Results. ER: Negative. PR: Negative. HER2: Positive by IHC. Performed on. Case: This case - the largest lymph node with metastasis. Pathological staging (pTN): pT 2N1. SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimen: Surgical Excision. Block Number: B2 (Lymph node with metastasis). ER: Negative. Allred Score: 0 = Proportion Score 0 + Intensity Score 0. PR: Negative. Allred Score: 0 = Proportion Score 0 + Intensity Score 0. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the. proportion score (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of. cells staining, 4 = 31-60% of cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak. intensity of staining, 2 = intermediate intensity of staining, 3 = strong intensity of staining), with a scoring. range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score. of less than or equal to 2. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Immunohistochemistry was performed usina the mouse anti-human ER (ER 1D5, 1:100) and PR (PGR. 136, 1:100) provided by. following the manufacturer s instructions. This. assay was not modified. Interpretation of the ER/PR immunohistochemical stain is guided by published. results in the medical literature, information provided by the reagent manufacturer and by internal. review of staining performance. SYNOPTIC REPORT - BREAST HER-2 RESULTS. Specimen: Surgical Excision. Block Number: B2 (Lymph node with metastasis). Interpretation: POSITIVE. Intensity: 3+. % Tumor Staining: 100%. Fish Ordered: METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Her2 analysis was performed using the FDA approved. HercepTest (TM) test kit. using rabbit anti-human HER2. This assay was not modified. External kit-slides. provided by the manufacturer (cell lines with high, low and negative HER2 protein expression) and in-. house known HER2 amplified control tissue were evaluated along with the test tissue. Adequate, well. preserved, clear-cut invasive carcinoma was identified for HER2 evaluation. Interpretation of the HER2. immunohistochemical stain is guided by published results in the medical literature, information provided. by the reagent manufacturer and by internal review of staining performance. This assay has been validated according to the 2007 joint recommendations and guidelines from. ASCO and CAP and from the NCCN HER2 testing in Breast Cancer Task Force. Pathology. Department takes full responsibility for this test's performance. CLINICAL HISTORY: :year-old woman, right breast, upper outer 4 cm mass, IDC, ER/PR negative; HER-2/neu positive,. with palpable adenopathy, here for lumpectomy and axillary lymph node dissection. PRE-OPERATIVE DIAGNOSIS: Right breast cancer. Microscopic/Diagnostic Dictation; Pathologist,. Final Review: Pathologist,. Final Review: Pathologist,. Final: Pathologist.",BRCA,1,True,"The report states that there are 2 positive lymph nodes out of 25 examined. This corresponds to N1 stage according to the rule: 'The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.'","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4-9 axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in 10 or more axillary lymph nodes is classified as N3.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4-9 axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in 10 or more axillary lymph nodes is classified as N3.",22.0,1951.0,90.0,True
1202,TCGA-E2-A14W.9ECD3DA1-25A4-4325-9B3B-6D7C12283C37,1,"SPECIMENS: A. SLN #1. B. SLN #2. C. LEFT BREAST. D. SLN #3. E. UPPER OUTER QUANDRANT LEFT BREAST. F. SLN #4. G. INFERIOR MEDIAL LEFT BREAST MARGIN. SPECIMEN(S): A. SLN #1. B. SLN #2. C. LEFT BREAST. D. SLN #3. E. UPPER OUTER QUANDRANT LEFT BREAST. F. SLN #4. G. INFERIOR MEDIAL LEFT BREAST MARGIN. INTRAOPERATIVE CONSULTATION DIAGNOSIS: TPA/TPB - SLN #1/SLN #2: Negative for tumor cells. TPD/TPF - SLN #3/SLI #4: Negative for tumor. Called by Dr to Dr. at. I (A, B). (D) and. (F). C - left breast: (gross exam only) 2.5 x 2 x 1.5 cm tumor located 1.2 cm from the closest/deep margin; tumor extends. to the nipple and areola, called by Dr. to Dr. at. GROSS DESCRIPTION: A. SLN #1. Received fresh is a tiny piece of lymphoid tissue within fibroadipose tissue, 0.4 x 0.2 x 0.2 cm. A touch prep is. performed; submitted entirely in cassette A1. B. SLN #2. Received fresh is a piece of lymphoid tissue within fibroadipose tissue, 0.4 x 0.2 x 0.2 cm. A touch prep is performed;. submitted entirely in cassette B1. C. LEFT BREAST, STITCH AT AXILLARY TAIL. Received fresh labeled with the patient's identification and ""left breast, stitch in axillary tail"" is an oriented 392g, 20. x. 14.5 x 2 cm mastectomy with 11.5 x 5.2 skin ellipse and 1.6cm inverted and ulcerated nipple. Ink code: Anterior/superior-blue, anterior/inferior-orange, posterior-black. The specimen is serially sectioned into 18 slices. from medial to lateral with the nipple in slice 5 revealing a 2.5 x 2 x 1.5 cm white-tan firm well-circumscribed mass. beneath the nipple, present in slices 5 to 7 that is 1.2 cm from the deep margin. A gross diagnosis was conveyed to. OR and tissue is procured. Representatively submitted: C1-C2: slice 5, mass and extension to nipple. C3: slice 5, mass and deep margin. C4: slice 6, superior posterior mass. C5: slice 6, anterior inferior mass. C6: slice 6, inferior posterior mass. C7: slice 7, mass and normal appearing parenchyma. C8: slice 8, normal appearing parenchyma adjacent to mass. C9: slice 3, upper inner quadrant. C10: slice 9, upper outer quadrant. C11: slice 10, lower outer quadrant. C12: slice 4, lower inner quadrant. C13: skin. C14-C17: nipple. C18: 1 axillary lymph node. D. SLN #3. Received fresh is a lymph node, 0.3 x 0.3 x 0.2 cm. A touch prep is performed and the lymph node is submitted. entirely for cassette D1. E. UPPER OUTER QUADRANT LEFT BREAST; STITCH AT NEW UPPER OUTER MARGIN. Received fresh labeled with the patient's identification and ""upper outer quadrant left breast; stitch at new upper. outer margin"" is an oriented 37g, 9 x 6.3 x 0.8 cm fibrofatty tissue. Final margin is inked black. Serial sectioning. reveals no discrete lesions. Representatively submitted in cassettes E1-E6. F. SLN #4. Received fresh is a lymph node, 0.3 x 0.3 x 0.2 cm. A touch prep is performed; submitted entirely in cassette F1. G. INFERIOR MEDIAL BREAST-LEFT; STITCH AT DEEP MARGIN. Received fresh labeled with the patient's identification and ""inferior medial breast-left; stitch at deep margin"" is an. oriented 3g, 4.1 x 2.5 x 0.6 cm fibrofatty tissue. Final margin is inked black. Serial sectioning reveals no discrete. lesions. Entirely submitted in cassettes G1-G4. DIAGNOSIS: A. SENTINEL LYMPH NODE #1, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NO TUMOR SEEN (0/1). B. SENTINEL LYMPH NODE #2, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NO TUMOR SEEN (0/1). C. BREAST, LEFT, MASTECTOMY: - INVASIVE DUCTAL CARCINOMA, POORLY DIFFERENTIATED. (SBR GRADE 3), WITH ULCERATION OF THE NIPPLE. - TUMOR MEASURES 2.5 CM IN GREATEST DIMENSION. - MARGINS, NO TUMOR SEEN. - ONE LYMPH NODE WITH NON-NECROTIZING GRANULOMAS, NO TUMOR. SEEN (0/1) (SEE NOTE). NOTE: Special stains have been ordered on the lymph node and those results will be reported in an addendum. A. CD31 stain has been ordered for evaluation of lymphvascular invasion and those results will be reported in an. addendum. D. SENTINEL LYMPH NODE #3, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NO TUMOR SEEN (0/1). E. BREAST, LEFT, UPPER OUTER QUADRANT, EXCISION: - FIBROADIPOSE TISSUE, NO TUMOR SEEN. F. SENTINEL LYMPH NODE #4, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NO TUMOR SEEN (0/1). G. BREAST, LEFT, INFERIOR MEDIAL MARGIN, EXCISION: - FIBROADIPOSE TISSUE, NO TUMOR SEEN. SYNOPTIC REPORT - BREAST. Specimen Type: Mastectomy. Needle Localization: Laterality: Left. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 2.5cm. Tumor Site: Central. Margins: Negative. Distance from closest margin: Greater than 1cm. deep. Tubular Score: 3. Nuclear Grade: 3. Mitotic Score: 3. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Absent. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node only. Lymph node status: Negative 0/5. DCIS not present. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Positive by FISH. Pathological staging (pTN): pT2N0. CLINICAL HISTORK. year-old. recent dx of left breast cancer in. core biopsy. -IDC ER/PR positive, Her2. (illegible) Now for left mastectomy and sentinel lymph node biopsy-2 cm retroareolar mass. PRE-OPERATIVE DIAGNOSIS: Left breast cancer. ADDENDUM: NOTE: A CD31 stain was performed on C4 and is negative showing no evidence of lymphvascular invasion. Special. stains (GMS, AFB, PAS) were performed on the lymph node (C18) and are negative showing no evidence of fungal. or acid fast organisms. The non-necrotizing granulomas would be consistent with the patient's history. Microscopic/Diagnostic Dictation: Pathologist,. Final Review: Pathologist,. Final: Pathologist,. Addendum: Pathologist,. Addendum Final: Pathologist,.",BRCA,0,True,"The report states that out of the 5 examined sentinel lymph nodes, none were found to have metastatic carcinoma (0/5). This indicates that the patient's N stage is N0, as per the rules: 'The absence of metastatic carcinoma in regional lymph nodes is classified as N0.' and 'The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.'","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4-9 axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in 10 or more axillary lymph nodes is classified as N3.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4-9 axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in 10 or more axillary lymph nodes is classified as N3.",22.0,1951.0,100.0,True
864,TCGA-AR-A1AU.5654FC27-47D3-4C7F-A0E7-A5B6140991C2,1,"Final Diagnosis. Breast, right, total mastectomy: Infiltrating ductal carcinoma, Nottingham grade III (of III),. [tubules 3/3, nuclei 3/3, mitoses 2/3; Nottingham score 8/9], forming multiple (2) masses (central-. -2.6 x 2.2 x 1.6 cm and upper inner quadrant--0.3 x 0.2 x 0.2 cm) [AJCC pT2]. Ductal carcinoma. in situ, high nuclear grade, composes less than 5% of the tumor volume. Angiolymphatic. invasion is absent. The non-neoplastic breast parenchyma shows nonproliferative fibrocytic. changes and a fibroadenoma (0.3 x 0.2 x 0.2 cm). Biopsy site changes present. The tumor does. not involve the nipple, overlying skin, or underlying chest wall. All surgical resection margins,. including the deep margin, are negative for tumor (minimum tumor free margin, 1.4 cm, anterior. margin, for the central tumor). Lymph nodes, right axillary non-sentinel, excision: Multiple (2 of 3) right axillary non-sentinel. lymph nodes are positive for metastatic carcinoma. One of the positive lymph nodes shows focal. extracapsular extension. Lymph nodes, right axillary sentinel, excision: Multiple (2) right axillary sentinel lymph nodes. are negative for metastatic carcinoma. Blue dye is identified in right axillary sentinel lymph node. No. 1. Blue dye is not identified in right axillary sentinel lymph node No. 2. Lymph nodes, right high axillary, excision: Multiple (5) right high axillary lymph nodes are. negative for tumor. Lymph nodes, right mid/low axillary, dissection: Multiple (2 of 27) right mid/low axillary lymph. nodes are positive for metastatic carcinoma [AJCC pN2]. Residual right breast tissue, excision: Residual breast tissue shows non-proliferative fibrocystic. changes. Breast, left, simple mastectomy: Benign breast parenchyma with proliferative fibrocystic. changes, including a complex sclerosing lesion. Negative for malignancy. Additional left breast tissue, excision: Benign breast parenchyma with non-proliferative. fibrocystic changes; negative for malignancy.",BRCA,2,True,"The report states that two of 3 right axillary non-sentinel lymph nodes are positive for metastatic carcinoma, and two of 27 right mid/low axillary lymph nodes are positive for metastatic carcinoma. This means that the patient has metastatic carcinoma in 4 or more axillary lymph nodes, which is classified as N2 according to the AJCC staging system.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4-9 axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in 10 or more axillary lymph nodes is classified as N3.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.",N2,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4-9 axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in 10 or more axillary lymph nodes is classified as N3.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.",23.0,2056.0,97.0,True
833,TCGA-AQ-A54O.B3884493-D0D2-445C-B9BB-BC475021EBA4,1,"Diagnosis. A: Sentinel lymph node, right axillary #1, removal. - No evidence of metastatic carcinoma in one lymph node (0/1). - See comment. B: Breast, right, total mastectomy. Tumor type: Infiltrating ductal carcinoma. Nottingham combined histologic grade 3. Tubule formation score: : 3. Nuclear Pleomorphism Score: 2. Mitotic count score: 3. Focality of tumor: unifocal. Tumor size (greatest dimension) : 35 mm. Lymphovascular invasion: not identified. In Situ Component: Minor component of ductal carcinoma in situ,. cribriform and solid types, nuclear grade 2 with necrosis, 2mm. in linear extent. Extensive intraductal component absent. Nipple/skin involvement: not identified. Margin status: Invasive component: negative, widely clear; 1.5 cm to closest. posterior. margin. In Situ component : negative; widely clear of all margins. Axillary lymph nodes: Total number with metastasis: 0. Total number examined: 14 ( see parts A & C). Microcalcifications not identified. Other findings: gynecomastia, biopsy site changes. See report of prior biopsy (. ') for results of ER, PR and. HER2 immunohistochemical studies. AJCC PATHOLOGIC TNM STAGE: pT2 pNO. Note: This pathologic stage assessment is based on information. available at the. time of this report, and is subject to change pending clinical. review and. additional information. C: Lymph nodes, right axillary, removal. - No evidence of metastatic carcinoma in 13 lymph nodes (0/13). - See comment. Comment: The axillary lymph nodes reveal lymphoid paracortical expansion,. which is. favored to be reactive in nature by H & E stains. Scattered. pigmented. histocytes are present suggestive of dermatopathic. lymphadenitis. Additional. immunohistochemical stains are pending to further evaluate this. process, results. of which will follow in an addendum report. Intraoperative Consult Diagnosis: Frozen section consultation was requested at. on. by in OR. FSA1,A2: Lymph node, right axillary SLN #1, biopsy. - No tumor seen. Drs. at. Frozen Section Pathologist: MD. Clinical History: with right poorly differentiated invasive. ductal carcinoma, Grade 3. Gross Description: Received are three appropriately labeled containers. Container A is additionally labeled ""right axillary SLN #1, hot. + blue. "" The. specimen is a 6 X 4.5 x 1.5 cm fatty soft tissue fragment. Examination of the. fat reveals a 2.0 X 2.0 x 1.0 cm blue lymph node candidate. This. candidate is. serially sectioned and submitted entirely in blocks FSA1 and. FSA2. Container B: Specimen fixation: formalin. Time in fixative: 28.5 hours. Type of mastectomy: simple mastectomy. Weight of specimen: 950 grams. Size of specimen: 26.0 cm medial to lateral, 26.7 cm superior to. inferior,. 4.0 cm anterior to posterior. Orientation of specimen: Sutures: Short=superior, long=lateral. Inking: anterior=blue, posterior=black, lateral=yellow. Skin ellipse dimensions: 18.6 x 9.3 cm. Nipple/areola Nipple, 1.0 cm; areola, 3.1 cm. Axillary tail: submitted separately. Biopsy site: present; Location is central breast/lower outer. quadrant;. Size: 0.8 X 0.5 X 0.5 cm. Appearance: Biopsy site (clip identified) is in the center of a. white/tan, firm area. Hemorrhage and fat necrosis. are noted in this area. Additional residual tumor is present. Discrete Mass (es) : present. Number of discrete masses: one. Size of mass (es)/biopsy site: 2.5 x 2.0 x 3.5 cm. Location of mass (es) : subareola/lowe outer quadrant. Distance of mass/biopsy site from surgical margin: The mass. measures 1.9 cm to. posterior margin, 8.5 cm to inferior margin, 10.5. cm to superior margin, 2.8 cm to anterior margin and is widely. clear. of medial/lateral margins. Gross involvement of skin or fascia/muscle by tumor: absent. Descript. remaining breast: consistent with yellow/tan. fibroad. issue. with increased fibrous areas noted in the subareolar. area; no other masses are identified. Other remarkable features: none. Tissue submi+ ed for special investigations: yes; Tumor to. Tissue Pr ment. Block Summary: (Inking: blue=anterior, black=posterior, yellow=lateral. B1 - nipple. B2 - areola. B3 - biopsy site. B4 - medial aspect of mass. B5-B8 - - central portion of mass. B9 - lateral aspect of mass. B10 - mass to posterior margin. B11 - representative dense fibrous tissue posterior to nipple. and anterior to mass. B12 - closest skin margin (inferior areola). B13 - upper inner quadrant. B14 - lower inner quadrant. B15 - lower outer quadrant. B16 - upper outer quadrant. B17 - mass to normal breast, superior. B18 - mass to normal breast, inferior. Container C is additionally labeled ""right axillary contents. "". The specimen. consists of two fragments of yellow/tan fibroadipose tissue that. measures 9.5 X. 6.5 x 3.0 cm in aggregate. Within the fibroadipose tissue,. fifteen lymph node. candidates are identified. These range in size from 0.4 up to. 1.5 cm in greatest. dimension. The largest lymph node candidate measures 2.3 X 1.5 x. 1.0 cm. Block summary: C1 - six lymph node candidates. C2 - five lymph node candidates (bisected node inked black). C3 - three lymph node candidates (bisected nodes inked black,. blue and. yellow). C4 - one lymph node candidate, sectioned. C5 - one lymph node candidate, sectioned. C6 - one lymph node candidate, sectioned. C7,C8 - largest lymph node candidate, sectioned. Procedures/Addenda: Addendum. Addendum. Immunohistochemical studies were performed on representative. blocks of axillary. lymph nodes (C6 and C7) and the results are as follows: CD20: Highlights many small lymphocytes in a generally nodular. distribution. CD3: Highlights majority of lymphocytes with focal expansion of. the paracortex. Interpretation: The immunohistochemical studies highlight an. essentially normal. pattern of distribution of B cells and T cells in the lymph. nodes, with primary. follicles composed predominantly of small B lymphocytes and. a. paracortex. populated by predominantly small T lymphocytes. Morphologic and. immunohistochemical findings are compatible with reactive lymph. nodes and do not. support a diagnosis of a lymphoproliferative disorder. The mild. paracortical. expansion can be seen as a feature of dermatopathic. lymphadenopathy.",BRCA,0,True,"The report states that there is no evidence of metastatic carcinoma in 14 axillary lymph nodes (0/14). This indicates that the patient's N stage is N0, as there is no malignancy found in the regional lymph nodes.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4-9 axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in 10 or more axillary lymph nodes is classified as N3.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4-9 axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in 10 or more axillary lymph nodes is classified as N3.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.",23.0,2056.0,100.0,True
1179,TCGA-D8-A4Z1.D77DF136-6F63-48B7-8187-6F8F98CC1F44,0,"Gender: F. Examination result. Clinical diagnosis (suspicion): ca mammae dex. Material: 1) Material: right breast with tumour (+possibly with AXILLARY LYMPH NODES DEPENDING ON THE EXAM. RESULT). Method of collection: Breast with no lymph nodes (mastectomia simplex). Histopathological Diagnosis: Including test No. Invasive lobular carcinoma and lobular carcinoma in situ of the right breast. (NHG2, pTlc,. pN 0 (sn)). (8520/3. Macroscopic description: Right breast, sized 20.4 x 13.8 x 4.6 cm, removed without armpit tissues and with a skin flap of 19.4 x 8.6 cm. Weight. 540 g. Tumour sized 1.6 x 1.4 x 1.6 cm in the inner lower quadrant, placed 2.1 cm from the lower edge, 1.6 cm from the base. and 0.9 cm from the skin. Microscopic description: Invasive lobular carcinoma - NHG2 (3+2+1/0 mitoses/10 HPF - visual area 0.55 mm) and lobular carcinoma in situ. with nuclear atypia < 10% of the tumour). Glandular tissue showing fibrocytoid lesions adenosis, usual ductal hyperplasia, fibroadenoma. Invasive lesions removed 1.6 cm from the base. Result of immunohistochemical examination. Estrogen receptors found in 75% of neoplastic cell nuclei. Progesterone receptors found in 10-75% of neoplastic cell nuclei. HER2 protein stained with Ventana's Pathway HER-2/neu (4B5) Rabbit Monoclonal Antibody. Negative reaction in invasive cancerous cells ( Score = 1+). The expression of proliferating cell nuclear. antigen Ki 67 in 10% cellular nuclei. CONTACT YOUR DOCTOR WITH THIS Criteria.",BRCA,0,True,"The report states 'pN 0 (sn)', which indicates no malignancy was found in the regional lymph nodes. According to the rules, if no malignancy is found in regional lymph nodes, the N stage is N0.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4-9 axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in 10 or more axillary lymph nodes is classified as N3.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The method of evaluation of sentinel lymph nodes can affect the N stage.
The presence of extracapsular extension in a lymph node upgrades the N stage by one level.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4-9 axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in 10 or more axillary lymph nodes is classified as N3.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.",24.0,2165.0,97.0,True
853,TCGA-AR-A1AJ.0DEAC35F-8B73-4A9F-B7FA-2F501B736B0E,0,"Final Diagnosis. Breast right, wide local excision: Infiltrating ductal carcinoma, Nottingham grade III (of III),. forming a mass, 1.2 x 1.1 x 0.9 cm. (AJCC pTIc). Angiolymphatic invasion is not identified. The surgical margins are negative for tumor. The closest margin (inferior) is free by 0.3 cm. Lymph nodes, right axillary sentinel, excision: Multiple (2) right axillary sentinel lymph nodes. are negative for tumor. Blue dye is not identified in either of the right axillary sentinel lymph. nodes. Immunohistochemical cytokeratin stain was performed on the paraffin embedded sentinel. lymph node tissue and confirms the H&E impression [AJCCpTN(i-)]. Lymph nodes, right axillary, excision: Multiple (6) right axillary lymph nodes are negative for. tumor. HER2/neu protein overexpression is negative, score of 0, according to the interpretation. guidelines in the FDA-approved HercepTest.",BRCA,0,True,"The report states that both the sentinel lymph nodes (2 nodes) and the additional 6 right axillary lymph nodes are all negative for tumor. No extranodal extension of metastatic carcinoma is mentioned. Therefore, the N stage is N0.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4-9 axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in 10 or more axillary lymph nodes is classified as N3.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.",N0,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4-9 axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in 10 or more axillary lymph nodes is classified as N3.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.",22.0,2001.0,96.0,True
1020,TCGA-BH-A0GY.A997FF30-F112-48BE-8FF1-15F8266A5E62,1,"FINAL DIAGNOSIS: PART 1: LEFI BREAST, SEGMENTAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA, NOTTINGHAM SCORE 8/9 (TUBULES 3, NUCLEI 3, MITOSIS 2), 2.6 CM. B. DUCTAL CARCINOMA IN SITU, MICROPAPILLARY AND SOLID TYPES WITH COMEDO NECROSIS, NUCLEAR. GRADE 3, REPRESENTING 5% OF THE TUMOR VOLUME. C. LYMPHOVASCULAR SPACE INVOLVEMENT SEEN. D. INVASIVE CARCINOMA IS 0.1 CM FROM INFERIOR MARGIN. E. DUCTAL CARCINOMA IN SITU IS <0.1 CM (1MM) FROM INFERIOR MARGIN. F. MARGINS FREE OF LESION. G. MICROCALCIFICATION ASSOCIATED WITH BENIGN CHANGES AND TUMOR. H. CHANGES CONSISTENT WITH BIOPSY SITE. I. PROLIFERATIVE FIBROCYSTIC CHANGES WITH ATYPICAL DUCTAL EPITHELIAL HYPERPLASIA AND. COLUMNAR CELL CHANGES. J. MICROSCOPIC PERIPHERAL PAPILLOMA AND SCLEROSING ADENOSIS. K. SKIN NOT REMARKABLE. PART 2: LEFT AXILLA, SENTINEL LYMPH NODE #1, EXCISION -. A. ONE LYMPH NODE POSITIVE FOR METASTATIC CARCINOMA (0.9 CM). B. NO EXTRACAPSULAR EXTENSION SEEN. PART 3: LEFT AXILLA, SENTINEL LYMPH NODE #2, EXCISION -. ONE LYMPH NODE WITH RARE CLUSTERS OF METASTATIC TUMOR CELLS IN PERIPHERAL SINUS. PART 4: LEFT AXILLA, LYMPH NODE EXCISION -. ONE LYMPH NODE WITH EXTENSIVE THERMAL EFFECT, PROBABLY FREE OF TUMOR. CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Segmental. Lower outer quadrant. SIZE OF TUMOR: MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: Maximum dimension invasive component: 2.6 cm. TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 3. Tubule formation: 3. Mitotic activity score: 2. Total Nottingham score: 8. ANGIOLYMPHATIC INVASION: Nottingham grade (1, 2, 3): 3. DERMAL LYMPHATIC INVASION: CALCIFICATION: Yes, benign zones. TUMOR TYPE, IN SITU: Yes, malignant zones. Soia. Micropapillary. Comedo. DCIS admixed and outside of invasive carcinoma component. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Percent of tumor occupied by in situ component: 5 %. SURG MARGINS INVOLVED BY IN SITU COMPONENT: Distance of invasive tumor to closest margin: 1 mm. PAGET'S DISEASE OF NIPPLE: Distance of in situ disease to closest margin: 0.7 mm. LYMPH NODES POSITIVE: 2. LYMPH NODES EXAMINED: 3. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SENTINEL NODE METASTASIS: SIZE OF NODAL METASTASES: LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: Diameter of largest lymph node metastasis: 9 mm. SKIN INVOLVED (ULCERATION): NON-NEOPLASTIC BREAST TISSUE: ADH, Papilloma, FCD. T STAGE, PATHOLOGIC: pT2. N STAGE, PATHOLOGIC: pN1a. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTORS: positive.",BRCA,1,True,"The pathology report indicates that of the 3 lymph nodes examined, 2 were positive for metastatic carcinoma. One node had a 0.9 cm metastasis and the other had rare clusters of tumor cells in the peripheral sinus. This information satisfies the criteria for N1 stage in the AJCC staging system for breast cancer.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.",20.0,1822.0,91.0,True
1225,TCGA-E2-A15R.0F708C6E-0262-46EE-8ED2-67E791D5C379,0,"SPECIMENS: A. SLN 1 RIGHT AXILLA. B. SLN 2 RIGHT AXILLA. C. SLN 3 RIGHT AXILLA. D. SLN 4 RIGHT AXILLA. E. RIGHT BREAST. SPECIMEN(S): A. SLN 1 RIGHT AXILLA. B. SLN 2 RIGHT AXILLA. C. SLN 3 RIGHT AXILLA. D. SLN 4 RIGHT AXILLA. E. RIGHT BREAST. INTRAOPERATIVE CONSULTATION DIAGNOSIS: TPA, Lymph node, sentinel, right axilla, biopsy: Negative for carcinoma. TPB, Lymph node, sentinel, right axilla, biopsy: Negative for carcinoma. TPC, Lymph node, sentinel, right axilla, biopsy: Negative for carcinoma. TPD, Lymph node, sentinel. right axilla, biopsy: Negative for carcinoma. Diagnoses called at. by Dr. GROSS DESCRIPTION: A. SLN 1 RIGHT AXILLA. Received fresh labeled with the patient's identification and designated ""sentinel lymph node number one right axilla"". is a tan lymph node measuring 2.2 x 1 x 0.8 cm. Touch preparation is performed. Entirely submitted, A1. B. SLN 2 RIGHT AXILLA. Received fresh labeled with the patient's identification and designated ""sentinel lymph node number two right axilla"". is a tan lymph node measuring 1.5 x 1 x 0.8 cm. Touch preparation is performed. Entirely submitted, B1. C. SLN 3 RIGHT AXILLA. Received fresh labeled with the patient's identification and designated ""sentinel lymph node number three right axilla"". is a tan lymph node measuring 0.6 x 0.4 x 0.3 cm. Touch preparation is performed. Entirely submitted, C1. D. SLN 4 RIGHT AXILLA. Received fresh labeled with the patient's identification and designated ""sentinel lymph node number four right axilla"". is a tan lymph node measuring 1 x 0.6 x 0:4 cm. Touch preparation is performed. Entirely submitted, D1. E. RIGHT BREAST. Received fresh labeled with the patient's identification and designated ""right breast"" is an oriented, 27 g, 5.3 x 4.5 x 3. cm lumpectomy specimen. The short suture designates superior, long-lateral. Ink code: Anterior-yellow, posterior-. black, medial-green, lateral-red, superior-blue, inferior-orange. The specimen is serially sectioned from superior to. inferior into 5 slices to reveal a firm lobulated tan mass, 2.2 x 1.5 x 0.9 cm, located 0.1-cm from the nearest anterior. margin. The entire specimen is submitted: E1-E3: Perpendicular sections superior margin. E4-E7: Slice 2, E5 demonstrating mass and nearest anterior margin. E8-E11: Slice 3, E9, E11 demonstrating mass and nearest anterior margin. E12-E15: Slice 4, submitted entirely. E16-E18: Perpendicular sections inferior margin. DIAGNOSIS: A. LYMPH NODE, SENTINEL #1, RIGHT AXILLA, EXCISION: - METASTATIC CARCINOMA TO ONE OF ONE LYMPH NODE (1/1), MEASURING 0.3-CM WITH EXTRANODAL. EXTENSION, SEE NOTE. B. LYMPH NODE, SENTINEL #2, RIGHT AXILLA, EXCISION: - METASTATIC CARCINOMA TO ONE OF ONE LYMPH NODE (1/1), MEASURING 0.1-CM WITH EXTRANODAL. EXTENSION, SEE NOTE. C. LYMPH NODE, SENTINEL #3, RIGHT AXILLA, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). D. LYMPH NODE, SENTINEL #4, RIGHT AXILLA, EXCISION: - METASTATIC CARCINOMA TO ONE OF ONE LYMPH NODE (1/1), MEASURING 0.6-CM WITH EXTRANODAL. EXTENSION, SEE NOTE. E. BREAST, RIGHT, WIDE LOCAL EXCISION: - INVASIVE DUCTAL CARCINOMA, SBR GRADE 2, MEASURING 1.9-CM. INTERMEDIATE NUCLEAR GRADE, DUCTAL CARCINOMA IN SITU, SOLID TYPE. - INVASIVE TUMOR PRESENT 0.15-CM FROM MEDIAL AND 0.1-CM FROM ANTERIOR SURGICAL RESECTION. MARGINS. - FOCAL LYMPHOVASCULAR INVASION IDENTIFIED. - BIOPSY SITE CHANGES WITH FIBROSIS,. - SEE SYNOPTIC REPORT AND SEE NOTE. NOTE: The touch preparation of SLN #1 and 2 shows no tumor cells. Therefore the false negativity is due to. sampling error. The touch preparation of SLN #4 shows two clusters of atypical cells. Dr. concurs. A few clusters branching out and focally separated from the main tumor mass are identified in a close proximity to. the medial margin (0.15-cm). The main tumor mass is 0.1-cm from the anterior surgical resection margin. SYNOPTIC REPORT - BREAST. Specimen Type: Excision. Needle Localization: Yes For mass. Laterality: Right. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 1.9cm. Margins: Negative. Distance from closest margin: Less than 0.15cm. medial and anterior. Tubular Score: 3. Nuclear Grade: 2. Mitotic Score: 2. Modified Scarff Bloom Richardson Grade: 2. Necrosis: Absent. Vascular/Lymphatic Invasion: Present. Extent: focal. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node. Lymph node status: Positive 3 / 4 Extranodal extension. DCIS present. Margins uninvolved by DCIS. DCIS Quantity: Estimate 5%. DCIS Type: Solid. DCIS Location:Associated with invasive tumor. Nuclear grade: Intermediate. Necrosis: Absent. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Negative by FISH. Performed on Case: Pathological staging (pTN): pT 1c N 1. Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition. CLINICAL HISTORY: year-old female right breast mass, invasive ductal carcinoma on core bx. Right needle localization excision with. sentinel lymph node biopsy. PRE-OPERATIVE DIAGNOSIS: Carcinoma, right breast. Microscopia/Diagnostic Dictation: Pathologist,. Final Review: Pathologist,. Final: Pathologist,.",BRCA,1,True,"The report states that there are 4 sentinel lymph nodes examined, and 3 out of 4 nodes have metastatic carcinoma, each with extranodal extension. This corresponds to N1 stage according to the rule: 'The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.'","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.",20.0,1822.0,100.0,True
796,TCGA-AO-A0JA.2E8A1816-E963-4063-B2F0-6289514084A5,1,"Clinical Diagnosis & History: Right multicentric IDC and ILC presents for bilateral TM, bilateral SLNBx. Specimens Submitted: 1: SP: Sentinel node #1 level 1 left axilla. 2: SP: Sentinel node #2 level 1 left axilla. 3: SP: Sentinel node #1 level 1 right axilla (fs). 4: SP: Sentinel node #2 level 1 right axilla (fs). 5: SP: Right breast and axillary contents level 1, 2, and 3. 6: SP: Left breast. 7: SP: Right rotter's node. 8: SP: Additional level 1 lymph right axilla node 1. 9: SP: Additional right level 2 axillary contents. 10: SP: Level 3 lymph node right axilla. DIAGNOSIS: 1). SENTINEL NODE #1 LEVEL 1 LEFT AXILLA; EXCISION: - ONE BENIGN LYMPH NODE (0/1). 2). SENTINEL NODE #2 LEVEL 1 LEFT AXILLA; EXCISION: - ONE BENIGN LYMPH NODE (0/1). 3). SENTINEL NODE #1 LEVEL 1 RIGHT AXILLA; EXCISION: - METASTATIC CARCINOMA INVOLVING ONE OF ONE LYMPH NODE (1/1). - THE METASTATIC CARCINOMA IS PRESENT AS SUB-CAPSULAR TUMOR CELL. CLUSTERS MEASURING <0 2MM AND COMPOSED OF 30-40 CELLS. THE TUMOR CELLS ARE. SEEN BOTH IN THE HE STAINED AND KERATIN (AE1:AE3) IMIMUNOSTAINED SECTIONS. 4). SENTINEL NODE #2 LEVEL 1 RIGHT AXILLA; EXCISION: - METASTATIC CARCINOMA INVOLVING ONE OF ONE LYMPH NODE (1/1). - THE METASTATIC FOCUS MEASURES 1.2 CM, WITH EXTRANODAL EXTENSION. (>2MM). 5). BREAST, RIGHT; MASTECTOMY: TUMOR #1: - INVASIVE DUCTAL CARCINOMA, WITH FOCAL LOBULAR GROWTH PATTERN,. HISTOLOGIC GRADE II/III (MODERATE TUBULE FORMATION), NUCLEAR GRADE II/III. (MODERATE VARIATION IN SIZE AND SHAPE). MEASURING `3.6 CM IN LARGEST. DIMENSION GROSSLY. - DUCTAL CARCINOMA IN-SITU (DCIS) IS ALSO IDENTIFIED, MICROPAPILLARY TYPE. WITH INTERMEDIATE NUCLEAR GRADE AND MINIMAL NECROSIS. - THE DCIS CONSTITUTES LESS THAN OR EQUAL TO 25% OF THE TOTAL TUMOR MASS,. AND IS PRESENT ADMIXED WITH THE INVASIVE COMPONENT. THE INVASIVE CARCINOMA IS LOCATED IN THE UPPER INNER QUADRANT, AT. 1:00. - THE DCIS IS LOCATED IN THE UPPER INNER QUADRANT. NO INVOLVEMENT OF THE NIPPLE BY EITHER IN SITU OR INVASIVE CARCINOMA. IS IDENTIFIED. - NO CALCIFICATIONS ARE IDENTIFIED IN EITHER THE INVASIVE OR IN SITU. COMPONENT. - EXTENSIVE VASCULAR INVASION IS PRESENT. - NO INVOLVEMENT OF THE SURGICAL MARGINS BY EITHER INVASIVE OR IN SITU. CARCINOMA IS IDENTIFIED. - INVASIVE CARCINOMA IS 3.3 CM FROM THE DEEP MARGIN GROSSLY. TUMOR #2: - INVASIVE DUCTAL CARCINOMA, NOS TYPE, WITH FOCAL LOBULAR GROWTH. PATTERN, HISTOLOGIC GRADE II/III (MODERATE TUBULE FORMATION) , NUCLEAR GRADE. II/III (MODERATE VARIATION IN SIZE AND SHAPE) . MEASURING 2.5 CM IN LARGEST. DIMENSION GROSSLY. - DUCTAL CARCINOMA IN-SITU (DCIS) IS ALSO IDENTIFIED, SOLID, CRIBRIFORM TYPE. WITH INTERMEDIATE NUCLEAR GRADE AND MODERATE NECROSIS. - LOBULAR INVOLVEMENT BY DCIS IS PRESENT. - THE DCIS CONSTITUTES LESS THAN OR EQUAL TO 25% OF THE TOTAL TUMOR. MASS, AND IS PRESENT ADMIXED WITH THE INVASIVE COMPONENT. - THE INVASIVE CARCINOMA IS LOCATED IN THE LOWER INNER QUADRANT AT. - THE DCIS IS LOCATED IN THE LOWER INNER QUADRANT. - NO. INVOLVEMENT OF THE NIPPLE BY EITHER IN SITU OR INVASIVE CARCINOMA IS. IDENTIFIED. - CALCIFICATIONS ARE PRESENT IN THE INVASIVE CARCINOMA ONLY. - VASCULAR INVASION IS PRESENT. - NO INVOLVEMENT OF THE SURGICAL MARGINS BY EITHER INVASIVE OR IN SITU. CARCINOMA IS IDENTIFIED. - INVASIVE CARCINOMA IS 4.5 CM FROM THE DEEP MARGIN GROSSLY. - THE NON-NEOPLASTIC BREAST TISSUE SHOWS USUAL DUCTAL HYPERPLASIA,. PAPILLARY APOCRINE HYPERPLASIA, COLUMNAR CELL CHANGE, AND CYSTS. - THE LYMPH NODE STATUS IS AS FOLLOWS (EXPRESSED AS THE NUMBER OF POSITIVE. LYMPH NODES IN RELATION TO THE TOTAL NUMBER OF LYMPH NODES EXAMINED) : 13/17. - THERE IS EXTRANODAL EXTENSION (>2mm) OF CARCINOMA. THE LARGEST. METASTATIC CARCINOMA MEASURES .1CM. - RESULTS OF SPECIAL STAINS (ER, PR, HER2-NEU) ARE AS FOLLOWS: TUMOR 1: ESTROGEN RECEPTOR. 90% nuclear staininy with woderate intensity. PROGESTERONE RECEPTOR. 1: <5% nucle: weak intensity. HER2. Negative ( 1+). (<10% of invasive tumor cells exhibit weak complete membranous staining;. Uniformity of staining: absent;. Homogeneous, dark circumferential pattern: absent). TUMOR 2: ESTROGEN RECEPTOR. 50-60% nuclear staining with moderate intensity. PROGESTERONE RECEPTOR. 10-20% nuclear staining with moderate intensity. Negative ( 1+). (<10% of invasive tumor cells exhibit weak complete membranous staining;. Uniformity of staining: absent;. Homogeneous, dark circumferential pa. absent). Comment: Controls are satisfactory. a PATHWAY anti-HER-2/neu is an. FDA-approved rabbit monoclonal primary antibody (clone 4B5) directed against. the internal domain of the c-erbB-2 oncoprotein (HER2) for. immunohistochemical detection of HER2 protein overexpression in breast. cancer tissue routinely processed for histologic evaluation. The HER2 test. results are reported in accordance with the ASCO/CAP guideline. recommendations for HER2 testing in breast cancer (J Clin Oncol 2007;. 25 (1) :118-145) The ER and PR rabbit monoclonal antibodies are also FDA. approved. 6). LEFT BREAST; MASTECTOMY: - BENIGN BREAST WITH PAPILLARY APOCRINE HYPERPLASIA, USUAL DUCTAL. HYPERPLASIA AND COLUMNAR CELL CHANGE. - BENIGN NIPPLE. 7). RIGHT ROTTER'S NODE; EXCISION: - METASTATIC CARCINOMA LARGELY REPLACING ONE OF ONE LYMPH NODE (1/1). - THE METASTATIC FOCUS MEASURES 0.9 CM, WITH NO EXTRANODAL EXTENSION. 8). ADDITIONAL LEVEL 1 LYMPH RIGHT AXILLA NODE 1; EXCISION: - METASTATIC CARCINOMA INVOLVING THREE OF THREE LYMPH NODES (3/3) . LARGEST METASTATIC CARCINOMA MEASURES .3CM. - EXTRANODAL EXTENSION IS PRESENT. 9). ADDITIONAL RIGHT LEVEL 2 AXILLARY CONTENTS; EXCISION: - METASTATIC CARCINOMA INVOLVING FOUR OF FOUR LYMPH NODES (4/4). LARGEST METASTATIC CARCINOMA MEASURES 0 5CM. - EXTRANODAL EXTENSION IS PRESENT. 10). LEVEL 3 LYMPH NODE RIGHT AXILLA; EXCISION: METASTATIC CARCINOMA LARGELY REPLACING ONE OF ONE LYMPH NODE (1/1) . LARGEST METASTATIC CARCINOMA MEASURES 0.2CM. - EXTRANODAL EXTENSION IS PRESENT. I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL), AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. Gross Description: 1) . The specimen is received for a canceled a canceled frozen section. consultation, placed in formalin labeled ""Sentinel node number one level. 1. left axilla"" and consists of a 1.4 x 0.5 x 0.5 cm piece of lymphoid fatty. tissue is bisected and entirely submitted. Summary of sections: U - undesignated. 2) The specimen is received for a canceled frozen section consultation,. placed in formalin, labeled ""Sentinel node number two, level one left. axilla"" and consists of 1.3 x 1.3 x 0.5 cm pink-tan lymph node which is. bisected and entirely submitted. Summary of sections: U - undesignated. 3) The specimen is received fresh for frozen section consultation, labeled. "". Sentinel node number one level 1 right axilla"" and consists of a 0.4 x 0.4. x 0.3 cm lymph node which is bisected and entirely submitted for frozen. section. Summary of sections: FSC frozen section control. 4). The specimen is received fresh for frozen section consultation,. labeled ""Sentinel node number two level 1 right axilla"" and consists of a. 1.2 x 1.0 x 1.0 cm lymph node which is bisected and entirely submitted for. frozen section. Summary of sections: FSC -- frozen section control. 5) The specimen is received fresh labeled, ""right breast and axillary. contents level 1,2, and 3"" and consists of a breast with attached axillary. contents. The breast measures 19 x 18 x 6 cm with overlying skin ellipse. measuring 18.5 x 7.5 cm. Situated on the skin surface is a nipple measuring. 1.5 x 1.5 x 0.5 cm and areola measuring 3.5 cm. The skin shows no scar. Axillary contents measures 12 x 7 x 2.5 cm. The posterior surface of the. breast is inked black and the anterior blue. The specimen is serially. sectioned to reveal a mass (mass 1) measuring 3.6 x 3.01 x 2.5 cm, and. located in the UIQ at 1 o' clock and 3.3 cm from the deep margin. A clip. is. identified in the mass 1. Another mass (mass 2) measuring 2.5 x 2.2 x 1.5 cm. LIQ at 5 o' clock located 4.5 cm from the deep margin is identified. The. remaining breast tissue shows fibroglandular tissue. The axillary tissue is. dissected to reveal multiple lymph nodes. Representative sections are. submitted. All dissected lymph nodes are entirely submitted. Summary of sections: N - nipple. NB - nipple base. D1 - deep margin for mass 1. D2 deep margin for mass 2. T1 mass 1. T2 mass 2. UIQ - upper inner quadrant. LIQ - lower inner quadrant. UOQ - upper outer quadrant. LOQ - lower outer quadrant. LN lymph nodes. M.D. 6) The specimen is received fresh labeled, ""left breast"" and consists of. a. breast measuring 25 x 18 x 5cm with overlying skin ellipse measuring 18 x. 8. cm. Situated on the skin surface is a nipple measuring 1.8 x 1.3 x 1cm and. areola measuring 3.5 cm. The skin is unremarkable. A suture demarcates the. axillary aspect. The posterior surface of the breast is inked black and the. axillary aspect is inked yellow. The specimen is serially sectioned to. reveal unremarkable fibroglandular tissue without mass lesion. Sectioning of. the axillary aspect reveals no grossly identifiable lymph nodes. Representative sections are submitted. Summary of sections: N - nipple. NB - nipple base. D - deep margin. UIQ - upper inner quadrant. LIQ - lower inner quadrant. UOQ - upper outer quadrant. LOQ - lower outer quadrant. 7) The specimen is received in formalin, labeled ""Right Rotter' s node"" and. consists of a single pink tan fleshy lymph node measuring 1 x 0.8 x 0.5 cm. The lymph node is entirely submitted. Summary of sections: LN- lymph node. 8) The specimen is received in formalin, labeled ""Additional level 1 lymph. node, right axilla"" and consists of four pink tan firm lymph nodes ranging. from 0.4 to 2.2 cm in greatest dimension. All identified lymph nodes are. submitted. Summary of sections: LN - - lymph nodes. BLN1- - bisected lymph node #1. BLN2' bisected lymph node #2. 9). The specimen is received in formalin, labeled ""Additional right level. two axillary contents"" and consists of a portion of yellow tan adipose. tissue, with four pink tan firm lymph nodes ranging from 0.6 to 1 cm. in. greatest dimension. All identified lymph nodes are submitted. Summary of sections: LN -- lymph nodes. 10) The specimen is received in formalin, labeled ""Level three lymph node,. right axilla"" and consists of a single pink tan fatty lymph node measuring. 0.8 x 0.3 x 0.2 cm. The lymph node is entirely submitted. Summary of sections: LN- lymph node. Summary of Sections: Part 1: SP: Sentinel node #1 level 1 left axilla. Block. Sect. Site. PCs. 1. u. 1. Part 2: SP: Sentinel node #2 level 1 left axilla. Block. Sect. Site. PC's. 1. u. 1. Part 3: SP: Sentinel node #1 level 1 right axilla (fs). Block. Sect. Site. PCs. 1. fsc. 1. Part 4: SP: Sentinel node #2 level 1 right axilla (fs). Block. Sect. Site. PCs. 1. fsc. 1. Part 5: SP: Right breast and axillary contents level 1, 2, and 3. Block. Sect. Site. PCs. 5. BLN. 10. 1. D1. 1. 1. D2. 1. 1. LIQ. 1. 5. LN. 15. 2. LOQ. 2. 1. N. 1. 1. NB. 1. 3. T1. 3. 3. T2. 3. 1. UIQ. 1. 2. UOO. 2. Part 6: SP: Left breast. Block. Sect. Site. PCs. 1. D. 1. 2. LIQ. 2. 2. LOQ. 2. 1. N. 2. 1. NB. 1. 2. UIQ. 2. 2. UOQ. 2. Part 7: SP: Right rotter's node. Block. Sect. Site. PCs. 1. LN. 1. Part 8: SP: Additional level 1 lymph right axilla node 1. Block. Sect. Site. PCs. 1. bln1. 2. 2. bln2. 2. 1. LN. 2. Part 9: SP: Additional right level 2 axillary contents. Block. Sect. Site. PCs. 1. LN. 4. Part 10: SP: Level 3 lymph node right axilla. Block. Sect. Site. PCs. 1. LN. Intraoperative Consultation: Note: The diagnoses given in this section pertain only to the tissue sample. examined at the time of the intraoperative consultation. 3). FROZEN SECTION DIAGNOSIS: SP: SENTINEL NODE #1 LEVEL 1 RIGHT. AXILLA (FS) : BENIGN LYMPH NODE (. PERMANENT DIAGNOSIS: SAME. 4). FROZEN SECTION DIAGNOSIS: SP: SENTINEL NODE #2 LEVEL 1 RIGHT. AXILLA (FS) METASTATIC CARCINOMA. PERMANENT DIAGNOSIS: SAME. .e: The diagnoses given in this section pertain only to the tissue sample. amined at the time of the intraoperative consultation. 3). FROZEN SECTION DIAGNOSIS: SP: SENTINEL NODE #1 LEVEL 1 RIGHT. AXILLA (FS) : BENIGN LYMPH NODE. PERMANENT DIAGNOSIS: SAME. 4). FROZEN SECTION DIAGNOSIS: SP: SENTINEL NODE #2 LEVEL 1 RIGHT. AXILLA (FS) : METASTATIC CARCINOMA. PERMANENT DIAGNOSIS: SAME.",BRCA,3,True,"Based on the pathology report, there are 4 out of 4 positive lymph nodes in the right axillary level 2 (9.d) and 3 out of 3 positive lymph nodes in the right axillary level 1 (8.a). This indicates that the patient has metastatic carcinoma in 7 out of 7 examined lymph nodes in the right axilla, which falls under N2 category according to the AJCC staging system for breast cancer.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.",N2,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.",20.0,1822.0,100.0,True
1137,TCGA-D8-A1X8.5F1C3B85-5E5C-428B-8779-3A5878DCE1F2,0,"page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - left breast with axillary tissues. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the left breast. Macroscopic description: Left breast sized 22.4 x 17.8 x 6.4 cm removed along with axillary tissues sized 12 x 5 x 3 cm and a skin flap of 24.2 x 11.3 cm. Weight 950 g. Tumour sized 2.7 x 1.4 x 2.8 cm found in the central part, removed 6.0 cm from the lower boundary, 0.3 cm from the base and 1.4. cm from the skin. Microscopic description: Carcinoma lobulare invasivum (classical type, partly solid) multifocale - NHG2 (3+2+1/0 mitoses/10 HPF - visual area. 0.55mm). Infiltratio carcinomatosa mamillae. In situ lesions of the type pagetoid spread and hyperplasia within the foci of adenosis sclerosans. Glandular tissue. showing lesions of the type fibrosa et cystica, adenosis sclerosans. AXILLARY LYMPH NODES: Metastases. carcinomatosae in lymphonodis (No IX/XI). Test result: Carcinoma lobulare mixtum invasivum mammae sinistrae. Metastases carcinomatosae in lymphonodis axillae (No IX/XI) (NHG2, pTIc, pN2a). Examination performed or. Results of immunohistochemical examination: Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in over 75% of neoplastic cell nuclei. HER2 protein stained with HercepTestâ„¢M by DAKO. Score = 2+. FISH verification recommended. Compliance validated by: 1. Examination: Histopathological examination. page 2 / 2. Gender: F. Histopathological diagnosis: Carcinoma lobulare invasivum mammae sinistrae. Invasive lobular carcinoma of the left breast. Metastases in lymphonodis axillae (No IX/XI) (NHG2, pTIc, pN2a). Cancer metastases in axillary lymph nodes (No IX/XI) (NHG2, pTIc, pN2a). Results of immunohistochemical examination: RESULT OF HER2/neu GENE AMPLIFICATION with the FISH method by Path Vysion HER2 DNA Probe Kit. HER-2 GENE AMPLIFICATION NOT FOUND.",BRCA,2,True,"The report mentions 'Metastases carcinomatosae in lymphonodis axillae (No IX/XI)' which indicates that the patient has metastatic carcinoma in 4 or more axillary lymph nodes. According to the rules, this is classified as N2.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.
The presence of metastatic carcinoma in 10 out of 11 axillary lymph nodes is classified as N2.",N2,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.
The presence of metastatic carcinoma in 10 out of 11 axillary lymph nodes is classified as N2.",21.0,1917.0,97.0,True
654,TCGA-A8-A08R.FC0C1BF3-74C3-4DFC-B9B5-2FD1728E287A,1,"Diagnosis: Poorly differentiated invasive ductal carcinoma (tumor diameter: 4 cm). Concluding tumor classification for the left breast: NOS, G III, pT2N1aLOVORO.",BRCA,1,True,"The report indicates that the patient has been diagnosed with a poorly differentiated invasive ductal carcinoma (tumor diameter: 4 cm) and the concluding tumor classification for the left breast is pT2N1aLOVORO. The 'N1' in the tumor classification indicates that the patient has metastatic carcinoma in 1-3 axillary lymph nodes, which is classified as N1 according to the rules provided.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.",20.0,1822.0,97.0,True
625,TCGA-A8-A07F.D1456192-83E7-4FC8-B783-90D615830156,1,"Diagnosis: 1. Ablated (left) breast sample with a moderately differentiated invasive ductal. carcinoma with an intraductal component (tumor diameter: 5.0 cm. Tumor classification: NOS, G II, pT2N1aLOVORO.",BRCA,1,True,"The report indicates that the patient has moderately differentiated invasive ductal carcinoma with a tumor diameter of 5.0 cm and is classified as pT2N1aLOVORO. The 'N1' in the classification refers to the N stage, which indicates that metastatic carcinoma is present in 1-3 axillary lymph nodes.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.",20.0,1822.0,100.0,True
1074,TCGA-BH-A1F6.7E9B0BE7-121E-423F-AA37-445BA922FC13,3,"NÂ°. PATIENT HISTORY: The patient is a year-old female. Date of last menstrual period: Not given. PRE OP DIAGNOSIS: Left breast cancer. POST OP DIAGNOSIS: Same. PROCEDURE: Left modified radical mastectomy. FINAL DIAGNOSIS: PART 1: LEFT BREAST, MODIFIED RADICAL MASTECTOMY -. A. INFILTRATING DUCTAL CARCINOMA OF BREAST, NOTTINGHAM SCORE 8/9 (TUBULES 3, NUCLEI 3, MITOSES 2). B. NEOPLASM MEASURES 5.5 CM IN MAXIMUM DIMENSION. C. NEOPLASM EXTENDS INTO DERMIS. D. MARGINS OF RESECTION FREE OF NEOPLASM. E. EXTENSIVE DERMAL LYMPHOVASCULAR EXTENSION IDENTIFIED (T4d). F. NO PAGET'S DISEASE OF NIPPLE IDENTIFIED. G. METASTATIC CARCINOMA IN INTRAMAMMARY LYMPH NODE, 1 OF 1, 0.7 CM IN DIAMETER WITH. EXTRACAPSULAR EXTENSION. PART 2: LEFT AXILLARY CONTENTS, AXILLARY DISSECTION. METASTATIC CARCINOMA IN LYMPH NODES, 3 OF 3. PART 3: LEFT AXILLARY CONTENTS, AXILLARY DISSECTION. METASTATIC CARCINOMA IN LYMPH NODES, 2 OF 2. COMMENT: Estrogen_ Progesterons and Her-2/Neu analyses were performed on the two previous specimens (outside block from: and di. wand interpreted on both specimens as ER negative, PR negative and Her-. 2/Neu negative. If repeat analyses are desired on current specimen, please contact the laboratory.",BRCA,2,True,"The report indicates that there is metastatic carcinoma in 4 or more axillary lymph nodes (part 2: 3 of 3 and part 3: 2 of 2), which corresponds to N2 according to the rules.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.",N2,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.",20.0,1822.0,100.0,True
699,TCGA-AC-A2BM.9F00B6F4-EE91-4A18-B533-127E39EF8554,1,"Print -. Back to List. TEST: Surgical Patholoav. Date & Time: REPORT STATUS: Final. FACILITY: See Addendum. Patient Name : }. ...ge: Service: Surgery. Gender : F. Takeit. Physician (s) : Speciment (s) Received. A: Left sentinel nodes. B: Left sentinel node #2. C: Left breast tissue. D: Left axillary contents. Pathologic Diagnosis. ""A"" -. Left sentinel node: Metastatic carcinoma in one. (of one) lymph node. Two foci of metastatic tumor are present,. the larger measuring 0.: cm. The metastatic tumor is to. confined. the lymph node. ""B"". Left sentinel lymph node #2: One lymph node negative. for malignancy. C. Meft breast tissue;. Histologic Type: t Invasive ductal carcinoma (NOS). Modified B-R Grade: 3. Tubular score: 3. Nuclear score: 3. Mitosis score: 3. Tumor Size: Greatest dimension: 2.5 cm. Additional dimensions: 1.! 5 x. Regional Lymph Nodes: Number of lymph nodes examined: 13. Number of lymph nodes involved: 1. Metastasis dectected by light microscopy. Margins of Invasive Carcinoma: Negative. Invasive carcinoma is located: 3 cm. away from the deep margin. Lymphovascular Invasion : Absent. Ductal Carcinoma In Situ: Absent. Paget's Disease: Absent. Distant Metastasis: Cannot be assessed. Print. Microcalcificatior. Absent. Additional Pathologic Findings : Fibroadenomas. Specimen Type: Mastectomy. Specimen Size: Greatest dimension: 28 cm. Tumor Laterality: Left. Tumor Site: Upper inner quadrant. Lower inner quadrant. Lymph Node Sampling: Sentinel lymph nodes and axillary. dissection. Comment. In Part ""C"", one contiguous lymph node is negative. for. malignancy. H&E and cytokeratin stains examined. pT2 pN1a pMX. ""D"" -. Left axillary contents: Ten lymph nodes negative for. malignancy. Left axillary contents: ESTROGEN AND PROGESTERONE RECEPTOR SYNOPSIS. Estrogen and progesterone receptor immunohistochemistry stains. are performed utilizing the 6f11 (ER) and 1A6 clones (PR) along. with the iview detection kit. The stains are performed on. formalin-fixed paraffin-embedded sections. Both special stains. have adequate controls. ESTROGEN RECEPTORS: Infiltrating malignant cells showing positive staining: 60. PROGESTERONE RECEPTORS: Infiltrating malignant cells showing positive staining: 10. %. ESTROGEN RECEPTOR RESULTS: Positive. PROGESTERONE RECEPTOR RESULTS: Positive. Note: Consensus. Statement on Adjuvant Therapy for Breast Cancer: Any positive nuclear ER immunostaining is considered a positive. result. These mmunohistochemistry reaction patterns were. developed and their performance characteristics determined by. They have not been cleared or. approved by the U.S. Food and Drug Administration. The FDA has. determined that such clearance or approval is not necessary. These tests are used for clinical purposes. They should not be. regarded as investigational or for research. This laboratory is. certified under the Clinical Laboratory Improvement Amendments of. 1988 (CLIA) as qualified to perform high complexity clinical. laboratory testing. Primary Pathologist: Addendum. Results from. HER2 by FISH: 1.4/Not Amplified. Clinical History. Left breast cancer. Intraoperative Consultation. A - Left sentinel node: Metastatic cancer. (Microscopic frozen. section) . B - Left sentinel node #2: Negative. (Microscopic frozen. section). Gross Description. A - The specimen is received fresh for frozen section labeled. ""left sentinel node. The specimen consists of a pink-tan lymph. node measuring 2.5 x 1.5 x 0.9 cm. The specimen is bisected and. entirely frozen in cassette ""FS-A1."" "". B - The specimen is received fresh for frozen section labeled. ""left sentinel node.' The specimen consists of a pink-tan lymph. node measuring 3 x 2 x 1.1 cm. The specimen is bisected and. entirely frozen in cassette ""FS-B1. "". C - The specimen is received in formalin and .labeled ""left breast. suture at 6 o'clock.' The specimen consists of a mastectomy. specimen without axillary tissue measuring 28 x 23.5 x 50 cm and. weighing 1559 gm. There is an overlying tan ellipse of skin. measuring 22 x 7 cm and showing an eccentric wrinkled brown. areola measuring 4. x 4.5 cm. Within the center of the areola. there is an inverted soft brown nipple measuring 1.1 x 1.1 x 0.9. cm. There are grossly no healed incisions or biopsy sites on the. skin surface however the medial edge of the areola is partially. stained with blue dye. Attached suture marks the 6 S'clock. margin. The deep margin is inked black and the specimen is. serially sectioned to reveal an irregular firm tumor between the. upper-inner and lower-inner quadrants approximately 1 cm from the. nipple measuring 2.5 x 2 x 1.5 cm. The tumor comes to within 3. cm of the deep margin and within 2 cm of the superficial margin. (inked blue) Further sectioning reveals a well-circumscribed. nodule within the lower-outer quadrant 3.5 cm from the nipple. measuring 1.5 x 1 x 1 cm. This nodule comes to within 3 cm of. the deep margin. The remaining specimen consists of lobulated. fat interspersed with a large amount of tan-white. irregularly-indurated tissue with scattered cysts filled with. clear fluid measuring up to 0.4 cm in diameter. A lymph node is. identified at the axillary margin measuring 1 x 1 x 0.7 cm. Representative sections are submitted in 12 cassettes. Block summary: ""1"" - vertical section of nipple, ""2"". cross-section of nipple, ""3-4"" - tumor, ""5"" - superficial and. deep margin nearest to tumor, ""6"" - nodule within the lower-outer. quadrant, ""7"" - upper-inner quadrant, ""8"" - lower-inner quadrant,. ""9"" - lower-outer quadrant, ""10"" - upper-outer quadrant, ""11"" -. tissue underlying the nipple stained with blue dye, ""12"" -. bisected lymph node at the axillary margin. D - The specimen is received in formalin and labeled ""left. axillary contents. "" The specimen consists of a tan-yellow portion. of axillary fatty tissue measuring 8 x 5.5 x 3.5 cm and weighing. 53 gm. Sectioning reveals 11 potential lymph nodes ranging from. 0.4 to 2.3 cm in greatest dimensions. The lymph nodes are. totally submitted in 4 cassettes. Block summary: ""1"" - 7 lymph nodes 1 of which is bisected, ""2"". 2 bisected lymph nodes, ""3"" - 1 bisected lymph node, ""4"" - 1. bisected lymph node. Microscopic Description. Microscopic examination has been performed on all slides. The. pathologic diagnosis encompasses the essential microscopic.",BRCA,1,True,"The report states that one out of 13 regional lymph nodes is involved, and metastasis was detected by light microscopy. This meets the criteria for N1 classification: 'The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.'","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.",20.0,1822.0,100.0,True
658,TCGA-A8-A08Z.DA7BD84B-C00E-40A0-9AE2-33FCE7995696,3,"Diagnosis: 1. Invasive breast carcinoma with focal angioinvasion and tumor infiltration of. the skin spindle with foci of ulceration (tumor diameter: 5.0 cm). Dorsal resection margin. tumor-free. In conclusion, this is a moderately differentiated invasive ductal carcinoma with focal. angioinvasion and ulceration of the skin spindle. Tumor classification: NOS, G II, pT4bN3aLIVORO.",BRCA,3,True,"The report indicates that the tumor has invaded the skin and measures 5.0 cm in diameter, which classifies it as pT4b. The report also states that the patient has metastatic carcinoma in 3 or more axillary lymph nodes (pN3a). However, the report does not provide information on extranodal extension of metastatic carcinoma. Therefore, based on the available information, the N stage is N3.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes with no extranodal extension is classified as N2.",N3,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes with no extranodal extension is classified as N2.",21.0,1943.0,97.0,True
791,TCGA-AO-A0J5.5EFC16F4-7FC7-479E-93F7-AEDC2D350A22,3,"Clinical Diagnosis & History: year old female with stage IV breast carcinoma, debulking surgery. Specimens Submitted: 1: SP: Right breast and axillary contents level 1. DIAGNOSIS: 1. BREAST, RIGHT; MODIFIED RADICAL MASTECTOMY: - INVASIVE CARCINOMA, HISTOLOGIC GRADE II/III (MODERATE TUBULE. FORMATION) TO HISTOLOGIC GRADE III/III (SLIGHT OR NO TUBULE FORMATION). NUCLEAR GRADE III/III (MARKED VARIATION IN SIZE AND SHAPE), MEASURING AT. LEAST 10 CM IN LARGEST DIMENSION GROSSLY. INVASIVE CARCINOMA SHOWS. MICROPAPILLARY FEATURES. FOCAL EXTRACELLULAR MUCIN IS ALSO NOTED. - DUCTAL CARCINOMA IN SITU (DCIS) IS ALSO IDENTIFIED, SOLID CRIBRIFORM. MICROPAPILLARY AND FLAT TYPES, WITH HIGH NUCLEAR GRADE, AND EXTENSIVE. NECROSIS. - LOBULAR INVOLVEMENT BY DCIS IS PRESENT. - THE DCIS CONSTITUTES LESS THAN OR EQUAL TO 25% OF THE TOTAL TUMOR MASS,. AND IS PRESENT ADMIXED WITH AND AWAY FROM THE INVASIVE COMPONENT. - THE INVASIVE CARCINOMA IS LOCATED IN ALL FOUR QUADRANTS. - THE DCIS IS LOCATED IN ALL FOUR QUADRANTS. - THE NIPPLE IS INVOLVED BY INVASIVE CARCINOMA. - CALCIFICATIONS ARE PRESENT IN BOTH THE IN SITU AND INVASIVE CARCINOMA. - VASCULAR INVASION IS PRESENT. - THE SKIN IS INVOLVED BY INVASIVE CARCINOMA BY DIRECT EXTENSION INTO THE. DERMIS. - THE ATTACHED SKELETAL MUSCLE IS EXTENSIVELY INVOLVED BY INVASIVE CARCINOMA. BY DIRECT EXTENSION. - INVASIVE CARCINOMA IS CLOSE (LESS THAN 0.1 CM) FROM THE NEAREST DEEP. MARGIN. THE NON-NEOPLASTIC BREAST TISSUE IS UNREMARKABLE. FOCAL CHANGES OF PRIOR PROCEDURE ARE NOTED IN THE AXILLARY TAIL. - METASTATIC CARCINOMA IS PRESENT IN TWO OUT OF TWO LEVEL I LYMPH NODES. (2/2) ADDITIONAL SECTIONS OF THE AXILLARY TISSUE HAVE BEEN SUBMITTED AND. THE FINDINGS WILL BE REPORTED IN AN ADDENDUM. - NUMEROUS FOCI OF METASTATIC CARCINOMA ARE NOTED IN THE AXILLARY SOFT. TISSUE, WITH THE LARGEST MEASURING AT LEAST 1.4 CM. Immunohistochemical stains were performed on formalin-fixed tissue with. the following results for invasive carcinoma (block 1-8): ESTROGEN RECEPTOR. 90% nuclear staining with strong. intensity. PROGESTERONR RECERTOR. Negative (no nuclear staining). HER2. Equivocal (focal 2+). FISH will be performed. (5% of invasive tumor cells exhibit complete membranous staining;. Uniformity of staining: absent;. Homogeneous, dark circumferential pattern: absent). The carcinoma is positive for E-cadherin, supporting lobular. differentiation. Comment: Controls are satisfactory. Ventana' a PATHWAY anti-HER-2/neu is. an FDA-approved rabbit monoclonal primary antibody (clone 4B5) directed. against the internal domain of the c-erbB-2 oncoprotein (HER2) for. immunohistochemical detection of HER2 protein overexpression in breast. cancer tissue routinely processed for histologic evaluation The HER2 test. results are reported in accordance with the ASCO/CAP guideline. recommendations for HER2 testing in breast cancer (J Clin Oncol 2007;. 25(1):118-145). The ER and PR rabbit monoclonal antibodies are also FDA. approved. Some of the imnunohistochemistry and ISH tests were developed and their. performance characteristics were determined by the Department of Pathology. They have not been cleared or approved by the US Food and Drug. Administration. The FDA has determined that such clearance or approval is. not necessary. These tests are used for clinical purposes. They should not. be regarded as investigational or for research. This laboratory is certified. under the Clinical Laboratory Improvement Amendments of 1988 (CLIA , 88). as. qualified to perform high complexity clinical laboratory testing. I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL) . AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. Gross Description: M.D. M.D. 1) The specimen is received fresh labeled, ""right breast and axillary. contents level 1"",. It consists of a breast with attached. axillary contents. The breast measures 20 x 15 x 5 cm with overlying skin. ellipse measuring 18 x 7 x 0.2 cm. Situated centrally on the skin surface is. a. fixed, and retracted nipple measuring 1.5 x 1.0 x 1.0 cm. The surrounding. skin is markedly thickened (up to 0.6 cm) . A suture demarcates the axillary. contents which measures 7 x 5 x 2 cm. The posterior surface of the breast is. inked black and the anterior blue. Part of the posterior surface of the. breast is covered by dark red skeletal muscle, measuring 11 x 4 x 0.5 cm. The specimen is serially sectioned to reveal an irregular tumor bed (10 x. 8.3 x 5.1 cm) with poorly defined white, firm and tan areas. The tumor bed. occupies almost the entire breast volume, extending throughout all four. quadrants. The tumor bed is located 0.2 cm from the posterior margin, 0.3 cm. from the anterior margin, and 0.5 cm from the skeletal muscle. The remaining. breast tissue shows yellow fatty areas with foci of fibrosis. The axillary. tissue is dissected to reveal 13 possible lymph nodes, ranging in size from. 0.4 cm to 1.2 cm. Representative sections are submitted. All dissected lymph. nodes are entirely submitted. The specimen is photographed. Tissue is. submitted to TPS. Summary of sections: N - nipple, nipple base and tumor. s - thickened skin. PM - posterior margin. AM - anterior margin. DSM - deep skeletal muscle. T - tumor central region and closest margins, continuous cross sections,. taken from medial to lateral. UIQ - upper inner quadrant. LIQ - lower inner quadrant. UOQ - upper outer quadrant. LOQ - lower outer quadrant. L1 - axilla, level one lymph nodes. AX axillary tail, entirely submitted. Summary of Sections: Part 1: SP: Right breast and axillary contents level 1. Block. Sect. Site. PCs. 1. AM. 1. 11. ax. 11. 1. DSM. 1. 9. L1. 9. 2. LIQ. 2. 2. LOQ. 2. 3. N. 3. 1. PM. 1. 1. s. 1. 10. T. 10. 2. UIQ. 2. 2. UOQ. 2. Procedures/Addenda: Addendum. Date Complete: By: 1. Addendum Diagnosis. PART #1. RIGHT BREAST AND AXILLARY CONTENTS: THE REMAINING AXILLARY TISSUE IS ENTIRELY SUBMITTED. NO ADDITIONAL LYMPH. NODES ARE IDENTIFIED. ,MD.",BRCA,1,True,"The report states that metastatic carcinoma is present in 4 or more axillary lymph nodes (2/2), which classifies the N stage as N2 according to the rules.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes with no extranodal extension is classified as N2.",N2,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes with no extranodal extension is classified as N2.",21.0,1943.0,100.0,True
1468,TCGA-OK-A5Q2.8F2F2141-EC62-4321-B799-054D32FEBA87,1,"Infiltrating Lobular Carcinoma. CATEGORY: BREAST INVASIVE CARCINOMA-INFILTRATING LOBULAR. CARCINOMA. FROM PRIMARY BREAST SURGERY. CLINICAL HX - Invasive lobular carcinoma. RIGHT BREAST, MASTECTOMY - Invasive lobular carcinoma, focally pleomorphic type,. 3.0cm in greatest microscopic dimension, associated with extensive duct carcinoma in-situ. (DCIS), intermediate nuclear grade, solid type with comedo necrosis. [Nottingham histologic. grading system utilized- SBR score 7; architectural grade 3, nuclear grade 2, mitotic grade 2). No. lymphatic invasion is identified. Deep margin negative for tumor. Vessel wall calcifications. Intraductal papilloma, radial scar and fibrocystic changes including sclerosing adenosis. Skin and. nipple, unremarkable. Prior biopsy site changes. RIGHT AXILLARY CONTENTS, EXCISION - Metastatic carcinoma present in two of the. thirteen lymph nodes (2/13). Largest metastatic focus measures 4mm in greatest microscopic. dimension. No extranodal extension is identified. Comment: AJCC pathologic stage pT2N1aMx. Synoptic summary will follow as an addendum. ADDENDUM 1: RIGHT BREAST, MASTECTOMY - Immunohistochemical stain for HER-2-NEU oncoprotein. is negative (performed on formalin-fixed paraffin embedded sections by manual semiquantitative. morphometric analysis with appropriate positive and negative controls). No membranous staining. is seen. The HER-2-NEU procedure was performed using monoclonal antibody 4B5 and DAB. detection system. (Staining interpretation: Weak = 1+; Moderate = 2+; Strong = 3+.). NOTE. This evaluation was performed according to ASCO/CAP guidelines: Positive HER2/neu. cases are those with strong and complete membrane staining (3+) in greater than 30% of invasive. cancer cells. Negative cases are defined as those with no staining (0) or weak, incomplete. membrane staining (1+) in any proportion of cells. Equivocal cases are those cases with strong. staining in less than or equal to 30% of cells, or less than strong but complete membrane staining. (2+) in at least 10% of cells. Immunohistochemical stains were performed on formalin-fixed. paraffin embedded tissue with appropriate positive and negative controls. ADDENDUM 2. Specimen Type - Mastectomy. Lymph node Sampling - Axillary dissection. Specimen Size. Greatest dimension 3cm. Histologic Type - Invasive lobular. Grading System - Nottingham. Tubule Formation - Minimal less than 10% (score = 3). Nuclear Pleomorphism - Moderate. increase in size, etc (score = 2). Mitotic Count - 40X objective field with a field area of 0.152. mm2: 6 to 10 mitoses per 10 HPF (score = 2). Total Nottingham Score - Grade II: 6-7 points. Margins uninvolved by invasive carcinoma. Distance from closest margin: 5mm. Deep Primary. Tumor [pT]: pT2 - Tumor greater than or equal to 2.0-5.0cm. Regional Nodes [pN]: pN1a: Metastasis in 1 to 3 axillary lymph nodes (at least 1 tumor deposit greater than 2.0mm). Number. involved: 2. Number examined: 13. Distant Metastasis [pM]: pMX - cannot be assessed. FROM DIAGNOSIS. CLINICAL HX - Right irregular mass, Right ax tail lymph node. RIGHT BREAST, 10:00. MASS, CORE BIOPSY - Invasive, lobular carcinoma with focal duct carcinoma in situ, solid. type, low nuclear grade. Intraductal papilloma involved by lobular carcinoma in-situ. RIGHT. AXILLA, LYMPH NODE, CORE BIOPSY - Lymph node with metastatic carcinoma. histologically identical to breast carcinoma. COMMENT. Prognostic/predictive markers are. being performed and results will follow as an addendum. ADDENDUM: Results of. immunoperoxidase steroid receptor protein determination on paraffin sections, visually evaluated. using DAB detection system and monoclonal antibodies (manual semiquantitative morphometric. 7. analysis): ESTROGEN RECEPTOR PROTEIN (ER- clone SP1): POSITIVE; PROGESTERONE. RECEPTOR PROTEIN (PR- clone 1E2): POSITIVE. Estimated percentage of nuclei staining. positive (ER): 100; Estimated percentage of nuclei staining positive (PR): 25. Intensity of. staining, ER: 3+ (strong). Intensity of staining, PR: 3+ (strong). Immunohistochemical stain for. HER-2-NEU oncoprotein is NEGATIVE (performed on formalin-fixed paraffin embedded. sections by manual semiquanitative morphometric analysis). No membranous staining is seen. The HER-2-NEU procedure was performed using monoclonal antibody 4B5 and DAB detection. system. 8.",BRCA,1,True,"The report states that there are 2 positive lymph nodes out of 13 examined (2/13) and no extranodal extension is identified. According to the rules, the presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes with no extranodal extension is classified as N2.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.",N1,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes with no extranodal extension is classified as N2.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.",23.0,2159.0,95.0,True
1500,TCGA-S3-A6ZH.030860D0-66DF-46FF-95A3-2AE4852D5C19,2,"Female. Admission Date: Discharge Date: Collected Date/Time: Received Date/Time: Final Diagnosis. A. LEFT HIGHEST AXILLARY NODE, EXCISION: - METASTATIC CARCINOMA IN ONE LYMPH NODE (1/1). B. LEFT BREAST AND AXILLARY CONTENTS, MASTECTOMY AND LYMPHADENECTOMY: - INVASIVE DUCTAL CARCINOMA, GRADE 3. - METASTATIC CARCINOMA IN THIRTEEN OF NINETEEN LYMPH NODES (13/19). - MARGINS ARE NOT INVOLVED. - SEE TEMPLATE. C. LEFT LEVEL I AXILLARY LYMPH NODE, EXCISION: - NO EVIDENCE OF CARCINOMA IN ONE LYMPH NODE (0/1). D. SKIN, LEFT AXILLA, EXCISION: - FOLLICLE INFUNDIBULAR CYST, RUPTURED AND INFLAMMED. (Electronic signature). Verified: Synoptic Report. SPECIMEN TYPE: Excision. LYMPH NODE SAMPLING: Axillary dissection. SPECIMEN SIZE: Greatest dimension: 24 cm. 'Additional dimensions: 18 x 5. LATERALITY: Left. TUMOR SITE: Print Date/Time: Distribute to: Patient T ~cations: Collected Date/Time: Received Date/Time: Upper outer quadrant. SIZE OF INVASIVE COMPONENT: Greatest dimension: 7 cm (3 cm in this specimen and 4 cm in previous lumpectomy. HISTOLOGIC TYPE: Invasive ductal carcinoma. HISTOLOGIC GRADE: Tubule formation: Tubule formation: Minimal less than 10% (score = 3). Nuclear pleomorphism: Nuclear pleomorphism: Marked variation in size, nucleoli, chromatin clumping, etc. (score = 3). Mitotic count (for those using the Nottingham system) - for a 25x objective with a field area of 0.274mm2: Mitotic count (25x objective): 10 to 20 mitoses per 10 HPF (score = 2). Nottingham Grade III: 8-9 points. PRIMARY TUMOR (pT): pT3: Tumor more than 5.0 cm in greatest dimension. REGIONAL LYMPH NODES (pN): pN3a: Metastasis in 10 or more axillary lymph nodes (at least 1 tumor deposit greater than 2.0 mm), or metastasis to the. infraclavicular lymph nodes. Number examined: 21. Number involved: 14. DISTANT METASTASIS (M): pMX: Cannot be assessed. MARGINS: Margins uninvolved by invasive carcinoma. Distance from closest margin: 15 mm. Specify which margin: posterior/deep. VENOUS/LYMPHATIC (LARGE/SMALL VESSEL) INVASION (V/L): Present. MICROCALCIFICATIONS: Not identified. ADDITIONAL PATHOLOGIC FINDINGS: adenosis. Biomarkers evaluated in previous specimen (. ER: positive, 98%. PR: positive, 8%. Her-2neu: equivocal 2+ by IHC, not amplified by FISH. Source of Specimen. A. LEFT HIGHEST AXILLARY NODE. B. LEFT BREAST AND LEFT AXILLARY CONTENTS. C. LEVEL I LEFT AXILLARY LYMPH NODE. D. LT AXILLA. Print Date/Time: Collected Date/Time: Received Date/Time: Clinical Information. female with left breast cancer on ultrasound core needle biopsy status post. PRE-OP DIAGNOSIS: Left breast cancer and axillary hydradenitis. POST-OP DIAGNOSIS: Same. TYPE OF PROCEDURE: Left mastectomy and left axillary hidradenitis node dissection. Gross Description. Specimen is received in 4 parts: A. The specimen is labeled ""LEFT HIGHEST AXILLARY NODE"" and is received unfixed. It consists of one nodule of fatty yellow-. tan tissue with staples measuring 1.2 x 0.7 x 0.5 cm. On sectioning, there is one lymph node identified measuring 0.7 cm in maximum. dimensions. The lymph node is bisected and entirely submitted in cassette A1. Time specimen was removed from the patient. Time specimen was sectioned and placed in formalin: Ischemic time: 30 minutes. B. The specimen is labeled ""LEFT BREAST AND AXILLARY CONTENTS and is received in formalin. (The specimen is in. the. formalin more than. It consist of mastectomy specimen with lymph nodes weighing 480 grams and. measuring 24 x 18 x 5 cm with brown skin ellipse measuring 17 x 4 cm, containing grossly unremarkable 1.5 cm in diameter nipple. [The skin is tagged with a black stitch designating 12:00]. The posterior margin is composed of smooth fascia which is inked black. The anterior margin of resection is inked with blue ink. The breast is slices in sagittal planes revealing 3 x 3 x 2.5 cm an ill-defined. white-tan mass which is 1.5 cm away from the deep fascial margin of resection. This mass is located in the upper outer quadrant. (approximately 2:00 position). The remaining portions reveal unremarkable yellow mammary fat with streaks of white-gray. mammary parenchyma. An axillary fat pad measuring 7 x 5 x 3 cm. On sectioning multiple lymph nodes are identified. Some lymph. nodes are white in and firm in consistency. The largest lymph node measuring 2 cm in greatest diameter. Representative sections are. submitted as follows: B1 = nipple. B2-B5 = mass. B6 = mass closest deep fascial margin of resection. B7 = upper inner quadrant. B8 = lower inner quadrant. B9 = lower outer quadrant. B10 = 6 lymph nodes. B11 = bisection of a single lymph node. B12 = bisection of a single lymph node. B13 = representative sections of 3 lymph nodes. B14 = bisection of a single lymph node. B15 = representative section of the single lymph node. B. 16 = bisection of a single lymph node. B-17 = two small lymph nodes. B. 18 = bisection of a single lymph node. Time specimen was removed from the patient: Print Date/Time: Collected Date/Time: Received Date/Time: Time specimen was sectioned and placed in formalin: Ischemic time: 20 minutes. C. The. specimen is labeled ""AXILLARY LYMPH NODE LEVEL 1"" and is received unfixed. It consists of two nodular pieces of fatty. yellow-tan tissue with metallic staples measuring 2.2 x 1.5 x 0.5 cm in aggregate. On sectioning, there are two lymph nodes measuring. 0.7 and 1.0 cm in maximum dimensions. The lymph nodes are entirely submitted in cassette C1. Time specimen was removed from the patier. Time specimen was sectioned and placed in formalin. Ischemic time: 11 minutes. D. The specimen is labeled ""LEFT AXILLARY HYDRADENITIS"" and is received in formalin. It consists of an unoriented brown. ellipse of skin with attached subcutaneous tissue measuring 3.0 x 1.2 x 1.2 cm. There is a central old scar measuring 0,4 x 0.3 cm in. maximum dimensions. On sectioning, there is a firm white area measuring 1.0 x 1.0 cm in maximum dimensions beneath the scar. Representative sections are submitted in cassettes D1-D2 scar with firm white area. Time specimen was removed from the patient: Time specimen was sectioned and placed in formalin: Ischemic time: 1 minute. Special Stains/Slides. 22 H&E. Tissue Code. Print Date/Time:",BRCA,3,True,"The report states that there are 14 positive lymph nodes out of 21 examined. This exceeds the criteria for N3a (metastasis in 10 or more axillary lymph nodes), making the N stage N3a.","If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes with no extranodal extension is classified as N2.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
AJCC N3a: Metastasis in 10 or more axillary lymph nodes (at least 1 tumor deposit greater than 2.0 mm), or metastasis to the infraclavicular lymph nodes.",N3a,"If no malignancy is found in regional lymph nodes, the N stage is N0.
The number of lymph nodes examined and the number of nodes with malignancy can be used to determine the N stage.
Immunohistochemistry can be used to confirm the presence of malignancy in lymph nodes, but its absence does not rule out malignancy.
The size and extent of the primary tumor do not affect the N stage.
The presence of lymphovascular invasion does not affect the N stage.
The histologic type and grade of the tumor do not affect the N stage.
Micrometastasis is considered a positive lymph node and classified as N1.
Isolated tumor cells in regional lymph nodes are not considered as positive lymph nodes and do not affect the N stage.
Extranodal extension of metastatic carcinoma increases the N stage by one level.
Substaging information does not affect the overall N stage category.
The absence of isolated tumor cells in regional lymph nodes does not affect the N stage.
The presence of metastatic carcinoma in 1-3 axillary lymph nodes is classified as N1.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes is classified as N2.
The presence of metastatic carcinoma in internal mammary or supraclavicular lymph nodes also upgrades the N stage.
Hematoxylin and eosin is an acceptable method of evaluation for the N stage.
The presence of ductal carcinoma in situ (DCIS) in lymph nodes does not affect the N stage.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
The absence of metastatic carcinoma in regional lymph nodes is classified as N0.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
The presence of estrogen and progesterone receptors, HER2 status, and Ki-67 index do not affect the N stage.
The presence of metastatic carcinoma in 4 or more axillary lymph nodes with no extranodal extension is classified as N2.
The N stage is determined by the number of positive lymph nodes, not the total number of lymph nodes examined.
Extranodal extension of metastatic carcinoma in 1 or more lymph nodes upgrades the N stage by one level.
AJCC N3a: Metastasis in 10 or more axillary lymph nodes (at least 1 tumor deposit greater than 2.0 mm), or metastasis to the infraclavicular lymph nodes.",24.0,2313.0,97.0,True
